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SUMMARY 
Introduction 
The global prevalence of overweight and obese individuals has increased 
dramatically over the past several decades. Since obesity is one of the strongest 
risk factors for developing type 2 diabetes (T2DM), it is not surprising that the 
prevalence of T2DM has also risen sharply with this obesity epidemic. 
Nevertheless, increase in total body fat mass alone does not fully explain the 
relationship between obesity and T2DM, and remains an area of interest and 
debate. The causal link is thought to be a combination of insulin resistance, 
ectopic fat accumulation, and systemic inflammation. 
MicroRNAs (miRNAs) are small, noncoding RNA molecules that regulate gene 
expression by targeting specific messenger RNA. Dysregulation of the expression 
of these miRNAs have been associated with several metabolic diseases including 
T2DM. Since the discovery of their presence in extracellular body fluids, a 
considerable body of evidence has been generated showing the potential use of 
these circulating miRNAs as diagnostic biomarkers for several diseases including 
T2DM.  
This thesis investigates the role of body fat distribution and White blood cells 
(WBC) in the pathogenesis of T2DM and further investigates putative circulating 
miRNAs as novel biomarkers for metabolic dysfunction leading to T2DM.  
The associations of circulating miRNA expression with markers 
of metabolic health: CAMERA trial 
A cross-sectional analysis was conducted to investigate the associations of 
circulating miRNAs mir-221, mir-222, mir-192, mir-193b, mir-144, and mir-155, 
with anthropometric and metabolic biomarkers using baseline plasma samples 
from the CAMERA trial.  To do this required the development of techniques not 
used previously to measure miRNA biomarkers at scale. These circulating miRNAs 
were chosen based on previous evidence showing that their dysregulation was 
associated with change in glycaemic status or body mass index (BMI). I observed 
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broad associations of the targeted circulating miRNAs with biomarkers of 
metabolic risk in a population without diabetes and with coronary heart disease 
and large waist circumference. I showed promising utility of these targeted 
circulating miRNAs as reproducible biomarkers for metabolic dysfunction, worthy 
of further study. 
The effect of metformin on the expression of circulating miRNA: 
The Carotid Atherosclerosis: MEtformin for insulin ResistAnce 
(CAMERA) trial 
Metformin is the first line therapy for type 2 diabetes, inducing modest weight 
loss and improved insulin sensitivity. In this study, the effect of metformin on the 
expression of these circulating miRNAs was explored using both the baseline 
samples and the 18-month plasma samples from the CAMERA randomised control 
trial (RCT). Randomisation to metformin failed to show any effect on the 
expression of circulating mir-222, mir-221, mir-192, mir-193b, mir-144, and mir-
155 in a population without diabetes and with coronary heart disease, and large 
waist but without diabetes, although the study was perhaps underpowered, and 
the effect of metformin in the study in general was very modest. 
The association of body fat distribution with inflammation and 
T2DM:UK Biobank study 
In this study, body fat distribution was examined using all adiposity measurement 
available in the UK Biobank study: anthropometric measurements, bio-impedance 
measurements, Dual-energy X-ray absorptiometry (DEXA) scans, and Magnetic 
resonance imaging (MRI) scans. A cross-sectional analysis was done to investigate 
the different pattern of body fat distribution between sexes and their association 
with T2DM and White blood cells (WBC) concentration as a marker of 
inflammation. Generally, central obesity was independently associated with T2DM 
in both genders and was a strong predictor for the development of T2DM than total 
body fat. Out of all the central obesity measures, high visceral adipose tissue 
(VAT) deposition was the strongest independent risk factor for T2DM and was also 
associated with total and differential WBC concentration. It was also showed that 
inflammation associated with T2DM is more strongly associated with VAT 
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deposition. In this study it was demonstrated that body fat distribution is likely to 
be more important for T2DM risk and systemic inflammation than total body fat. 
Reduction of adipose levels of inflammation when treating 
obesity (REALITY): Feasibility study 
From the previous study, it was concluded that obesity-related adverse health 
consequences appear to be related to fat distribution rather than total amount of 
fat gained. For a better understanding of the role of adipose tissue expandability 
and inflammation in the pathogenesis of T2DM, a study was proposed where 
bariatric surgery can be used as a model of metabolic change (before and after 
weight loss) to study adipocyte size, inflammation, and miRNA expression, the 
REALITY study. A feasibility study was performed to test the possibility of conducting 
such study in Glasgow. First, samples collection, transport, processing, and storage 
were worked out. This was done by reviewing the literature, consulting experts in 
the field, and then developing a Standard Operating Procedure (SOP). After that, 
specimen collection was discussed and coordinated with clinical staff. Overall, the 
feasibility of the REALITY study was tested, and the results showed that the 
designed protocol was accomplishable and ready to be tested in a full-scale study. 
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1 GENERAL INTRODUCTION  
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1.1 Obesity  
Obesity is one of the most significant public health problems affecting populations 
worldwide; the prevalence of obesity continues to increase. The concern is not 
about the extra fat tissue gained but instead about the significant health 
consequences that accompany obesity. During the past four decades, experts, 
scientists, and health professionals have attempted to reverse the obesity 
epidemic, but unfortunately it has been increasing gradually worldwide. What 
makes it challenging to tackle is that causes of obesity are multifactorial and no 
single approach will reverse the trend. 
Since obesity is considered a global public health concern, an effort is needed to 
understand both the reason behind the rapid increase in numbers affected and its 
relationship with chronic diseases, to find appropriate pathophysiological 
pathways that might be susceptible to intervention. 
1.1.1 Definition 
Obesity and being overweight are defined as conditions of excessive fat 
accumulation in the body leading to adverse health problems, with overweight 
being a pre-obesity state where intervention is recommended. Although obesity 
has been long considered as a complicating factor in a variety of diseases, it is 
now recognized as a disease itself. This was agreed on after the World Health 
Organization (WHO) published a ground-breaking document in 2000 clearly stating 
that obesity was a disease specifically a “complex, incompletely understood, 
serious and ‘chronic’ disease” and considered it as part of the non-communicable 
diseases that required prevention and management strategies at both individual 
and society level (World Health Organization, 2000). 
1.1.2 Prevalence 
Several epidemiological studies have reported that the prevalence of obesity is 
rising globally and rapidly worldwide across all age groups: adults, adolescents, 
and children. The WHO recent estimation for adults with overweight and obesity 
is that in 2016, more than 1.9 billion adults had a BMI in the overweight range and 
of these over 650 million adults had obesity (Figure 1-1a);and over 340 million 
children and adolescents aged 5-19 years had overweight or obesity (World Health 
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Organization, 2018). Overall, in 2016, about 39% of the adult population had a BMI 
in the overweight range, and 13% had obesity, and just over 18% of children and 
adolescents aged 5-19 years had overweight or obesity. A systematic analysis 
published in the Lancet 2014 on the global prevalence of obesity and overweight 
between the years 1980 and 2013, estimated that the number of individuals with 
overweight and obesity has increased from 921 million in 1980 to 2.1 billion in 
2013 worldwide (Ng et al., 2014). In Scotland, the 2017 Scottish Health Survey 
showed that 65% of adults age 16 and above were overweight, and of this, 29 % 
were obese (Scottish Government, 2017). Moreover, the Scottish Government 
suggests that the prevalence of adult obesity could reach over 40% by the year 
2030 (Scottish Government, 2010). It was a problem in the high income countries 
but now it expanded to middle and low income countries too (World Health 
Organization, 2018).  
All these data showed that the worldwide prevalence of obesity has almost tripled 
since 1975 (Figure 1-1b), and this trend is projected to continue over the coming 
years. Despite the best intentions to overcome this problem, no country has been 
successful in reversing their rates of obesity.
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a. Obese adults, 2016 
 
b. Obese adults, 1975 
 
Figure 1-1: The differences in the global distribution of adults with obesity  
Global distribution of obese adults (18+ years) between the years 1975 and 2016.The definition of 
obesity based on body mass index (BMI ≥ 30). a. Map for the year 1975, b. map for the year 2016 
reproduced from (Ritchie & Roser, 2019) with permission. 
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1.1.3 Burden  
Obesity is the underlying cause of metabolic disturbances that lead to type two 
diabetes mellitus (T2DM), as well as being a risk factor for hypertension (HT), 
dyslipidaemias, non-alcoholic fatty liver disease (NAFLD), cardiovascular diseases 
(CVD), and cancer. These chronic conditions placed a massive burden on the 
health care system because of the increased health care costs and prolonged 
medical care. The WHO reported that 44% of the diabetes burden, 23% of the 
ischemic heart disease burden, and approximately 7 – 41% of certain cancer 
burdens are related to overweight and obesity (World Health Organization, 2014). 
The Emerging Risk Factor Collaboration (ERFC) individual participants meta-
analysis showed, in 221,934 participants with no baseline CVD and ten years of 
follow-up, that every increase of 1 standard deviation (SD) in body mass index 
(BMI) (4.3 kg/m2 increase) was associated with a 23% increased risk of CVD (95% 
confidence interval (CI): 1.17-1.29) after adjusting for age, sex, and smoking 
status (Wormser et al., 2011). Although this study concluded that adiposity indices 
[BMI, waist circumference (WC), and waist to height ratio (WHR)] are not essential 
predictors for use in CVD risk scores, as intermediate factors, they are strongly 
associated with these risk factors for other chronic conditions such as blood 
pressure, lipid, and diabetes. 
Obesity affects more than just health but also has a severe impact on economic 
development. In 2014, it was estimated that the global expenditure on obesity 
health care was $2.0 trillion, or 2.8% of the global gross domestic product (GDP) 
(Dobbs et al., 2014). In the United Kingdom (UK), the overall economic cost of 
obesity was estimated at £27 billion (Fenton, 2017). Moreover, there is an indirect 
hidden burden caused by obesity which is loss of work productivity because of sick 
leave, lower performance, permanent disability, and premature death (Goettler, 
Grosse & Sonntag, 2017).  
Finkelstein et al. showed that even a small reduction in obesity prevalence could 
save a lot in medical expenditure. They estimated that even a one percent 
reduction from the predicted obesity rate trend to 2030 would reduce medical 
spending by $84.9 ± $9.3 billion over two decades (Finkelstein et al., 2012). 
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1.1.4 Causes of Obesity 
The aetiology of obesity is complex and involves many factors that interact with 
each other such as dietary patterns, sedentary lifestyle, socioeconomic status, 
genes, and psychological profile. All these factors have participated in the 
dramatic global increase in obesity. Apart from a relatively small number of 
people with specific metabolic disorders, the fundamental cause of obesity is the 
“modern lifestyle” that encourages increased caloric consumption and discourages 
physical activity (Figure 1-2). The term “toxic environment” was suggested by 
Brownell and colleagues to describe a series of social and economic changes that 
have occurred and have led to the rising prevalence of obesity (Battle & Brownell, 
1996). The toxic environment promotes obesity by encouraging the consumption 
of excess calories through increasing meal portion size, the availability of pre-
packaged energy-dense food, and sugar-sweetened soft drinks. Also, this toxic 
environment encourages a sedentary lifestyle.  
Genes play a part in obesity as shown by a sub-population with a pre-existing 
genetic predisposition to excess fat accumulation (Walley, Blakemore & Froguel, 
2006). Researchers have identified genes with significant roles in obesity (Choquet 
& Meyre, 2011). These genes are mostly found within families or groups from the 
same ethnic background. The differences in how people respond to the same 
environment suggest that genes do play a role in the development of obesity. 
Wang and colleagues did a prospective cohort study to examine the interaction 
between adherence to a healthy dietary pattern and genetic predisposition to 
obesity (Wang et al., 2018). The authors assessed two large cohorts of United 
states of America (USA) health professionals (The Nurses’ Health Study and The 
Health Professionals Follow-up Study) between the years 1986 and 2006 including 
8828 females and 5218 males of European ancestry and were free from diabetes, 
cancer, or cardiovascular at baseline. Healthy dietary patterns were assessed 
using three dietary indices: The Alternate Healthy Eating Index 2010 (AHEI-2010), 
Dietary Approach to Stop Hypertension (DASH), and the Alternate Mediterranean 
Diet (AMED). The authors concluded that adherence to a healthy dietary pattern 
could attenuate the genetic association with weight gain, and it was stronger in 
participants with a higher genetic predisposition to obesity. 
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Figure 1-2: Causes of obesity 
Overweight, and obesity occurs when energy intake exceeds energy expenditure over an extended 
period. The rise in overweight and obesity prevalence must be explained by a combination of 
physiological and behavioural factors triggered by the changes in the food environment and the 
environmentally driven reductions in physical activity. Depending on the genetic susceptibility, age, 
and sex of individuals, such changes result in variable weight gain. 
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1.1.5 Body fat distribution 
In humans, adipose tissue is divided into two types according to their anatomical 
location: subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) 
(Figure 1-3). These regional differences are of physiological and pathological 
importance. 
1.1.5.1 Subcutaneous Adipose Tissue (SAT) 
The subcutaneous adipose tissue (SAT) is present as a continuous layer beneath 
the skin (Arner, 1997). It accounts for about 80% of body fat in a healthy person. 
SAT represents the normal body storage for excess energy intake (Drolet et al., 
2008; Ibrahim, 2010). Some evidence suggests that excess fat in SAT results in 
fewer health complications (Fox et al., 2007). 
1.1.5.2 Visceral Adipose Tissue (VAT) 
Visceral adipose tissue (VAT) is located inside the thorax (mediastinum) and 
abdominal cavity surrounding the inner organs in distinct areas: omental, 
mesenteric, perirenal, retroperitoneal, parametrial, periovaric, epididymal, and 
perivisceral. Visceral adipose tissue accounts for up to 10 – 20% of total fat in 
healthy men and 5 – 8% in women and this increases with age in both sexes 
(Karastergiou et al., 2012; Wajchenberg, 2014). Accumulation of fat in this area 
is considered an independent risk factor for T2DM (Neeland et al., 2012) and leads 
to metabolic consequences of obesity (Matsuzawa, Funahashi & Nakamura, 2011). 
1.1.5.3 The differences between SAT and VAT 
Subcutaneous and visceral adipose tissue differ in several aspects, including 
adipocyte size, adipokines secretion, lipolytic activity, vascularity innervation, 
and receptors (Wajchenberg, 2000). These differences are more pronounced in 
obesity. For example, adipokine expression and secretion is different between 
the two depots. VAT is more infiltrated with macrophages and lymphocytes than 
SAT in patients with obesity (Lesna et al., 2016). As such, leptin and adiponectin, 
metabolically beneficial adipokines, are secreted in higher amounts from SAT 
(Lihn et al., 2004; Sarr et al., 2017), whereas pro-inflammatory adipokines such 
as monocyte chemotactic protein-1 (MCP-1), interleukin-1β (IL-1β), and 
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interleukin-6 (IL-6) are more highly secreted from VAT (Bruun et al., 2005; 
Rakotoarivelo et al., 2018). Additionally, adipokines produced by VAT are 
secreted directly into the portal vein whereas adipokines produced by SAT are 
secreted into the circulation. Moreover, VAT is more sensitive to the lipolytic 
effects of catecholamines, which provide a large amount of free fatty acids 
(Wajchenberg, 2000). 
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Figure 1-3: Location of visceral and subcutaneous fat deposits; reproduced with permission 
from (Lipman, 2009).  
Visceral adipose tissue (VAT) is located inside the thorax (mediastinum) and abdominal cavity. 
Subcutaneous adipose tissue (SAT) is located as a continuous layer underneath the skin. 
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1.1.5.4 Sex differences in body fat distribution 
Sex differences in fat distribution and associations with metabolic health are well 
established, but the biological foundations of these associations remain poorly 
understood (Karastergiou et al., 2012; Palmer, 2013; Kautzky-Willer, Harreiter & 
Pacini, 2016). They are determined by a complex interaction of hormones, genes, 
and environment. Generally, for the same BMI, females typically present with 
higher body fat compared to males. Additionally, body fat distribution is different 
between males and females (Chang, Varghese & Singer, 2018). Females tend to 
store fat on hips, thighs, and buttocks, in the subcutaneous area, giving them a 
pear shape, also known as gynoid obesity (Figure 1-4a). Males accumulate fat 
predominately in the abdominal region, mostly in the visceral area, giving them 
an apple shape, also referred to as android obesity (Figure 1-4b). These 
differences in body distribution are also observed in lean males and females. 
On the contrary, these differences in body fat distribution tend to disappear with 
age. As they age, both males and females tend to store fat more in the abdominal 
area with females developing more android obesity, particularly after menopause 
(Demerath et al., 2007). In addition, hyperandrogenism in females with polycystic 
ovary syndrome (PCOS) is frequently associated with increased abdominal fat 
(Carmina et al., 2007). All the above shows the importance of sex hormones in 
body fat distribution. The factors and mechanisms that direct this sexual 
dimorphism in body fat distribution are critical to the understanding of metabolic 
consequences of obesity. 
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Figure 1-4: Gender differences in body fat distribution 
a. Females body store fat on hips, thighs, and buttocks, in the subcutaneous area, giving them a 
pear shape, also known as gynoid obesity. b. Males accumulate fat mostly in the abdominal region 
in the visceral area, giving them an apple shape, also referred to as android obesity. 
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1.1.6 Assessment and diagnosis 
Although the excess fat mass in obesity is associated with many diseases (Smith & 
Ravussin, 2002), studies have shown that the distribution and function of the fat 
mass are considered to be the major causal factor. Therefore, it is crucial to 
accurately identify people who are at risk and to estimate the level of the risk not 
only for the individual but also at the population and policy levels. Human body 
fat can be quantified in several ways, varying in complexity and ease of use. 
Several methods have been suggested to measure the degree of obesity, fat mass, 
and distribution. They can be categorised into two types: direct or indirect body 
fat estimation. Each method has advantages and disadvantages, and the method 
to be used will depend on the aims and circumstances of a particular exercise. 
Most of the time, combined methods are used to estimate the level and 
distribution of adiposity. 
1.1.6.1 Indirect body fat measurements 
Indirect methods provide estimates or indices of body composition based on 
results from direct or criterion methods. Indirect methods include anthropometry 
and bioelectrical impedance analysis (BIA). This type of measurements depends 
on biological interrelationships among direct or criterion measured body 
components and tissues and their distribution among normal individuals. As a 
result, indirect methods tend to have larger predictive errors than direct methods 
and are affected by sample specificity and disease conditions. 
Body mass index (BMI) 
Body Mass Index (BMI) is the most popular tool to estimate obesity and overweight 
in adults. Both the World Health Organization (WHO) and the National Institutes 
of Health (NIH) uses BMI for the classification of overweight and obesity. It has the 
advantage that a subject’s height and weight are easy, non-invasive, and 
inexpensive to measure, which makes it a good measure of general adiposity in 
epidemiological studies. The BMI is calculated using the ratio of weight divided by 
the square of height (Kg/m2). Table 1-1 shows the classification of overweight and 
obesity by BMI based on the WHO guidelines (World Health Organization, 2017). 
The healthy range for adults is between 18.5 and 24.9. A BMI range between 25 
and 29.9 is defined as overweight, and obesity is defined as BMI of 30 and higher. 
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Obesity is further classified into three categories: class I (30-34.9), class II (35-
39.9), and class III (≥ 40). Since extreme obesity is spreading worldwide, 
researchers have further divided class III obesity into two categories: super obesity 
(50-59) and super-super obesity (≥ 60) (Laghi, 2018). Large scale prospective 
studies have shown that high adiposity measured by body mass index (BMI) is 
associated with increased risk of all-cause mortality (Gonzalez et al., 2011; Aune 
et al., 2016). 
Although BMI is one of the most commonly used anthropometric measurements to 
assess adiposity, it has its limitations. Body mass index uses total body weight and 
does not distinguish between lean and fat mass, providing no information about 
body fat distribution (Adab, Pallan & Whincup, 2018). Additionally, the cut-off 
points used to diagnose overweight and obesity are assumed to be independent of 
factors such as age, sex, race/ethnicity, and body composition all of which are 
known to affect body fat (Zhu & Leung, 2015; Zhu et al., 2017; Park et al., 2015).
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Table 1-1: Classification of overweight and obese adults by BMI using the WHO guidelines 
(World Health Organization, 2017)  
Category  BMI (Kg/m2)  
Underweight < 18.5 
Normal 18.5 – 24.9 
Overweight 25 – 29.9 
Obesity class I 30 – 34.9 
Obesity class II 35 – 39.9 
Obesity class III ≥ 40 
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Waist circumference (WC) 
Waist circumference (WC) is a non-direct, simple, inexpensive, and yet effective 
tool for assessing central obesity. Studies have shown that it correlates well with 
abdominal obesity assessed by imaging methods (Harrington et al., 2013), and is 
highly associated with type 2 diabetes (T2DM) (Wahrenberg et al., 2005; Feller, 
Boeing & Pischon, 2010), cardiovascular diseases (CVD)(Yusuf et al., 2005; De 
Koning et al., 2007), and mortality (Cerhan et al., 2014). Different measurement 
locations have been proposed in the literature for measuring WC (Ross et al., 2008; 
Seimon et al., 2018). Ross et al. did a systematic review of 120 studies (236 
samples) to determine whether measurement protocol influenced the relationship 
of WC with morbidity of CVD and T2DM and with mortality from all causes and 
from CVD. The result of the study suggested that WC measurement protocol has 
no substantial influence on the association between WC and all-cause of mortality, 
CVD, and diabetes at the population level (Ross et al., 2008). Although measuring 
WC at some of these positions require more skills, using bony structures as a stable 
landmark that are not affected by changes in weight is easier and more accurate 
than using the umbilicus or minimal circumference (Ma et al., 2013). Both the 
World Health Organization (WHO) and the National Institutes of Health (NIH) use 
bony structures in measuring WC. WHO recommend using the midpoint between 
the lowest rib and the iliac crest while the NIH protocol recommend using the 
highest point at the iliac crest (Figure 1-5).  
Selection of the most optimal cut points for WC values to predict cardiometabolic 
risk is sophisticated because they are likely to be influenced by age, sex, 
race/ethnicity, BMI, and other factors. Also, WC may over or under evaluate the 
risk for tall and short individuals with similar WC. In 2005, the International 
Diabetes Federation (IDF) proposed ethnic and sex values for WC (Table 1-2) 
(Zimmet, Alberti & Serrano Ríos, 2005).
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Figure 1-5: Waist circumference measurement sites for men and women per WHO and NIH. 
Following the WHO protocol, the measure is taken midway between the highest point of the iliac 
crest and the bottom of the ribcage. Following the NIH protocol, the measure is taken at the highest 
point of the iliac crest reproduced from (Patry-Parisien, Shields & Bryan, 2012) with permission. 
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Table 1-2: Ethnic-specific values for waist circumference guidelines proposed by the IDF 
(2007) in which sex and ethnic-group (not a country of residence) specific (Alberti, 2007) 
Country/Ethnic Group Waist Circumference (WC) 
Europids 
Male 
Female 
≥ 94 cm 
≥ 80 cm 
South Asian 
Male 
Female 
≥ 90 cm 
≥ 80 cm 
Chinese 
Male 
Female 
≥ 90 cm 
≥ 80 cm 
Japanese 
Male 
Female 
≥ 90 cm 
≥ 80 cm 
Ethnic South and Central Americans 
Use South Asian 
recommendations until more 
specific data are available 
Sub-Saharan Africans 
Use European data until more 
specific data are available 
Eastern Mediterranean and Middle East (Arab) 
population 
Use European data until more 
specific data are available 
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Bioelectric Impedance Analysis (BIA) 
Bioelectric Impedance Analysis (BIA) estimate body composition by measuring the 
resistance of the body as a conductor to a minimal alternating electrical current. 
It gives an estimation for total body water (TBW), fat-free mass (FFM), and fat 
mass (FM). BIA is widely used because it is affordable, portable, and easy to use. 
Besides, it provides instant results and is risk-free for patients. The BIA 
measurements depend on the tissue, water and electrolyte content which are 
affected by age, sex, ethnicity, disease state, level of fatness, physical activity, 
nutrition states, hydration levels, phase of the menstrual cycle, and underlying 
medical conditions (Dehghan & Merchant, 2008). In order to be reliable, BIA 
requires different equations to be used depending on ethnicity, age, gender, level 
of physical activity, and amount of body fat. While BIA measurements correlate 
with total abdominal fat (Browning et al., 2012), it cannot be used for measuring 
VAT. BIA is widely used, and it is suitable for giving a general estimation for body 
composition, but there are still doubts about its accuracy and precision (Franco-
Villoria et al., 2016). 
1.1.6.2 Direct body fat measurements 
Direct body fat methods measure the body composition, such as its density, or 
describe amounts and distributions of adipose tissues, muscle, and skeletal. Direct 
body fat measurements include computed X-ray tomography (CT), magnetic 
resonance imaging (MRI), and dual-energy X-ray absorptiometry (DEXA). 
Dual-Energy X-Ray Absorptiometry (DEXA) has a significant role in body fat 
assessment because it has higher accuracy and precision for the differentiation of 
lean and fat tissues (Duren et al., 2008). It uses low-level x-rays that pass through 
different types of tissues at different rates providing estimates of fat mass, fat-
free mass, and bone density. Since it requires very little radiation, this makes it 
suitable for repeated measures in clinical settings. Although DEXA has been shown 
to correlate strongly with VAT measured using CT (Micklesfield et al., 2012) and 
MRI (Neeland et al., 2016), there are certain manufacturers and models have been 
found to underestimate or overestimate body fat at low or high body fat 
percentage levels (Schoeller et al., 2005).  
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On the other hand, Computed Tomography (CT) scan and Magnetic Resonance 
Imaging (MRI) can distinguish the various adipose tissue depots in the body (Ross, 
2003) and also allow the measurement of fat in other non-adipose tissue 
compartments such as muscles and liver (ectopic fat deposits) (Wang, Chen & 
Eitzman, 2014). Both are considered as the gold-standard imaging techniques for 
body fat analysis (Seidell, Bakker & van der Kooy, 1990). The absence of radiation 
with MRI makes it more appropriate than CT, particularly when several measures 
are required overtime in the same individual or when populations such as children 
are being investigated. Although CT and MRI have the advantage of distinguishing 
subcutaneous and visceral fat, they have one limitation that is neither MRI nor CT 
can accommodate individuals with severe obesity. Due to their high cost, 
sophisticated equipment, and labor-intensive image analysis, the use of CT and 
MRI to assess adiposity are limited.  
1.1.7 Treatment  
Obesity is now considered a chronic disease that requires treatment. It is a 
complex problem with no single solution to apply to any individual. Also, there is 
convincing evidence showing that tackling obesity can improve or even reverse 
the co-morbidity associated with it. Therefore, the main goals for treating obesity 
is to provide a sustained weight loss, improve/remission of obesity-related 
comorbidities, as well as improve quality of life. 
Several strategies for weight loss have been introduced, including dietary changes, 
exercise, and physical activity, behavioural therapy, pharmacotherapy, and 
bariatric surgeries. Each approach has its advantages and disadvantages. Choosing 
the right plan depends on age, sex, degree of obesity, comorbidity, and personal 
preference. Besides, losing weight may require choosing one or a combination of 
these treatments 
Out of all the methods used to treat obesity and its comorbidity, bariatric 
surgeries are by far the most effective in obtaining substantial and durable weight 
loss leading to improvement and remission of obesity-associated diseases such as 
T2DM. Gloy V. L. et al. did a meta-analysis to quantify the overall effects of 
bariatric surgery compared with non-surgical treatment for obesity (Gloy et al., 
2013). The meta-analysis included 11 RCTs studies with 796 participants. The 
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results showed more body weight loss [mean difference −26 kg (95% CI= −31 to 
−21)] for the bariatric surgery treatment group compared with non-surgical 
treatment group and also improvements in metabolic parameters. Although 
bariatric surgery has shown positive outcomes regarding weight loss and reversing 
obesity-related comorbidities, the invasiveness, high financial cost, and long-term 
problems such as micronutrient deficiencies make it not a suitable option for all 
patients.  
Since the cornerstone approach for treating obesity is a modification of diet and 
exercise, several weight loss programs have been introduced that mimic the 
results of bariatric surgeries in reversing co-morbidities such as T2DM by achieving 
similar weight loss. For example, the Look AHEAD (Action for Health in Diabetes) 
study was a randomised control trial (RCT) designed to assess the effects of an 
intensive lifestyle intervention (ILI) on clinically important health outcomes in 
overweight/obese individuals with type 2 diabetes (Wadden et al., 2014).The 
study delivered a heavily supported programme combining physical activity and 
dietary advice, and achieved a mean weight loss of 8.6 kg. Remission was observed 
in 11.5% of participants after 1 year and 7.5% after 4 years. Although the study 
did not find significant differences in cardiovascular morbidity and mortality 
between study groups after 8 years of follow up, it did demonstrate significant 
differences in weight loss, maintenance, and improvements in many other aspects 
of diabetes morbidity (Salvia, 2017). Moreover, the Diabetes Remission Clinical 
Trial (DiRECT) was also a RCT conducted at primary care practices in the UK (Leslie 
et al., 2016). The study uses an intensive weight management program within 
routine primary care practice to treat T2DM. Participants were randomly assigned 
(1:1) to either a structured weight-management program (intervention) or best-
practice care in accordance with guidelines (control). The intervention group 
included withdrawal of diabetes and antihypertensive drugs, total diet 
replacement (825–853 kcal/day formula diet for 3–5 months), stepped food 
reintroduction (2–8 weeks), and structured support for long-term weight loss 
maintenance. The co-primary outcomes were a weight loss of at least 15 kg, and 
remission of diabetes, defined as Hemoglobin A1c (HbA1c) less than 6·5% (48 
mmol/mol) after the withdrawal of diabetes drugs at baseline (remission was 
determined independently at 12 and 24 months) (Figure 1-6). At 12 months, 24% 
of participants in the intervention group achieved a weight loss of 15 kg or more; 
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half achieved 10 kg loss. Diabetes remission was achieved in 46% of participants 
in the intervention group compared to 4% in the control group at 12 months [odds 
ratio (OR) 19·7, 95% CI 7·8–49·8; p < 0·0001]. The remission was closely related to 
the degree of weight loss maintained at 12 months, with 86% of participants 
achieving at least 15 kg weight loss (Lean et al., 2017). At 24 months, 11% of 
participants in the intervention group and 2% of participants in the control group 
had a weight loss of at least 15 kg (OR = 7·49, 95% CI= 2·05 to 27·32; p = 0·0023). 
Diabetes remission was achieved in 36% of participants in the intervention group 
and 3% of the control group (OR = 25·82, 95% CI = 8·25 to 80·84; p < 0·0001)(Lean 
et al., 2019). 
These data demonstrate the importance of weight loss in tackling the T2DM 
epidemic and suggests that substantial weight loss is an achievable target in at 
least some patients.
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Figure 1-6: Diabetes remission in the Diabetes Remission Clinical Trial (DiRECT)   
Primary outcomes and remission of type 2 diabetes in relation to weight loss at 12 and 24 months. 
Regression models adjusted for practice list size, study centre, and a random effect for practice. (A) 
The first co-primary outcome, the achievement of at least 15 kg weight loss, by the randomised 
group. (B) The second co-primary outcome, remission of type 2 diabetes (HbA1c <48 mmol/mol 
[6·5%] and off anti-diabetes drugs since baseline), by the randomised group. (C) Remission of type 
2 diabetes in relation to weight loss achieved (both randomised groups combined) reproduced from 
(Lean et al., 2019) with permission.
24 
 
1.2 Obesity and T2DM  
It is well established that obesity is a significant risk factor for developing T2DM, 
as well as being prevalent in those with T2DM. A meta-analysis published in 2010 
showed that the relative risk (RR) for developing T2DM in patients with obesity 
was 7.19 (95% CI: 5.74, 9.00) and 2.99 (95% CI: 2.42, 3.72) in patients who were 
overweight (Abdullah et al. 2010). Given the fact that the prevalence of obesity 
is rising globally, it is not surprising to see that the incidence of T2DM also rises 
sharply with this obesity epidemic. The relation between body fat and the risk of 
T2DM is complicated and not fully understood. Moreover, not all people with 
obesity are at high risk for T2DM (Hinnouho et al. 2015). 
It has been observed that around 30% of individuals with obesity maintain normal 
metabolic function “metabolically healthy obesity” (Freeman & Pennings, 2012; 
Hinnouho et al., 2015; Bell, Kivimaki & Hamer, 2014), whereas some individuals 
with mildly overweight or even healthy weight suffer from severe metabolic 
abnormalities (Bradshaw, Monda & Stevens, 2012; St-Onge, Janssen & Heymsfield, 
2004). Another extreme example is patients with lipodystrophy (a heterogeneous 
group of rare disorders characterised by the generalized or partial absence of 
adipose tissue). These patients suffer from severe insulin resistance (IR), 
hyperlipidemia, fatty liver, and diabetes despite the lack of adipose tissue 
(Bindlish, Presswala & Schwartz, 2015). Although the concept of metabolically 
healthy obesity is controversial (Iliodromiti et al., 2018), all these observations 
show that there is much more than just total fat gain that can explain this relation. 
So far, three components have been identified that can explain the relationship 
between obesity and T2DM: body fat distribution, inflammation, and insulin 
resistance. 
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1.2.1 Body fat distribution 
More than 60 years ago, Professor Jean Vague from the University of Marseille in 
France was the first to propose that body fat distribution was a better predictor 
for obesity complications than excess fat mass. He suggested that although 
females usually have twice the fat levels as males, they live longer with less 
morbidity from the metabolic complications of obesity (Vague, 1947). Vague used 
the term "android obesity" to define the pattern of fat distribution mostly 
characterised by an accumulation of adipose tissue over the trunk whereas he 
referred to the lower body fat pattern commonly found in women as "gynoid 
obesity" where adipose tissue accumulates mostly around the hips and thighs. He 
classified android type as high-risk obesity and gynoid type as low-risk obesity. 
These remarkable clinical observations did not receive immediate attention from 
the medical community. 
1.2.1.1 Fat distribution and T2DM 
Several extensive imaging studies have shown the importance of fat distribution 
in assessing metabolic abnormalities. In that regard, a large epidemiological study 
using data from the Framingham Heart Study (FHS) showed that in 3093 
participants who underwent CT scan to assess SAT and VAT and without diabetes, 
the odds ratio (OR) for insulin resistance per 1 SD increase in SAT was 2.5 (95% CI: 
2.2 – 2.7; P < 0.0001), whereas the OR for insulin resistance per 1 SD increase in 
VAT was 3.5 (95% CI: 3.1 – 3.9; P < 0.0001) after adjusting for age, sex, smoking, 
alcohol, menopausal status, and hormone replacement therapy. These results 
demonstrate that both SAT and VAT were correlated with insulin resistance, but 
the correlation with VAT was stronger (Preis et al., 2010). In contrast, McLaughlin 
et al., demonstrated that after adjustment for BMI, VAT was associated with 
insulin resistance while SAT was protective against insulin resistance - a 1 SD 
increase in SAT mass decreased the odds of insulin resistance by 48%, whereas a 1 
SD increase in VAT mass increased the odds of insulin resistance by 80%. The study 
included 115 healthy, overweight, or moderately obese adults, and CT scans were 
used to quantify body fat distribution. Moreover, a cross-sectional study using data 
from the Dallas Heart Study (DHS) showed that among the 954 participants with 
obesity, VAT was associated with an adverse metabolic, dyslipidemic, and 
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atherogenic obesity phenotype while, SAT was associated with a more benign 
phenotype (Neeland et al., 2013). 
The relation of body fat distribution and IR was further supported by the surgical 
removal of visceral adipose tissues in both animals and humans (Gabriely et al., 
2002; Thörne et al., 2002). By contrast, surgical removal of SAT with liposuction 
showed no significant improvement in obesity-associated metabolic abnormalities 
(Klein et al., 2004).  
1.2.2 Inflammatory Hypothesis of Obesity 
Obesity is associated with a particular type of inflammation referred to as chronic 
low-grade systematic inflammation. This type of inflammation is characterised by 
increased infiltration of immune cells into adipose tissue and a modest increase 
in circulating pro-inflammatory cytokines with the absence of clinical signs. 
Despite its much lower intensity compared to acute inflammation, the stimulus of 
chronic inflammation persists, causing a profound effect on the body metabolic 
pathways. The trigger of this type of inflammation in obesity is not precisely clear, 
but it is thought to be related to the storage of excess amount of fat causing 
hypertrophy and necrosis of adipocytes leading to a significant alteration in the 
immune cells population in adipose tissue (Neels & Olefsky, 2006).  
Obesity-induced systemic inflammation is believed to originate mainly in adipose 
tissue (Mraz & Haluzik, 2014). Adipose tissue inflammation is characterised by a 
significant increase in macrophages and, to a lesser extent, other immune cells 
(Wensveen et al., 2015). Macrophages are the largest subpopulation of adipose 
tissue immune cells. Their function is to maintain adipose tissue homeostasis by 
patrolling for pathogens, eliminating dead cells, and resolving inflammation. They 
can change their phenotype according to the changing environment, from anti-
inflammatory to pro-inflammatory type (Boutens & Stienstra, 2016). Adipose 
tissue macrophages (ATM) are found in both lean and obese (subjects), but they 
differ in number, localisation, and inflammatory status (Figure 1-7). In lean 
subjects, ATM makes up approximately 5 – 10% of the total number of cells and 
are distributed throughout the adipose tissue (AT), expressing fewer inflammatory 
properties. Whereas in subjects with obesity, ATM can be as high as 50% of the 
total number of cells mostly located around dead adipocytes forming crown-like 
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structures (CLS), while displaying profound pro-inflammatory features (Weisberg 
et al., 2003; Lumeng et al., 2007). The increasing number of macrophages is 
because of the production of inflammatory adipokines such as monocyte 
chemoattractant protein-1 (MCP-1) by the resident macrophages attracting more 
blood monocytes into the stromal vascular fraction of adipose tissue (Boutens & 
Stienstra, 2016). The physiological role of recruited macrophages is probably to 
clear dead adipocytes (Rutering et al., 2017). Macrophages recruitment result in 
a pro-inflammatory state leading to secretion of many cytokines including tumour 
necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) and 
recruit more immune cells in adipose tissue. All these cytokines contribute to local 
and systematic low-grade inflammation.  
C-reactive protein (CRP) is a nonspecific acute-phase reactant and a sensitive 
marker of systemic inflammation that is synthesised by the liver in response to IL-
6 stimuli. The high concentration of CRP has been linked to many disease states, 
including T2DM (Wang et al., 2012). Extensive cross-sectional studies showed that 
CRP is positively associated with higher BMI, especially in patients with metabolic 
syndrome (Aronson et al., 2004; Ramdas et al., 2016). This was supported by a 
systematic review done by Selvin et al. to test if weight loss interventions are 
directly associated with a decline in CRP levels (Selvin, Paynter & Erlinger, 2015). 
The study included weight loss intervention studies (surgical, dietary, and 
exercise) from 1966 to 2006. They found that weight loss was associated with 
reduced CRP level (for each 1 kg, the mean change in CRP was – 0.13 mg/L). Also, 
a large cross-sectional study including 2410 patients with vascular diseases who 
had ultrasonography to analyse subcutaneous and visceral fat mass, showed that 
visceral fat is associated with increased plasma concentration of CRP (Faber et 
al., 2010). 
1.2.2.1 Inflammation and T2DM 
Low-grade chronic systematic inflammation found in obesity has been implicated 
in the pathogeneses of several diseases, including T2DM (Akash, Rehman & Chen, 
2013; Kohlgruber & Lynch, 2015). Researchers discovered that people with T2DM 
have elevated levels of inflammatory cytokines. These inflammatory cytokines 
contribute to the development of T2DM by altering insulin-signalling pathways and 
action (Chen et al., 2015). This was confirmed by data from epidemiological 
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studies demonstrating that increased levels of markers and mediators of 
inflammation correlated with the incidence of T2DM (Bertoni et al., 2010; 
Spranger et al., 2003; Herder, Carstensen & Ouwens, 2013). Furthermore, 
prospective studies have also confirmed and extended these findings by showing 
that participants who developed T2DM during the follow-up period had high levels 
of inflammatory markers at baseline compared to subjects who did not develop 
the disease (Freeman et al., 2002; Hu et al., 2004; Kolb & Mandrup-Poulsen, 2005; 
Wang et al., 2013a).  
The emerging role of inflammation in the pathogeneses of T2DM has led to a 
growing interest in targeting inflammation to improve, treat, and prevent the 
disease. Increasing evidence has suggested the possibility of targeting 
inflammation as a promising approach for the treatment of T2DM (Pollack et al., 
2016). 
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Figure 1-7: Functional differences between lean and obese adipose tissue.  
In lean adipose tissue (AT) promote anti-inflammatory polarisation of macrophages. Adipose tissue 
(AT) expansion during weight gain leads to recruitment of macrophages through a variety of signals. 
These macrophages predominantly localised around dead adipocytes forming crown-like structures 
(CLSs) around dead adipocytes. 
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1.2.3 Insulin resistance 
Insulin resistance (IR) is a pre-diabetes condition, characterised by failure of 
target organs, primarily the liver, muscle, and adipose tissue, to respond normally 
to insulin resulting in a compensatory increase in beta-cell insulin production and 
hyperinsulinemia. When increased insulin secretion is no longer enough to prevent 
hyperglycaemia, the subject progresses from insulin resistance to T2DM. The 
progression from IR to T2DM takes many years to occur. Several prospective human 
studies have highlighted the importance of insulin resistance in the pathogenesis 
of T2DM, where they showed that IR could be used as a predictor for the future 
development of T2DM. For instance, in the Whitehall II study, they followed up 
6538 British civil servants free of diabetes mellitus at baseline  for 13 years, those 
who developed diabetes had decreased baseline insulin sensitivity at 13 years 
before diagnosis and a significant reduction in insulin sensitivity during the past 5 
years compared with those who didn’t develop diabetes (Tabák et al., 2009).  
Despite the high number of studies on IR, its pathogenesis remains elusive. 
Obesity is a known risk factor for the development of insulin resistance. Several 
studies showed that insulin resistance (IR) is strongly associated with the 
metabolic disturbance that occurs in obesity, and probably it precedes their onset 
(Hardya, Czecha & Corvera, 2014). Although obesity and excessive insulin levels 
are associated conditions, whether obesity causes high levels of insulin or vice 
versa is not clear. However, it has been postulated that the association between 
obesity and insulin resistance is likely a cause and effect relationship (Kahn, Hull 
& Utzschneider, 2006). Others proposed that IR associated with obesity is a 
defence mechanism that protects critical tissues from nutrient excess induced 
metabolic dysfunction (Hoehn et al., 2009; Nolan et al., 2015). This was supported 
by human and animal studies, which indicated that weight loss or gain correlates 
closely with increasing or decreasing insulin sensitivity respectively (Yang et al., 
2015; Clamp et al., 2017). For example, in the Prevention of Diabetes and Obesity 
in South Asians (PODOSA) Trial the authors investigated the effect of a lifestyle 
intervention on cardiometabolic biomarkers in 151 South Asian participants who 
were at risk for developing T2DM (Welsh et al., 2016). After 3 years, there was an 
adjusted mean reduction of 1·44 kg (95% CI 0.18 to 2.71) in weight and 1.59 cm 
(95% CI 0.08 to 3.09) in waist circumference in the intervention, compared with 
control and every 1kg weight reduction during follow-up was associated with a 
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decrease in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (− 
4.5%, p < 0.001). Other studies have suggested that high concentrations of 
circulating insulin  (hyperinsulinemia) can lead to increased storage of fat leading 
to obesity and obesity-related conditions such dyslipidaemia, hypertension, and 
atherosclerosis (Castro et al., 2014). The relationship between obesity and IR is 
seen across all ethnic groups and is evident across the full range of body weights 
(Kodama et al., 2013). 
The presence of excess adipose tissue mass alone is not always responsible for the 
obesity-associated insulin resistance. In humans, the expansion of visceral adipose 
tissue depots is associated with IR, and many would argue that expansion of 
subcutaneous adipose tissue is associated with decreased risk for developing IR 
(Hocking et al., 2013; Shimizu, Yoshida & Minamino, 2015). McLaughlin et al. 
confirm this argument by studying 115 healthy adults who were overweight or 
moderately obese (McLaughlin et al., 2011). The results showed that VAT was 
higher in participants with insulin resistance and SAT and thigh fat were 
significantly lower compared to participants who were insulin sensitive. In logistic 
regression analysis, each SD increase in VAT increased the odds of being IR by 80%, 
whereas each increase in SAT decreased the odds by 48%; each increase in thigh 
fat decreased the odds by 59% and retained significance after adjusting for other 
depots. 
Furthermore, this observation was also described in animals. Moitra and co-
workers, who had developed transgenic fatless mice, found that fatless mice 
developed T2DM despite the absence of fat tissue in the body and became 
hyperinsulinemia and hyperglycaemic at one and four weeks of age, respectively 
(Moitra et al., 1998). Also, in adipose-specific GLUT4–knockout mice, disruption 
of insulin-stimulated glucose uptake by adipocyte was enough to cause peripheral 
insulin resistance and glucose intolerance but without changes in adipose tissue 
mass (Boucher, Kleinridders & Kahn, 2014).  
1.2.3.1 Measurement of Insulin resistance 
Glucose clamp technique has been considered as the gold standard method in the 
literature for measuring insulin resistance. It measures the amount of glucose 
necessary to compensate for increased insulin levels without causing 
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hypoglycaemia. However, the method is time consuming, expensive, labour 
intensive, technically difficult to perform and suitable only for studies with a small 
number of subjects.  
Homeostasis model assessment for insulin resistance (HOMA-IR), which 
was proposed in 1985 (Matthews et al., 1985), is a relatively simple 
mathematical index for assessing insulin resistance. It is based on the 
relationship of basal glucose and insulin levels which reflect the balance 
between hepatic glucose output and insulin secretion and is maintained 
by a feedback loop between liver and β cells(Wallace, Levy & Matthews, 
2004). The major advantage of HOMA-IR is that it requires only one draw 
of blood from a fasting patient. It does not require extensive technical 
expertise and constitutes a much lower cost compared with euglycemic 
hyperinsulinemia clamp. Thus, HOMA-IR is more practical for use in large 
scale epidemiological studies and for clinical situations. In 1998, Levy, 
Mathews and Herman developed a computerized model for HOMA-IR, 
which is commonly referred to as HOMA2 (Levy JC, Matthews DR, 1998) 
that is available for use by researchers online at: 
http://www.dtu.ox.ac.uk/index.htm?maindoc=/publications/ 
1.2.4 Adipose Tissue Expandability and Ectopic Fat Accumulation 
One theory that might explain the association between obesity and T2DM is the 
defect in adipose tissue expandability and ectopic fat accumulation (Figure 1-8), 
which includes all the three components mentioned above.  
Normally excess calories are well handled by SAT adipocytes. In prolonged positive 
energy balance conditions, excess energy is stored in SAT either by increasing: the 
number of adipocytes (hyperplasia) or the size of pre-existing adipocytes 
(hypertrophy). Although adipocytes can change their diameter 20-fold and their 
volume several thousand-fold (Guengerich et al., 2001), there is a limit to this 
expansion. The maximum volume an adipocyte can reach to maintain their normal 
function is called the critical cell size, which is different between the sexes, and 
it is genetically determined (De Ferranti & Mozaffarian, 2008). When the 
adipocytes become overburdened by the great excess of calories and their ability 
to expand becomes limited, an imbalance occurs leading to the release of non- 
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esterified fatty acids (NEFAs) and triglycerides (TAGs) into the circulation instead 
of being stored inside the adipocyte (Campbell P. J., Carlson & Nurjhan, 1994). 
Higher concentrations of circulating NEFAs and TAGs start to accumulate 
ectopically in non-adipose tissues such as skeletal muscle, liver, heart, pancreas, 
and VAT that normally contain only small amounts. These tissues are more 
susceptible to the toxic effects of this accumulation (lipotoxicity) as they are not 
designed to store large amounts of lipids (Schaffer, 2003). Numerous harmful 
effects have been associated with the unhealthy enlarged adipocytes, including 
inflammation, fibrosis, hypoxia, altered adipokines secretion, and mitochondrial 
dysfunction. 
The relationship between ectopic fat accumulation and metabolic abnormalities 
has been confirmed in many studies showing the presence of ectopic fat is 
associated with insulin resistance and T2DM. (Franssens et al., 2016; Targher, 
Marchesini & Byrne, 2016; Gaborit et al., 2015). The deposition of excess FFAs 
interferes with insulin signalling in several ways. In humans, increased plasma FFAs 
lead to intramyocellular lipid accumulation which plays a critical role in the 
pathogenesis of insulin resistance and type 2 diabetes (Shulman, 2000). 
Intracellular FFAs or their metabolites activate a serine/threonine kinase cascade 
that ultimately results in reduced insulin receptor substrate-1 tyrosine 
phosphorylation, reduced insulin receptor substrate-1- associated 
phosphatidylinositol 3-kinase activity and failure to promote translocation of the 
GLUT4 glucose transporter to the plasma membrane in response to insulin 
stimulation (Ragheb et al., 2010). Moreover, hypertrophic adipocyte and ectopic 
fat accumulation is associated with an infiltration of macrophages into the adipose 
tissue (Surmi & Hasty, 2008). This promotes  the increase secretion of several 
cytokines like IL-6, IL-8, and MCP-1 which have been shown to reduce both IRS-1 
and GLUT4 expression and induce insulin resistance (Gustafson et al., 2009).  
In addition, other studies showed that adipocyte hyperplasia protective against 
metabolic abnormalities (Hoffstedt et al., 2010; Kim et al., 2014). This was 
supported by studies done on individuals with metabolically healthy obesity where 
a higher ratio of small to large adipocytes were found in their subcutaneous 
abdominal adipose tissue and with the alterations in adipose tissue immune cells 
(Weyer et al., 2000; Klöting et al., 2010; Cotillard et al., 2014). 
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Moreover, a randomised control trial done using suction lipectomy to determine 
if surgical removal of fat is restored after one year in non-obese women, and lead 
to an anatomical redistribution of fat (Hernandez et al., 2011). The results showed 
that after one year, fat was restored and redistributed from the thigh to the 
abdominal area suggesting that peripheral fat storage may protect from increase 
fat in the central region.  
Taken together, these studies showed the significant role of SAT adipocyte 
expandability and its role in accommodating excess TAGs and defect in this role 
is likely to be an essential contributor to the development of metabolic 
dysfunction associated with obesity. 
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Figure 1-8: Adipose tissue expandability and ectopic fat accumulation.  
During chronic excessive energy intake and low physical activity, high nutrient flux into adipose 
tissue. Adipocytes respond by increasing their size (hypertrophy) or number (hyperplasia). Limited 
expandability of adipose tissue number through hyperplasia produce hyperplastic adipocyte, which 
becomes dysfunctional leading to inflammation, insulin resistance, and ectopic fat accumulation 
outside the SAT. All these factors contribute to the development of T2DM. 
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1.3 Circulating microRNAs and T2DM 
1.3.1 MicroRNA 
MicroRNAs (miRNAs) are a class of small, single-stranded, non-coding RNAs (20–25 
nucleotides long) found in the genomes of eukaryotic organisms. These appear not 
to be fragments of cellular debris but play a significant role in physiological and 
pathological mechanisms in our body (Deiuliis, 2015). MicroRNA regulate post-
transcriptional processes through silencing target messenger RNAs (mRNAs) either 
by inhibiting translation or by degrading the target mRNA (Filipowicz, 
Bhattacharyya & Sonenberg, 2008). They were initially discovered in 
Caenorhabditis elegans in 1993 (Lee, Feinbaum & Ambros, 1993). Later in 2000, 
the second highly conserved microRNA let-7 was discovered (Reinhart et al., 2000) 
and since then, many new microRNAs have been identified. According to the latest 
estimates, 2603 mature miRNAs have been discovered in humans 
(http://www.mirbase.org). Each microRNA has the potential to target and 
regulate several genes (Slack, Rupaimoole & Slack, 2017). Therefore, their 
involvement in biological processes is not surprising, and their dysfunction can be 
a sign of various diseases (e.g., cancer, cardiovascular diseases, and diabetes). 
Moreover, a study in mice showed that deletion of either Drosha or Dicer causes 
the loss of most miRNAs, leading to severe pathology (Bernstein et al., 2003) which 
emphasise the role of miRNAs in the development of diseases. 
1.3.2 Biogenesis of MicroRNA 
MicroRNA biogenesis is a complex, highly regulated molecular mechanism that 
involves multiple steps (Figure 1-9). The process of miRNA formation starts in the 
nucleus with the transcription of miRNA by RNA polymerase II or III from 
chromosomal DNA (intergenic or intragenic region) to produce hairpin-shaped 
primary miRNA transcripts (pri-miRNA). After that, pri-miRNA is processed by the 
Microprocessor complex, which consists of the RNase III enzyme Drosha and DGCR8 
(DiGeorge syndrome critical region gene 8), to produce a double-stranded stem-
loop structure called precursor miRNA (pre-miRNA). Then, the pre-miRNA is 
actively transported outside the nucleus by Exportin 5 (XPO5) into the cytoplasm, 
where it is further cleaved by the enzyme Dicer, which is another ribonuclease III 
enzyme, to produce a 22-nucleotide double-stranded miRNA duplex consist of the 
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mature miRNA and a complementary strand. Finally, the mature strand of the 
dicer duplex is loaded onto Argonaute proteins, forming RNA-induced silencing 
complex (RISC). The mature miRNA guides the RISC complex to complementary 
sequences within the 3' untranslated region (UTR) of target mRNA(s), leading to 
translational repression and/or transcript degradation (De Guire et al., 2013; 
Regazzi, Guay & Regazzi, 2013; Sebastiani et al., 2017). The other strand 
(complementary strand) is thought to be degraded normally in the cytoplasm 
(Ender & Meister, 2010). 
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Figure 1-9:  Biogenesis and release of miRNAs.  
1. Pre-miRNAs are generated in the nucleus by the ribonuclease III enzyme Drosha after cleavage 
of pro-miRNAs. 2. The pre-miRNAs are then transported in the cytoplasm through a process 
involving Exportin-5 and the GTP-binding protein Ran. 3. The pre-miRNAs are further cleaved by 
Dicer to yield 21–23 nucleotide duplexes. 4. One strand of the miRNA duplex can either associate to 
the RISC complex and guide translational repression of target mRNAs or be released by the cells. 
In the latter case, the mature miRNA binds to RNA-binding proteins such as 5. Argonaute-2, or 6. 
lipoproteins. Alternatively, the miRNAs can be loaded in 7. microvesicles formed by plasma 
membrane blebbing, or in 8. exosomes that are released in the extracellular space upon exocytic 
fusion of multivesicular bodies with the plasma membrane. Reproduced from (Regazzi, 2013) with 
permission. 
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1.3.3 Circulating MicroRNA 
MicroRNAs were thought to be exclusively intracellular until recent studies that 
showed miRNAs are also extracellular, being present in a cell-free circulating form 
in the bloodstream (plasma or serum) and other body fluids, such as milk, urine, 
and saliva (Mitchell et al., 2008). The detection of intact miRNAs in body fluids 
was surprising because usually RNAs in the extracellular environment are degraded 
by the high RNase activity. However, the discovery of many circulating miRNA in 
extracellular fluids suggests that they are protected from degradation through a 
protective mechanism. The mechanisms for the release of these miRNAs in the 
extracellular environment is not clear. MiRNAs circulate in different forms which 
can be roughly subdivided into vesicle-associated (exosomes, microvesicles, and 
apoptotic bodies) (Valadi et al., 2007; Zernecke et al., 2009; Sohel, 2016) and 
non-vesicle associated, with RNA-binding proteins (Argonaute 2)(Arroyo et al., 
2011) or high density lipoprotein complexes (HDL), Figure 1-9 (Vickers et al., 
2014). 
An essential feature of circulating miRNA is their remarkable stability which 
interested researchers to use them as biological biomarkers for disease. Studies 
have shown that circulating miRNAs remain stable even if they were exposed to 
severe conditions such as multiple freeze-thaw cycles, prolonged storage time, 
high or low pH, and even boiling (Gilad et al., 2008; Sohel, 2016). 
The discovery of circulating miRNAs was considered a major scientific 
breakthrough and since their discovery, a substantial body of evidence was 
introduced showing the potential use of these circulating miRNAs as diagnostic 
biomarkers for several diseases (De Guire et al., 2013; DiStefano & Gerhard, 2016; 
Mitchell et al., 2008; Regazzi, Guay & Regazzi, 2013; Creemers, Tijsen & Pinto, 
2012). For example, one of the most widely studied miRNAs to date is mir-122. It 
is highly expressed in liver tissue and has been considered as a promising 
biomarker of hepatocellular injury, hepatic biology, and liver diseases (Jopling, 
2012; Pirola et al., 2015; Musaddaq et al., 2019). 
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1.3.4 Circulating miRNAs as biomarkers for T2DM 
In recent years, the role of circulating miRNA in the pathophysiology of diabetes 
has been appreciated but it still not been fully explored.  Several circulating 
miRNAs have been found to be associated with the risk factors involved in T2DM 
pathogenesis, such as insulin resistance, β-cell dysfunction, and obesity.  
In 2010, Zampetaki and colleagues were the first groups to identify several 
circulating miRNAs that were related to T2DM (Zampetaki et al., 2010). They did 
a prospective study that included > 800 blood samples randomly selected from the 
Bruneck population (Bolzano Province, Italy). Five miRNAs (mir-15a, mir-28-3p, 
mir-29b, mir-126, and mir-223) were identified to be dysregulated in either pre-
diabetes or T2DM and non-healthy controls. 
In 2011, Kong L et al. found seven circulating miRNAs (miR-9, miR-29a, miR-30d, 
miR-34a, miR-124a, miR-146a, and miR-375) that were elevated in the serum of 
patients with T2DM compared to patients with pre-diabetes and individuals with 
normal glucose tolerance (Kong et al., 2011).  
In 2012, Karolina et al. studied circulating miRNAs present in the blood and 
exosomes of 265 patients with different health conditions associated with the 
metabolic syndrome (MetS) (Karolina et al., 2012). There was an upregulation of 
miR-27a, miR-150, miR-192, miR-320a, and miR-375 in both patients with T2DM 
and MetS. Also, there was a strong correlation between high fasting blood glucose 
and increased levels of miR-27a and miR-320a. 
In 2013, Pescador et al. investigated the expression of serum miRNA to determine 
whether miRNA expression was deregulated and if any observed deregulation was 
specific to either obesity or diabetes or both. They selected 69 participants and 
divided them into four groups: normal, healthy controls (n = 20), patients with 
T2DM (n = 13), patients with obesity (n = 20), and patients with T2DM and obesity 
(n = 16). The results demonstrated that the levels of circulating  miR-15b, miR-
138 and miR-376a in serum could be used to distinguish patients who have both 
obesity and T2DM from patients who only have obesity or only have T2DM 
(Pescador et al., 2013). 
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In 2014, a cross-sectional analysis was done by Ortega et al. were they identified 
10 circulating miRNAs (mir-140-5p, mir-142-3p, mir-222, mir-423-5p, mir-125b, 
mir-192, mir-195, mir-130b, mir-532-5p, and mir-126) that were dysregulated in 
the plasma of 48 patients with T2DM compared to 45 individuals with normal 
glucose tolerance (Ortega et al., 2014). They also did a randomised, double-
blinded, and placebo-controlled 3-month trial of metformin treatment on 35 
patients with T2DM. The results showed three circulating miRNAs (mir-140, mir-
222, and mir-192) of the ten identified circulating miRNAs shifted their 
concentration after treatment with metformin suggesting their potential use for 
T2DM management.  
In 2015, a meta-analysis was done by Zhu & Leung to identify potential miRNA 
biomarkers of type 2 diabetes. The meta-analysis identified 40 significantly 
dysregulated miRNAs in T2DM both cellular and circulating miRNAs. The authors 
reported eight circulating miRNAs (miR-103, miR-107, miR-132, miR-144, miR-142-
3p, miR-29a, miR-34a, and miR-375) as potential blood biomarkers (Zhu & Leung, 
2015). 
In 2016, a more extensive cohort study was done by Wang et al. consisting of 68 
patients with T2DM, 68 patients with T2DM-associated microvascular 
complications, and 68 controls.  They identified five circulating miRNAs (mir-661, 
mir-571, mir- 770-5p, mir-892b, and mir-1303) were significantly upregulated in 
patients with T2DM. Moreover, levels of these five miRNAs were markedly higher 
in patients with complications than those without complications. (Wang et al., 
2016). 
In 2017, a systematic review was published on the relationship between miRNAs 
and T2DM (He et al., 2017). The review included 59 independent studies, including 
a total of 2671 patients with T2DM and 2573 healthy controls. The samples 
included adipose tissue, islet, skeletal muscle, whole blood, PBMC (peripheral 
blood mononuclear cell), and serum and plasma. The authors identified 158 
dysregulated miRNAs associated with T2DM in all seven tissues included, and they 
revealed that several pathways related to T2DM may be targeted by these miRNAs. 
Out of the 158 miRNAs identified, 31 miRNAs were circulating in plasma or serum. 
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In 2018, Ma et al. investigated the relationship of circulating miRNAs with insulin 
sensitivity, as measured by the gold standard hyperinsulinemic-euglycemic clamp 
technique. The study included 81 patients without diabetes, sedentary, and 
weight-stable across a wide range of insulin sensitivities. The results showed that 
circulating mir-16, mir-107, mir-33, mir-150, and mir-222 were associated with 
insulin sensitivity and metabolic risk factors (Ma, Fu and Garvey, 2018). 
To date, the list of circulating miRNAs involved in the pathogenesis of T2DM is still 
expanding. However, individual studies are generally of very small size by modern 
epidemiological standards, reflecting difficulty in the measurement of miRNA at 
scale (Chapter 3.1.2). Although existing studies provide many novel insights into 
the potential aetiology of T2DM, they will be prone to small study bias. The critical 
question is whether changes in the expression of these miRNAs are specific for 
T2DM, which is an essential factor for a circulating miRNA to be a therapeutic 
target or a clinical biomarker. 
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1.4 Aim and objectives of this thesis 
This thesis aims to investigate the relationship between obesity, inflammation, 
and type two diabetes (T2DM) and gain a better understanding of how these three 
relate. I also aimed to identify putative circulating miRNAs as novel biomarkers 
for metabolic dysfunction. To fulfil these aims, I will used three studies with 
different designs and different population phenotypes data sets: 
1. Using the Carotid Atherosclerosis: MEtformin for insulin ResistAnce 
(CAMERA) study (Preiss et al., 2014) which is a randomised, placebo-
controlled double-blinded trial. Participants were without diabetes, had 
large waist circumferences and coronary heart disease (CHD). Plasma 
samples will be used for: 
a) To develop a reliable and reproducible protocol for optimal extraction, 
quantification, and analysis of miRNA expression in human plasma 
samples that can be implemented in a large-scale study. 
b) Investigation in a cross-sectional analysis of the association of the 
expression of targeted circulating miRNAs with: 
i. Anthropometric biomarkers including weight, BMI, waist, and 
body fat.  
ii. Insulin sensitivity biomarkers including fasting blood glucose 
(FBG), insulin, Homeostasis model assessment of insulin 
resistance (HOMA-IR), HbA1c, and adiponectin.  
iii. Liver enzymes including gamma glutamyl transferase (GGT) 
and alanine aminotransferase (ALT). 
iv. Inflammatory biomarkers including CRP and white blood cells 
(WBC) count. 
c) Exploration of the effect of randomisation to metformin on the 
expression of targeted circulating miRNAs. 
 44 
 
2. Using the UK Biobank, a large-scale prospective epidemiological study, I 
will investigate in a cross-sectional analysis: 
a) Different patterns of body fat distribution (anthropometrics 
measurements, bio-impedance measurements, DEXA measurements, 
and MRI measurements) in both sexes and their association with 
T2DM. 
b) The association between the body fat distribution measurements and 
WBC count. 
c) The association of WBC count with T2DM. 
d) Investigate whether WBC count is a link between adiposity and the 
development of T2DM. 
3. Using the SurgiCal Obesity Treatment Study (SCOTS) a prospective cohort 
study of patients undergoing bariatric surgical procedures in Scotland, I will 
evaluate the feasibility of the proposed study The REduction of Adipose 
Levels of Inflammation when Treating obesitY (REALITY). To do that I will: 
a) Asses patient’s recruitment, their willingness to participate and give 
both adipose tissue and blood samples. 
b) Determine the optimal method for collecting adipose tissue 
(RNALater vs snap freezing). I will compare between the two 
methods in terms of the amount of total RNA extracted, the 
expression of housekeeping genes (mir-103, mir-331, And RNU44), 
and the expression of the selected miRNAs (mir-222. Mir-221, mir-
192, mir-193b, mir-144, and mir-155). 
c) Examine the two types of controls to normalise the expression of 
circulating miRNAs. 
d) Measure the expression of the selected six circulating miRNAs in 
plasma samples. 
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e) Measure adipocyte diameter using semiautomated method. 
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2 GENERAL METHODS
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2.1 Introduction 
In this chapter, all the general methods, equipment, kits, and reagents used to 
produce this thesis are described. All analyses were carried out in the laboratory 
facilities of the Institute of Cardiovascular and Medical Sciences (ICAMS) at the 
University of Glasgow by the author, unless otherwise acknowledged. 
2.1.1 Studies used in this thesis 
2.1.1.1 The CAMERA Trial 
The Carotid Atherosclerosis: MEtformin for insulin ResistAnce (CAMERA) study 
(Preiss et al., 2014) was a randomised, placebo-controlled double-blinded trial 
done at the Glasgow Clinical Research Centre (Glasgow, UK) between the years 
2009 and 2012 prior to design of this thesis. Use of this study is therefore post-
hoc. The study was designed to assess the cardiovascular benefits of metformin in 
individuals without diabetes and with coronary heart diseases. I used baseline and 
18-month plasma samples from 154 participants. Details of the study are found in 
chapter 3 and 4. 
2.1.1.2 UK biobank 
UK Biobank is a unique large scale prospective epidemiological study, open to data 
access requests from bona fide researchers worldwide. The aim of the study was 
to improve, prevent, diagnose and treat a wide range of illnesses including cancer, 
heart diseases, and diabetes, providing unparalleled power and phenotyping in a 
single observational study. Baseline assessment recruited more than 502,000 
people between the years 2006 and 2010 (Sudlow et al., 2015). The imaging study 
began in May 2014 and aims to recall 100,000 participants for detailed imaging 
scans of vital organs (brain, heart, abdomen, bones, carotid artery, and body 
composition) as well as a repeat of the baseline measurements. The study included 
Body MRI scan, and DEXA scan of the whole body, in specific participant subsets. 
I used all the baseline and imaging study data in our study.  Details of the study 
are found in chapter 5. 
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2.1.1.3 The SCOTS study 
SurgiCal Obesity Treatment Study (SCOTS) is a prospective cohort study of 
patients undergoing bariatric surgical procedures in Scotland. The study recruited 
450 patients to assess medium term outcomes and complications of bariatric 
surgery. The patients are followed-up for 10 years post-bariatric surgery using 
multiple data collection methods. Five patients who were due to have bariatric 
surgery were included in our study (Logue et al., 2015). Details of the study are 
found in chapter 6. 
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2.2 MiRNA Isolation and Quantification 
2.2.1 MiRNA Extraction from plasma samples 
Extraction of miRNA was performed using the miRNeasy Mini Kit (Qiagen, Hilden, 
Germany Cat. No. 217004) which is designed for purification of total RNA, 
including miRNA and other small molecules, from cultured cells and both human 
and animal tissues. This kit combines phenol/guanidine-based lysis of samples and 
the silica membrane-based purification of total RNA.  
2.2.1.1 Extraction 
All work was done under a fume hood and on top of ice. 300 µL of plasma sample 
was separated into two 1.5 mL Eppendorf tubes (150 µL each tube). Five volumes 
(750 µL) of QIAzol Lysis Reagent (Qiagen, Hilden, Germany Cat. No.79306) was 
added to each tube and mixed by vortex until all precipitate disappeared. Tubes 
were then placed in the fume hood at room temperature for 5 minutes to ensure 
complete dissociation of nucleoprotein complexes. Chloroform (150 µL) was added 
next to all tubes containing the homogenate, mixed by vortex and allowed to stand 
for 3 minutes at room temperature. Following centrifugation for 15 minutes (8000 
G, ͶԨ), the upper clear aqueous phase was separated into two new 1.5 mL 
Eppendorf tubes (250 µL each), making a total of 4 tubes for each plasma sample. 
1.5 volume of 100% ethanol was added to each tube. One RNeasy Mini spin column 
was prepared for each sample by placing it into 2 mL collecting tube. All four 
tubes of the same sample were added to the same column. One by one, the 
samples were mixed by pipetting, collected (up to 700 µL) into the column, and 
centrifuged (8000 G, 4 minutes, at room temperature), with the flow-through 
being discarded. This was repeated three more times for the remainder of the 
samples. Buffers in the kit were prepared as instructed by the manufacturer. 
RNeasy Mini spin column was washed with 700 µL of RWT buffer and centrifuged 
(8000 G, 2 minutes, at room temperature). Flow-through was discarded. The 
column was washed again with 700 µL RPE buffer and centrifuged (8000 G, 2 
minutes, at room temperature). Flow-through was discarded. 500 µL of 75% 
ethanol was added onto the RNeasy Mini spin column and centrifuged (8000 G, 2 
minutes, at room temperature). The spin column was put into a new 2 mL 
collection tube and dried by centrifugation (8000 G, 5 minutes, at room 
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temperature). After that, the spin column was transferred onto a new 1.5 mL 
collection tube. 20 µL of RNase-free water was pipetted directly onto the spin 
column and centrifuged (8000 G, 2 minutes, at room temperature). Using the same 
flow-through, the previous step was repeated twice more to concentrate the RNA. 
The sample was kept on ice until nanodrop RNA quantification. 
2.2.2 MiRNA extraction from Adipose tissue 
MiRNAs were extracted from adipose tissue using the QIAGEN RNeasy Lipid tissue 
mini kit (QIAGEN, Crawley, UK, Cat. No. 74804).  
2.2.2.1 Homogenization of Adipose Tissue Using the Tissuelyser 
Adipose tissues were homogenized using the Tissuelyser (QIAGEN, Germany, 
Cat.No.85220). Approximately, 100 mg of adipose tissue was disruptive by rapid 
agitation in the presence of 5 mm mean diameter Stainless steel beads (QIAGEN, 
Cat.No.69989) and lysing buffer (1 mL of QIAzol).  
2.2.2.2 Extraction 
Following homogenization, 200 µL of chloroform was added. Mixture mixed 
thoroughly by vortex and samples spun at 12,000 g for 15 minutes at 4Ԩ. The 
aqueous layer (approximately 600 µL) was removed and placed in a fresh RNAse 
free tube. RNA was precipitated by addition of 70% ethanol and transferred to a 
RNeasy mini spin column. If necessary, samples were treated with DNase (See 
section DNase Treatment of RNA). Columns then underwent a series of washes to 
remove impurities before being eluted in 50 µL of RNase free H2O. RNA was stored 
at -80Ԩ. 
2.2.2.3 DNase Treatment of RNA 
Further DNA removal was necessary before analysis of miRNA by TaqMan qRT-PCR 
to remove DNA contaminants that can be detected during qRT-PCR and potentially 
cause experimental artefacts. DNase treatment was performed by incubation of 
samples in on-column DNase digestion set (QIAGEN, Cat.No.79254) according to 
manufacturer’s protocol. For each sample 10μl of DNase I stock solution was mixed 
with 70μl Buffer RDD, applied to column and allowed to incubate at room 
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temperature for 15 minutes. This step was performed during the first column wash 
of the miRNEasy protocol. Following DNAse treatment, the miRNeasy wash 
protocol was continued. 
2.2.3 Total RNA Quantification using Nanodrop  
The concentration of RNA in each sample was measured using the Nanodrop 1000, 
micro-volume ultraviolet-visible spectrophotometer (Thermo Fisher Scientific, 
Waltham, Massachusetts v3.7) with the ND-100 software per the manufacturer’s 
instructions. 2 µL of nuclease free water was carefully pipetted onto the end of a 
fibre optic cable/receiving fibre and used as a blank. Subsequently, 2 µL of each 
sample was measured in a similar method to the water blank. Concentration 
measurements were recorded, along with the ratio of sample absorbance 
(260/280, 260/230) to check for nucleic acid purity as well as protein and phenol 
contamination. Measurements were taken twice and stored atെͺͲԨ.  
2.2.4 MiRNA Reverse Transcription 
MiRNA reverse transcription (RT) was done to generate complementary DNA 
(cDNA) from an RNA using the enzyme Reverse transcriptase. Taqman MicroRNA 
Reverse Transcription Kit was used (Applied Biosystems, Foster City, California, 
no.4366596) as per manufacturer’s protocol. Primers for each miRNA (RT, 5X) 
were used to prepare master mix.  
Samples Preparation 
A total of 9 ng miRNAs is required. The dilution was made using nuclease free 
water (Appendix 1). A fixed volume of 5 µL from the total RNA was used for the 
RT process.   
Master Mix Preparation 
One master mix was prepared for each miRNA primer. Each master mix contained 
dNTP (100 mM), multiscribe, 10X RT buffer, RNase inhibitor, nuclease free water 
and the specific miRNA primers allocated (5X, RT) (Appendix 1). The master mix 
was mixed and kept on ice.  
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Protocol 
A 96-well plate was prepared, marked and kept on ice. 4.5 µL of diluted RNA 
samples were added to each well as allocated and the plate was spun. 3 µL of the 
master mix was added to each well and the plate was spun. The plate was sealed 
with adhesive sealing sheets and ran on a Polymerase Chain Reaction (PCR) block 
for RT reaction. Thermal cycle conditions were: ͳ͸Ԩfor 30 mins, ͶʹԨ for 30 mins, ͺͷԨ for 5 mins, ͶԨ for 30 mins and then held at ͳʹԨ. The plate was kept in െʹͲԨ until used for QPCR. 
2.2.5 Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR) 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using 
the 2X Universal TaqMan Master Mix (Applied Biosystems, Foster City, California) 
and TaqMan primers for each miRNA (TM, 20X). Samples were running in duplicate 
including the positive and negative QC. 
Plate Preparation 
The 96-well cDNA plate was taken out from െʹͲԨ and kept on ice until thaw. 7.5 
µL RNase free water was added into each well and spun at 4Ԩto bring everything 
down.  
Master Mix Preparation 
Calculations of the amount of master mix required is shown in (Appendix 2). One 
tube was prepared for each miRNA primer. To each tube, 2X TaqMan master mix, 
20X primers/probes, and RNase free water was added. 
Protocol 
An MicroAmp optical 384-well reaction plate was prepared, marked, and kept on 
ice.1.4 µL of the cDNA product was pipetted on the side of the well and 
centrifuged. After that, 8.6 µL of master mix was pipetted into each well, 
centrifuged and sealed with an optical adhesive lid.  
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Quantitative real-time PCR (qRT-PCR) was performed using the QuantStudio 7 Flex 
Real-Time PCR System (Applied Biosystems, Foster City, California V1.3). The 
Thermal cycling conditions were 95Ԩfor 10 mins., followed by 40 cycles of 95Ԩ 
for 15 s and 60Ԩ for 60 s. For each miRNA, four runs of qRT-PCR were done 
including quality control (QC) sample and negative control sample (both in 
duplicate). Data were analysed with the QuantStudio 7 software (Applied 
Biosystems, Foster City, California V1.3) to determine the threshold cycle (Ct). 
2.3 Normalisation and Control for qRT-PCR Data 
To produce reliable qRT-PCR data, corrections of variation must be made to 
miRNAs expression analysis, to adjust for reaction efficiency. This is an important 
step that needs to be done before interpreting qRT-PCR results (Hellemans & 
Vandesompele, 2011). There are two sources of variation, biological and technical 
variation. Our aim was to measure the biological differences and reduce the 
technical effect, which can be introduced at any steps from sample collection to 
miRNA amplification.  
The optimal method for normalisation is to use a theoretical constantly expressed 
housekeeping gene, because they represent endogenous controls that are affected 
by the same source of variability as the target gene. This method has been widely 
used for measuring the expression of mRNA and miRNA extracted from tissues and 
cells. However, using this method on plasma/serum samples is challenging 
because very few studies are available. Endogenous controls are frequently 
selected based on empirical observations, with little biological insight. Different 
studies reported different miRNA reference genes (Moldovan et al., 2014; Shaffer, 
Schlumpberger & Lader, 2012). For choosing an appropriate endogenous control, 
it is important to first check whether the selected miRNA expression is stable 
between the samples before using it as a normaliser. Also, one makes sure that 
the chosen miRNA is not affected by diseases or clinical interventions, such as 
medications, which may vary between patients or between samples in an 
intervention study. Use of an exogenous control means one does not have to worry 
about biological effects, but the introduction of the exogenous control is subject 
to its own potential for technical errors. 
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To verify if the qPCR experiment passes initial quality control, technical replicates 
of the controls and samples must be within 0.5 cycles (1 cycle represent a doubling 
of material). This is achieved by calculating the standard deviation (SD) of 
triplicates measurement of the same sample. The SD should not exceed 0.25 
(Institute of research in immunology and cancer University of Montreal, 
n.d.)(Institute of research in immunology and cancer University of Montreal, n.d.) 
(http://genomique.iric.ca/resources/files/Understanding_qPCR_results). 
Moreover, a random plasma sample was used as a quality control sample to try to 
control for variation between runs.  
Mean and standard deviation (SD) were calculated for endogenous control, 
exogenous control, and QC sample. In addition, the coefficient of variation (CV) 
for both intra and inter assay were calculated for all the three controls. Although 
calculating CV is not generally used for evaluating precision of qRT-PCR results, 
this was our attempt to quantify error.  
2.3.1 Plasma samples 
For measuring miRNAs in plasma, I evaluated both types of controls: endogenous 
control and exogenous control.  
2.3.1.1 Exogenous Control 
A miRNeasy Serum/Plasma spike-in control (Qiagen, Hilden, Germany Cat. No. 
219610) was used. It is a Caenorhabditis elegans (C. elegans) mir-39 miRNA mimic 
and is supplied lyophilized at 10 pmol per tube (Appendix 3). Spike-in controls can 
be added to the sample in two ways: 1) before extraction, or 2) before 
transcription of RNA. Although the latter avoid differences in template quality and 
provide more stable results, I choose to spike-in the exogenous control before 
extraction to provide a more reliable estimate of the whole technical variability 
that maybe introduce at different steps. Also, the synthetic miRNA was added 
(spiked-in) after the addition of the denaturing agents (QIazol) to avoid its 
degradation by plasma RNase. A trial run was conducted using 8 random normal 
samples to test the stability of mir-39 and its reliability as a control. 
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2.3.1.2 Endogenous Control 
Mir-520d-5p was tested as a possible endogenous control since it was reported to 
be an excellent housekeeping control candidate for studies of plasma miRNA due 
to its consistent results and a very narrow standard deviation (Rice et al., 2014). 
A trial run was conducted using the same 8 random normal samples used in testing 
mir-39, to test its potential use as an endogenous control gene. 
2.3.2 Adipose samples 
Three housekeeping miRNAs were tested (mir-103, mir-331, and RNU44) which 
have been shown to be a stable miRNA endogenous control in adipose tissue 
(Neville et al., 2011; Kristensen et al., 2017). 
2.4 Circulating Adiponectin 
The plasma adiponectin concentrations were measured by Enzyme Linked 
Immunosorbent Assay (ELISA) Kit (Quantikine Human Adiponectin/Acrp30 
Immunoassay, Cat. No. SRP300). The assay employs the Quantitative sandwich 
enzyme immunoassay technique with a 96 well polystyrene microplate coated with 
a monoclonal antibody specific for human adiponectin globular domain (Figure 
2-1). 
The kit is designed to measure the amount of adiponectin in serum or plasma 
samples. The assay sensitivity is 2ng/mL without dilution of samples. Intra- and 
Inter coefficient of variation is 4.1% and 4% respectively at adiponectin 
concentration = 7 μg/ml.
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Figure 2-1: Sandwich ELISA reaction 
1.The capture antibodies are bound to the surface of each well. 2. The antigen-containing sample is 
added to the plate and captured by the bounded antibodies. 3. Specific antibodies are added and 
bind to the antigen hence the word sandwich. 4. Enzyme-linked secondary antibodies are added and 
bind specifically to the antibodies. 5. A substrate is added to be converted by the enzyme into a 
colour or fluorescent. 
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2.4.1 Adiponectin ELISA Method 
All samples were 100-fold diluted. Human adiponectin standards, substrate, and 
washing buffer were prepared according to the manufacture instructions. Initially, 
100 µL of assay diluent was added to each well. 50 µL of serially diluted human 
adiponectin standards and prepared quality control 1 and 2 (Cat. No. QC36, R&D 
System) were added in duplicate to the designated wells. Sequentially 50 μl of the 
unknown samples were added to the remaining wells of the microplate. The plate 
was covered with adhesive strip and incubated at room temperature for 2 hours. 
After that, plate was washed 4 times using 400 µL of wash buffer per well and 200 
µL of Human Adiponectin Conjugate was added to each well and incubated for 2 
hours. Then, the plate was washed and 200 µL of substrate was added and 
incubated for 30 minutes at room temperature protected from light. The reaction 
was stopped by adding 50 μl of the stop solution to each well. 
The optical density was read at 450 nm with wavelength correction set to 540 nm 
using SpectraMax 190 absorbance microplate reader (Molecular Devices, LLC). The 
concentrations of unknown samples were determined using a standard curve which 
was constructed by plotting the mean absorbance for each standard against their 
concentration using a log/log point analysis as shown in (Figure 2-2). 
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Figure 2-2: Adiponectin standard curve  
Standard curve for adiponectin is constructed by plotting the mean absorbance for each standard 
against their concentration using a log/log point analysis. 
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2.5 Statistical Analysis 
2.5.1 Cohort demographics and classical risk factors 
All continuous classical risk factor variables were tested for normality by visual 
inspection of their histograms and normal Q-Q plots. Descriptive statistics were 
expressed as mean ± SD for normally distributed variables, and median [and inter-
quartile range] for not normally distributed variables. Note that throughout the 
thesis, use of a “±” denotes a standard deviation after a mean, and use of a [range] 
after a number denotes a median and interquartile range. Non-parametric 
variables were normalized by log transformation to use parametric tests. 
Categorical variables were summarized as number (%). Comparison between mean 
values of continuous variable were evaluated using Student’s two tailed t test. All 
the statistical tests were performed using IBM SPSS (Statistical Package for Social 
Sciences) windows version 22 (SPSS Inc. Chicago, USA) and Microsoft excel 2016. 
The criterion for statistical significance was p < 0.05. As this is a hypothesis 
generating exploratory study, I did not employ any formal correction for multiple 
comparisons.  
2.5.2 RT-qPCR Data Analysis 
The Ct represents the number of cycles required to attain a threshold 
concentration for the miRNA of interest. Each PCR cycle increases the 
concentration 2-fold, and therefore the Ct value as a concentration is naturally 
expressed as log 2 and are therefore normally distributed. 
The mean Ct and standard deviation (SD) between the triplicate measures for 
controls and samples were calculated. The technical triplicates must be within 
0.5 cycles (1 cycle represent a doubling of material). The triplicate is valid when 
the SD is smaller than 0.25. If the SD is over 0.25, measurements were repeated. 
To measure the precision and repeatability of our RT-qPCR results, the coefficient 
of variation (CV) for both intra and inter assay were calculated for exogenous 
control (mir-39 spiked-in control), endogenous control (mir-520d-5p, mir-103, mir-
331-3p, and RNU44). Although calculating CV is not used for evaluating precision 
of qRT-PCR results, this was our attempt to quantify error. Intra-assay CVs of <10% 
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and Inter-assay CVs of < 15% are generally considered acceptable in most quality 
control settings outside of routine clinical biochemistry.  
2.5.3 Cross-Sectional Analysis 
Pearson correlation (r) was used to investigate the association of the six miRNAs 
expressions with markers of metabolic health using baseline samples. 
2.5.4 Relative Quantification method (RQ) 
The relative quantification (RQ) method was used to compare paired observations 
at different timepoints. It allows the quantification of the change in gene 
expression level of a target gene across two samples, in our case baseline and 18-
month samples. The results were expressed as fold change of expression level in 
the 18 months sample compared to the baseline sample. This is done by first, 
calculating the differences in Ct between the target miRNA with that of the 
spiked-in external control (mir-39) from the same sample (∆Ct). After that, the 
∆Ct was then used to calculate the ∆∆Ct (∆Ct baseline - ∆Ct after 18 months). 
Finally, RQ was calculated using the formula (2-∆∆Ct). RQ value is generally 
considered significant when there is a minimum of two-fold change in the 
established literature (Marabita et al., 2016).  
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3 CROSS-SECTIONAL ASSOCIATIONS OF 
CIRCULATING MIRNAS EXPRESSION WITH 
MARKERS OF METABOLIC HEALTH: CAMERA 
TRIAL
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3.1 Introduction 
Insulin resistance (IR) is a critical feature and major contributor to the developing 
of Type 2 diabetes (T2DM)(Ma, Fu & Garvey, 2018b). Although the cause of IR is 
still unknown, it is closely related to obesity, particularly central obesity 
(Westphal, 2008). Both central obesity and IR are signs of metabolic disturbance 
that proceed T2DM. Waist circumference (WC) is a convenient index for measuring 
abdominal obesity (Grundy et al., 2013). Besides, it is more strongly correlated 
with intra-abdominal fat content and has been used as a predictor for the 
prevalence or incidence of T2DM (Qiao & Nyamdorj, 2010; Siren, Eriksson & 
Vanhanen, 2012).  
Recently, circulating miRNAs have been proposed as new disease biomarkers that 
can help in the diagnoses, prognosis, and monitoring of several diseases. This was 
supported by a strong body of evidence showing that dysregulation of their 
expression was associated with several diseases (De Guire et al., 2013; DiStefano 
& Gerhard, 2016; Mitchell et al., 2008; Regazzi, Guay & Regazzi, 2013; Creemers, 
Tijsen & Pinto, 2012). Also, these circulating miRNAs are surprisingly stable and 
can resist aggressive physiological conditions such as extreme variations in pH, 
boiling, multiple freeze-thaw cycles, and extended storage, despite the presence 
of blood RNases. 
A meta-analysis published in 2015 (Villard et al., 2015) were the authors 
investigated circulating miRNAs for diagnosing obesity and T2DM in human. A total 
of 26 studies were included. These studies compared the expression of circulating 
miRNAs between two conditions (obese vs. controls, diabetes or pre-diabetes vs. 
controls) or the effect of lifestyle interventions (exercise, metformin treatment 
or bypass surgery) on their expression. Six studies compared miRNAs levels 
between subjects with obesity vs. subjects who were lean, eight studies compared 
patients with pre-diabetes vs. subjects who were control, and 14 studies 
compared subjects with diabetes vs. subjects who were BMI-matched and without 
diabetes. A total of 10 miRNAs were found to be altered in blood of patients 
suffering from T2DM (increased: mir-320a, mir-142-3p, mir-222, mir-29a, mir-27a, 
mir-375; decreased: mir-197, mir-20b, mir-17, mir-652) and 7 miRNAs in blood of 
subjects with obesity were identified (increased: mir-142-3p, mir-140-5p, mir-
222; decreased:mir-21-5p, mir-221-3p, mir-125-5p, mir-103-5p). Both patients 
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with obesity or T2DM had elevated concentrations of mir-142-3p and mir-222. This 
study suggested that a specific profile of circulating miRNAs could become a 
valuable biomarker to identify those who are at risk for developing T2DM. 
3.1.1 The CAMERA Trial 
The Carotid Atherosclerosis: MEtformin for insulin ResistAnce (CAMERA) study 
(Preiss et al., 2014) was a randomised, placebo-controlled double-blinded trial 
done at the Glasgow Clinical Research Centre (Glasgow, UK) between the years 
2009 and 2012. The study was designed to assess the cardiovascular benefits of 
metformin in individuals without diabetes. The primary outcome was carotid 
intima media thickness (cIMT), and the study was powered to detect that 
metformin had no effect on cIMT and little or no effect on several surrogate 
markers of cardiovascular disease. 
Caucasian ethnicity participants were recruited aged 35-75 on statins with proven 
coronary heart disease (previous acute coronary syndrome, coronary artery bypass 
surgery, or angiographically proven coronary heart disease), large waist 
circumferences (in agreement with the International Diabetes Foundation 
guidelines, ≥ 94 cm in males, ≥ 80 cm in females) (Alberti, Zimmet & Shaw, 2006), 
and prescribed a statin (type and dose were not adjusted).  
Exclusion criteria were diabetes or participants with either HbA1c ≥ 7% or fasting 
blood glucose (FBG) ≥ 7 mmol/L (participant with HbA1c of 6 - 6.9 and FBG < 7 
mmol/L at the screening had an oral glucose tolerance test; those with post-
challenge glucose of ≥ 11.1 mmol/L were excluded). Moreover, pregnancy or 
lactation, premenopausal women not taking hormonal replacement (daily oral 
contraception or regular injectable hormonal contraception were excluded from 
the study. Patients who had acute coronary syndrome within the previous 3 
months uncontrolled angina,  class 3 or 4 heart failure (according to the New York 
heart association functional classification), hepatic impairment, renal impairment 
(estimated glomerular filtration rate < 45 mL/min per 1.73 m2 at screening), 
hypersensitivity to metformin, acute illness (dehydration, severe infection, shock, 
acute cardiac failure), and suspected tissue hypoxia were also excluded.  
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Written informed consent was provided from each participant. The study was 
approved by the Medicines and Healthcare Products Regulatory Agency and West 
Glasgow Research Ethics Committee and done in accordance with the principles 
of the Declaration of Helsinki and good clinical practice guidelines. A total of 173 
participants were randomly assigned to metformin or placebo (1:1) on the CAMERA 
website and followed for 18 months (Figure 3-1). The randomisation sequence was 
generated independently by the Robertson Centre for biostatistics. All patients, 
investigator, trial staff, and statisticians were masked to treatment allocation.  
For the first week, participants were taken one tablet (850 mg metformin or 
placebo). Later, the dose was increased to 2 tablets daily (one with the morning 
meal and one with the evening meal). A total of 29 participants reduce their tablet 
intake to 1 per day (19 in the metformin group and 10 in the placebo group). After 
that, 15 participants were excluded from the study after primary outcome analysis 
(11 in the metformin group and 4 in the placebo group) leading to a total number 
of 158 participants (75 in the metformin group and 83 in the placebo group). 
Finally, 4 participants were excluded from our study because they didn’t have 
both baseline and 18-month plasma samples. 
3.1.1.1 Power calculation 
Assuming the minimum relevant difference to detect between metformin and 
placebo groups is 1dCt (a 2-fold change) with a dCt SD of 1.5 in each group, a 
sample size of 81 and 73 in each group gives 98% power with an alpha of 0.05. For 
dCt of 0.8 and 0.7 respectively, the power would be 91% and 82%. 
Samples from the CAMERA trial were used to conduct this study for several 
reasons. First, it included a large sample of participants (154). Second, 
participants were subjected to a strict inclusion and exclusion criteria. Third, well 
standardized approach to sample collection, processing, and storage. Finally, 
although the participants without diabetes, they were high risk participants 
(previous CHD and high WC) who will be good candidates for exploring the 
expression of circulating miRNAs. 
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Figure 3-1: CAMERA trial profile 
Illustration of baseline inclusion of participant blood samples in the miRNA study 
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3.1.2 MiRNA biomarker candidate selection to include in our 
study- A hypothesis-driven approach  
Large numbers of miRNAs were identified to be differentially expressed in 
metabolic diseases. Although there are high number of publications reporting 
different circulating miRNAs associated with cardiometabolic diseases, only a few 
of these miRNAs associations were reproduced across several studies. The reasons 
for this may be: 1) miRNA profiling is a multi-step process and there is no 
standardised protocol, each study uses different sample types, different collection 
methods and different methodologies, and thus come to different conclusions, 2) 
no gold standard control to normalize the expression of these circulating miRNAs, 
and finally, 3) most studies used a very small sample size which increases the risk 
of type 2 error.  
In order to make an evidence based informed decision as to which miRNAs to 
include in this study, A hypothesis-driven approach based on previously available 
evidence and not an exploratory approach was used. The reason for this because 
it is more focused, more efficient, require less time, and cheaper which makes it 
more suitable for large studies. This was done by performing a pseudo-systematic 
literature search of articles published in English from 2000 to 2016 using PubMed 
database. The key words for searching the database were: “miRNA”, “human”, 
“blood”, “insulin resistance”, “diabetes”, “adipose tissue”, and “obesity”. The 
yielded article abstracts were reviewed, focusing on studies of miRNA in blood 
samples. A candidate list of biomarkers was drawn up. A pragmatic decision was 
made to include six miRNAs, mir-222, mir-221, mir-144, mir-155, mir-192 and mir-
193b (Table 3-1) subjectively based on:  
1) greatest existing evidence that change in glycaemic control or BMI would 
influence their expression  
2) frequency of citation in the literature  
3) traded off with feasibility of technical completion 
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3.2 Hypothesis 
The expression levels of the chosen circulating miRNAs (mir-221, mir-222, mir-
192, mir-193b, mir-144, and mir-155) are associated with markers of metabolic 
disturbance including anthropometric measurements, glycaemic markers, and 
inflammatory markers. 
3.3 Aim 
1) To develop a reliable and reproducible protocol for optimal extraction, 
quantification, normalisation, and analysis of miRNA expression in human 
plasma samples that can be implemented in a large-scale study. 
2) Investigate cross-sectional associations of the six selected circulating miRNAs 
using baseline plasma samples from the CAMERA trial with: 
a) Anthropometric biomarkers including weight, BMI, waist, and body fat.  
b) Insulin sensitivity biomarkers including fasting blood glucose (FBG), insulin, 
Homeostasis model assessment of insulin resistance (HOMA-IR), HbA1c, and 
adiponectin.  
c) Liver enzymes including gamma glutamyl transferase (GGT) and alanine 
aminotransferase (ALT). 
d) Inflammatory biomarkers including CRP and white blood cells (WBC) count. 
3) Explore the potential usage of the selected circulating miRNAs as biomarkers 
for metabolic dysfunction.
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3.4 Methods 
3.4.1 Samples 
All the baseline Ethylenediaminetetraacetic acid (EDTA) plasma samples of the 
CAMERA trial (154 samples) were used in this study.  
3.4.2 Micro RNA Isolation and Quantification 
Details on RNA extraction and miRNA quantification can be found in the general 
method chapter 2. To summarise, plasma samples were defrosted, and then the 
total RNA was extracted and purified. This was achieved using a commercially 
available kit which uses a column-based extraction method (Chapter 2.2.1). Once 
the RNA was extracted from the plasma, reverse transcription was performed on 
the RNA using specific primers for the chosen miRNAs (mir-222, mir-221, mir-192, 
mir-193b, mir-155, and mir-144) to generate miRNA Complementary DNA (cDNA). 
The cDNA was then used in qRT-PCR experiments to measure the expression of the 
chosen miRNAs (Chapter2.2.5). 
3.4.3 Normalisation and quality control for qRT-PCR results 
The two methods for miRNA normalisation (endogenous and exogenous controls) 
were tested in our study samples. Moreover, a random plasma sample was used as 
a quality control (QC) sample to try to control for variation between runs.  
3.4.3.1 Endogenous Control 
A trial run was conducted using eight random plasma samples to test the possibility 
of using mir-520d-5p as a reliable endogenous control gene.  
3.4.3.2 Exogenous Control 
A trial run was conducted using the same eight random normal samples used for 
testing endogenous control to assess the efficiency of mir-39 as an exogenous 
control in our studied samples.  
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3.4.3.3 Quality Control Sample (CQ) 
To evaluate the repeatability and precision of the RT-qPCR results, a quality 
control sample (QC) sample was included in each run (4 runs per miRNA). Inter-
assay variation of the QC sample for each miRNA was calculated.   
3.4.4 Measurement of Insulin Sensitivity and Insulin Resistance 
Fasting glucose (mmol/L) and fasting insulin (µIU/ml) values were used to 
calculate insulin sensitivity based on the homeostasis model assessment (HOMA-
IR) available online (University of Oxford, 2014) at 
 http://www.dtu.ox.ac.uk/index.htm?maindoc=/publications/ 
The cut-off values for HOMA-IR varies according to ethnicity (Esteghamati et al., 
2010; Gayoso-Diz et al., 2013; Bermúdez et al., 2014; Lee et al., 2016). These 
normal HOMA-IR values ranges from 1.7-2.0 in healthy human adults. In this study 
I chose to use HOMA-IR ≥ 2 to diagnose insulin resistance. 
3.4.5 Statistical Analysis 
The selected miRNAs were normalised to cel-mir-39 and expressed as delta (dCt). 
This removes artefact due to differences in extraction efficiency between 
samples. All continuous classical risk factor variables were tested for normality by 
visual inspection of their histograms and normal Q-Q plots. Descriptive statistics 
were expressed as mean ± SD for normally distributed variables, and median ± 
inter-quartile range for not normally distributed variables. Non-parametric 
variables were normalised by log transformation to use parametric tests. 
Categorical variables were summarised as number (%). Comparison between mean 
values of a continuous variable between two groups (males and females) and 
(HOMA-IR ≤ 2 and HOMA-IR > 2) were evaluated using Student’s two-tailed t-test 
for continues variables and chi-square test for categorical parameters. Pearson 
correlation (r) was used to investigate the association of the six miRNAs 
expressions with markers of metabolic health using baseline samples. Multiple 
linear regression analysis was used to determine whether the metabolic variables 
of interest are an independent predictor for the expression of the selected circulating 
miRNAs. Linearity checked by checking residuals were normally distributed and no 
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Multicollinearity between the independent variables. I identified confounders 
were interested in adjusting for a priori, namely age, sex and body fat because 
they are independent risk factors for insulin resistance. The exposure variable was 
the metabolic biomarker, and the expression of circulating miRNA the outcome 
variable. Because dCt values are on a log2 scale, back transformation of the beta 
coefficient yields the ratio of the geometric means (i.e. a percentage change) in 
the miRNA for a unit change in the exposure. 
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3.5 RESULTS 
3.5.1 Normalisation and quality control for qRT-PCR results 
3.5.1.1 Endogenous Control 
The results of the pilot of quality control procedures showed low and inconsistent 
expression of mir-520d-5p between the samples (Ct > 40). Therefore, mir-520d-5p 
was not used as an endogenous control gene. 
3.5.1.2 Exogenous Control 
The result of the quality control pilot showed low variation between triplicates 
(SD = 0.15, CV = 0.6) and between the samples (SD = 0.2, CV = 0.8) (Table 3-2). 
After that, I measured mir-39 for the entire study (Table 3-3). Although the inter-
assay CV was low (CV = 3.54) and acceptable (< 15%), it still shows more variation 
between runs compared to intra-assay (SD > 0.25). 
3.5.1.3 Quality control (QC) sample 
Table 3-4 shows the results of the quality control sample for each miRNA. The QC 
sample was stable and showed no variation between runs (CV < 1%). These results 
ensure that the variation detected between samples is not because of analytical 
variation but due to real biological differences.
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Table 3-2: mir-39 Intra and inter-assay CV% for the trial run 
Intra-Assay Inter-Assay 
Mean 25.2 Mean 25.1 
SD 0.15 SD 0.2 
CV 0.6 CV 0.8 
CV: Coefficient of Variation, SD: Standard Deviation 
 
Table 3-3: mir-39 Intra and inter-assay CV% for the entire study 
Intra-Assay Inter-Assay 
Mean 24.93 Mean 24.93 
SD 0.11 SD 0.88 
CV 0.45 CV 3.54 
CV: Coefficient of Variation, SD: Standard Deviation 
 
Table 3-4: Inter-assay CV for QC sample 
miRNA Mean SD Inter- Assay CV 
mir-221 28.44 0.23 0.81 
mir-222 29.56 0.23 0.77 
mir-192 33.52 0.18 0.54 
mir-193 35.57 0.21 0.60 
mir-144 35.43 0.21 0.60 
mir-155 33.08 0.23 0.69 
CV: Coefficient of Variation, SD: Standard Deviation 
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3.5.2 General characteristics of the study population grouped by 
sex 
Since sex is an important factor that affects the risk of metabolic diseases, I 
grouped the study population by gender (males n= 119 and females n= 35) (Table 
3-5). The mean age of males (64 ± 8) was not different from the females (64 ± 8).  
As expected, there were differences between sexes in anthropometrics 
measurements, with males having higher weight and WC while females had more 
fat mass (p < 0.001). There was a difference in biochemical biomarkers between 
the two groups. Males had higher glucose and (males = 5.3 mmol/L ± 0.5 and 
females = 5 mmol/L ± 0.6, p = < 0.001), and Alanine aminotransferase (ALT) (males 
median 26 U/L [interquartile range (IQR) 21-34] and females median 25.8 U/L [15-
29], p = < 0.05). Females had higher adiponectin (males = 5.1 µg/mL [3.8-7.2] and 
females = 8.6 µg/mL [5.5-11.8], p = < 0.001) and total cholesterol (TC) (females 
median = 4.8 mmol/L [4.1-4.9] and males median = 4.2 mmol/L [3.5-4.6], p = < 
0.01) compared to males. Moreover, inflammatory markers measured by C-
reactive protein (CRP) and WBC were nominally higher in females than males, but 
both were not statistically significant (p > 0.05). 
Fewer studies focus on the sex difference suggested that miRNAs may be 
differentially expressed between males and females (Wang et al., 2013; Sharma 
and Eghbali, 2014; Ameling et al., 2015). In this study, only two of the six 
circulating miRNAs measured showed sex differences in their expression. Mir-193b 
and mir-144 were more expressed in males (dCt = 9.1 ± 1.5 and 10 ± 1.3 
respectively) compared to females (dCt = 9.7 ± 1.4 and 10.6 ± 1.3 respectively) (p 
< 0.05). 
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Table 3-5: Characteristics of the study population grouped by Sex 
 Male 
n = 119 
Mean (SD) 
Female 
n = 35 
Mean (SD) 
P-value 
Demographic Characteristics 
   
Age (years) 64 (8) 63 (8) 0.438 
Smoking history 
Current 
Former 
Never 
 
18 (15%) 
60 (50%) 
41 (35%) 
 
14 (40%) 
18 (18%) 
3 (9%) 
 0.001 
Blood pressure (mm Hg) 140/80 (19.1/11.5) 140/77 (19.9/7.2) 0.942/0.088 
Anthropometric Characteristics 
   
Body weight (kg) 91.0 (11.3) 75.4 (13.3) < 0.001 
Body mass index (kg/m2) * 30.0 (27.0 - 32.4) 29.2 (26.1 - 34.7) 0.527 
Waist circumference (cm) 106.3 (8.3) 98.1 (10.2) < 0.001 
Body fat (kg) * 30.7 (27.8 - 33.0) 42.6 (38.5 - 46.1) < 0.001 
Biochemical Characteristics 
(Fasting) 
   
Glucose (mmol/L) 5.3 (0.5) 5.0 (0.6) 0.003 
Insulin (pmol/L) * 10.1 (7.2 - 14.3) 9.5 (7.3 - 12.9) 0.501 
HOMA-IR* 2.4 (1.6 - 3.4) 2.2 (1.6 - 2.8) 0.207 
HbA1c (mmol/mol) 38.6 (36 - 41) 38.1 (37 - 40) 0.433 
Adiponectin (µg/mL) * 5.1(3.8 - 7.2) 8.6(5.5 - 11.8) < 0.001 
Triglyceride (mmol/L) *  1.4 (1.1 - 1.9) 1.7 (1.1 - 2.3) 0.152 
Total Cholesterol (mmol/L) * 4.2 (3.5 - 4.6) 4.6 (4.1 - 4.9) 0.003 
HDL (mmol/L) * 1.1 (1.0 - 1.4) 1.1 (1.0 - 1.3) 0.466 
Alanine aminotransferase (U/L) * 26.0 (21 - 34) 25.8 (15 - 29) 0.028 
γ-glutamyl transferase (U/L) * 37.6 (23 - 58) 30.0 (21 - 43) 0.182 
Inflammatory markers (Fasting) 
   
High sensitivity CRP (mg/L) * 1.7 (0.8 - 3.3) 2.5 (1 - 4.6) 0.114 
WBC (x109 /L) * 6.5 (5.7 - 8.0) 7.0 (5.9 - 7.5) 0.698 
Circulating miRNA Expression 
   
mir-222 (dCt) 3.93 (1.7) 4.03 (1.5) 0.926 
mir-221 (dCt) 1.70 (1.6) 2.00 (1.8) 0.689 
mir-144 (dCt) 10.00 (1.3) 10.60 (1.3) 0.049 
mir-155 (dCt) 8.00 (1.2) 8.20 (1.3) 0.389 
mir-192 (dCt) 8.80 (1.6) 9.20 (1.5) 0.166 
mir-193b (dCt) 9.10 (1.5) 9.70 (1.4) 0.032 
Categorical variables were summarised as number (%). 
Variables not normally distributed were summarised as median (inter-quartile range).  
HOMA-IR: Homeostatic model assessment for insulin resistance, HDL: high density lipoprotein, CRP: high 
sensitivity C reactive protein, WBC: white blood cells, mir: micro RNA, dCt: delta cycle threshold. 
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3.5.3 General characteristics of the study population grouped by 
HOMA-IR 
The studied population was also classified as being either insulin sensitive (IS) or 
insulin resistance (IR) based on HOMA-IR. The HOMA-IR cut-off point chosen to 
make this distinction was HOMA-IR ≤ 2 for insulin sensitive (IS) and HOMA-IR >2 for 
insulin resistance (IR). Table 3-6 summarises the general characteristics of the two 
groups (IS, n = 59 and IR, n = 95).  
There were no differences (p < 0.05) in age, sex, smoking history, and blood 
pressure between the two groups. As expected, there was a difference in all the 
anthropometric measurements between the two groups (p < 0.001) with the insulin 
resistance group (IR) having higher anthropometric values, e.g., Weight (IR = 90.5 
kg ± 13.2 and IS = 82.4 kg ± 12.4, p = < 0.001). Total adiponectin concentration 
was lower in IR group compared to IS counterparts [IR = 5.0 µg/ml (3.5-7.5) and IS 
= 6.2 µg/ml (5.0-10.3), p < 0.05]. In this study, there was no difference in all lipids 
profile measured between the two groups (TAG, HDL, and TC). When comparing 
inflammatory markers between the two groups, there was no difference in CRP 
while WBC concentration was slightly higher in IS sensitive group (IS = 6.9 mg/L 
(6.1-8.6) compared to IR = 6.4 mg/L (5.6-7.5), p < 0.05). 
Out of all the circulating miRNAs included in this study, mir-144 was the only 
miRNAs whose expression was different between the two groups. Mir-144 
expression was higher in the IS group compared to the IR group (p < 0.05).  
 
79 
 
Table 3-6: Characteristics of the Study population group according to their insulin 
sensitivity 
 IS (HOMA < 2) 
n = 59 
Mean (SD) 
IR (HOMA > 2) 
n = 95 
Mean (SD) 
P-value 
Demographic Characteristics 
 
   
Age (years) 64 (9) 63 (8) 0.683 
Gender 
Male 
Female 
 
43 (73%) 
16 (27%) 
 
76 (80%) 
19 (20%) 
0.305 
Smoking history 
Current 
Former 
Never 
 
14 (24%) 
26 (44%) 
19 (32%) 
 
18 (19%) 
52 (55%) 
25 (26%) 
0.436 
Blood pressure (mm Hg) 
140 / 80  
(20 / 18) 
139 / 79  
(19 / 11) 
0.738/0.449 
 
Anthropometric Characteristics 
 
   
Body weight (kg) 82.4 (12.4) 90.5 (13.2) < 0.001 
Body mass index (kg/m2) * 
28.8  
(26.2 -31.4) 
30.8  
(27.9 -33.6) 
< 0.001 
Waist circumference (cm) 101 (8.6) 107 (9.6) < 0.001 
Body fat (kg) * 
25.2  
(21.1-30.3) 
29.3  
(24.7-35.0) 
< 0.001 
 
Biochemical Characteristics 
(Fasting) 
 
   
Glucose (mmol/L) 5.0 (0.53) 5.4 (0.53) 0.001 
Insulin (pmol/L) * 
6.8  
(5.3-7.7) 
12.4  
(10.3-16.3) 
0.001 
HbA1c (mmol/mol) * 38.1 (36-39) 38.7 (37-41) 0.267 
Adiponectin (µg/mL) * 6.2 (5.0-10.3) 5.0 (3.5-7.5)  0.01 
Triglyceride (mmol/L) *  1.7 (1.2-2.2) 1.4 (1.1-1.9) 0.382 
Total Cholesterol (mmol/L) * 4.4 (3.7-4.7) 4.2 (3.6-4.7) 0.349 
HDL (mmol/L) * 1.1 (1.0-1.4) 1.1 (1.0-1.3) 0.976 
Alanine aminotransferase (U/L) * 22.0 (18-31) 26.0 (20-35) 0.338 
γ-glutamyl transferase (U/L) * 
29.0 
 (20-50) 
38.0 
 (26-59) 
0.072 
Inflammatory markers (Fasting) 
   
High sensitivity CRP (mg/L) * 1.7 (0.8-3.5) 2.0 (0.93-3.5) 0.245 
WBC (x109 /L) * 6.9 (6.1-8.6) 6.4 (5.6-7.5) 0.022 
 
Circulating miRNA Expression 
 
   
mir-222 (dCt) 3.94 (1.3) 3.96 (1.9) 0.826 
mir-221 (dCt) 1.83 (1.6) 1.72 (1.6) 0.793 
mir-144 (dCt) 10.42 (1.4) 9.98 (1.3) 0.049 
mir-155 (dCt) 8.13 (1.1) 7.95 (1.3) 0.476 
mir-192 (dCt) 9.16 (1.6) 8.80 (1.6) 0.192 
mir-193b (dCt) 9.37 (1.4) 9.11 (1.6) 0.368 
#: Categorical variables were summarised as number (%). 
*: Continuous variables not normally distributed were summarised as median (inter-quartile range).  
HOMA-IR: Homeostatic model assessment for insulin resistance, HDL: high density lipoprotein, CRP: 
high sensitivity C reactive protein, WBC: white blood cells, mir: micro RNA, dCt: delta cycle threshold. 
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3.5.4 Correlation between Circulating miRNAs Expression and 
Markers of Metabolic Disturbance 
To determine the association of the selected circulating miRNAs (mir-222, mir-
221, mir-192, mir-193b, mir-144, and mir155) with markers of metabolic 
disturbance in a high-risk population for developing T2DM, a cross-sectional 
analysis using Pearson correlation was done. Results are shown in Table 3-7 (for 
anthropometrics measurements), Table 3-8 (for markers of insulin sensitivity), 
Table 3-9 (for liver enzymes), and Table 3-10 (for inflammatory markers). 
3.5.4.1 Circulating miRNAs Expression and Anthropometrics Variables   
Several circulating miRNAs have been identified in obesity and found to be strongly 
associated with adiposity measurements such as BMI, total fat mass, and waist 
circumference. The relationship between the expression of the candidate miRNAs 
and some of the adiposity biomarkers (weight, BMI, body fat, and waist) was 
tested and results are shown in Table 3-7. There was no association between these 
anthropometric markers and the expression of the chosen circulating miRNAs. 
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3.5.4.2 Circulating miRNAs with markers of insulin sensitivity 
Table 3-8 demonstrates the correlation between miRNAs expression and markers 
of insulin sensitivity. Four miRNAs (mir-192, mir-193b, mir-155, and mir-144) were 
positively correlated with glucose concentration with mir-144 showing the 
strongest correlation with glucose (r = 0.251, p < 0.01). Out of all the six miRNAs 
included in our study, mir-144 was the only miRNA that showed positive 
correlation with insulin and HOMA-IR (r = 0.184, p < 0.05, and r = 0.207, p < 0.01, 
respectively). Total adiponectin concentration showed negative correlation with 
the expression of mir-221, mir-192 and mir-193b (r = 0.205, 0.179, and 0.189 
respectively, p < 0.05). The expression of mir-221 and mir-222 were positively 
correlated with only HbA1c (r = 0.202, p < 0.05 and r = 0.245, p < 0.01, 
respectively). Other miRNAs (mir-193b, and mir-155) also showed positive 
associations with HbA1c (r = 0.17 and 0.175, respectively, p < 0.05). 
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3.5.4.3 Circulating miRNAs and liver enzymes 
Table 3-9 demonstrates the correlation between liver enzymes GGT and ALT with 
the expression of the selected miRNAs. All the six miRNAs expressions, except for 
mir-222, were positively correlated with liver enzymes with mir-192 and mir-193b 
showing the strongest association with GGT (r = 0.278 and 0.402 respectively, p < 
0.01) and ALT (r = 0.399 and 0.616 respectively, p < 0.01).  
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3.5.4.4 Circulating miRNAs and inflammatory biomarkers 
In this study, CRP and WBC were used as markers for inflammation. Table 3-10 
shows the correlation between the expression of the six selected circulating 
miRNAs and both CRP and WBC. None of the candidate miRNAs chosen were 
associated with CRP or WBC concentration in the current sample study. 
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3.5.5 Multiple linear regression analysis 
Multiple linear regression analysis was used to determine whether the above 
associations between the expression of circulating miRNAs (dependent variable) 
and independent variables of interest remained significant after adjusting for 
other confounding independent variables, age, sex, and body fat. I elected to only 
show significant associations for clarity; miRNA that had no unadjusted association 
with metabolic markers were omitted from relevant tables. 
Table 3-11 shows the association of the expression of circulating mir-144 with 
markers of insulin sensitivity (FBG, insulin, and HOMA-IR). In models adjusting for 
age, sex, and body fat, FBG showed the strongest association with the expression 
of circulating mir-144. For a 1mmol/L increase in fasting plasma glucose (FBG), 
the expression of circulating mir-144 was 35% (95% CI = 20% - 50%, p < 0.01) 
elevated. Similarly, higher HOMA-IR and fasting insulin were positively associated 
with the expression of circulating mir-144, for every unit increase in HOMA-IR, the 
expression of circulating mir-144 was 10.2% (95% CI = 2.5% - 17.2%, p < 0.05) higher 
and for every 1 pmol/L increase in insulin the expression of circulating mir-144 
was 2% elevated. Adjustment for age, gender, and body fat did not attenuate 
these associations. The expression of the other circulating miRNAs showed 
variable associations with markers of insulin resistance and glycaemia, but none 
of the expression of the chosen circulating miRNAs was associated with markers 
of adiposity.  
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Table 3-11: Linear regression model showing the associations of insulin sensitivity markers 
vs. mir-144 expression at baseline. Effect estimates are % effect on miRNA dCt values 95% 
CI). 
miRNA Predictor 
Model 1 Model 2 Model 3 
B  
(95% CI) 
B 
 (95% CI) 
B  
(95% CI) 
mir-144 
FBG 
(per 1mmol/L) 
35%** 
 (20 – 50) 
32%**  
(10 – 48) 
32%* 
 (9 – 49) 
Insulin 
(per 1pmol/L) 
2%*  
(0.1 – 5) 
2%*  
(0.1 – 4) 
2%*  
(0.1 – 5) 
HOMA-IR 
(per 1 unit) 
10%*  
(3 – 17) 
10%*  
(2 – 16) 
10%*  
(2 – 17) 
Model 1: No adjustment 
Model 2: adjustment for age and sex 
Model 3: adjustment for age, sex and body fat 
CI = confident interval, B = regression coefficient, FBG = fasting blood glucose. 
* p < 0.05, ** p < 0.01 
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Additionally, the expression of circulating mir-192 and 193b showed strong 
associations with liver enzyme. In models adjusting for age, gender, and body fat, 
these association remined strong (Table 3-12). For every 10-unit increase in ALT, 
the expression of circulating mir-192 was 28% (95% CI = 16% - 38%, p < 0.001) 
elevated and the expression of circulating mir-193b was 40% (95% CI = 30% - 50%, 
p < 0.001). For every 10-unit increase in GGT, the expression of circulating mir-
192 (95% CI = 3% - 10%, p < 0.001) was 10% higher and the expression of circulating 
mir-193b was 10% (95% CI = 6% - 10%, p < 0.001) higher.  
In the previous section, total adiponectin was negatively correlated with the 
expression of circulating mir-221, mir-192, and mir-193b. Multiple linear 
regression models adjusting for age, gender, and body fat were done (Table 3-13).  
The expression of circulating mir-221 was inversely associated with adiponectin 
concentration. This association remained significant even after adjusting for age, 
sex, and body fat. In contrast, the expression of circulating mir-192 and mir-193 
were no longer related to adiponectin in multivariable models after further 
adjustment for the same confounding factors. 
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Table 3-12: Linear regression model showing the associations of liver enzymes vs. mir-192 
and 193b expression at baseline. Effect estimates are % effect on miRNA dCt values. 
miRNA Predictor 
Model 1 Model 2 Model 3 
B (95% CI) 
p-value 
B (95% CI) 
p-value 
B (95% CI) 
p-value 
mir-193b 
GGT 
(per 10 U/L 
increase) 
10%*** 
(6 – 10) 
10%*** 
(5 – 10) 
10%*** 
(5 – 10) 
ALT 
(per 10 U/L 
increase) 
40%*** 
(30 – 50) 
40%*** 
(30 – 50) 
40%*** 
(30 – 50) 
mir-192 
 
GGT 
(per 10 U/L 
increase) 
10%*** 
(0.1 – 10) 
10%*** 
(0.1 – 10) 
10%*** 
(0.1 – 10) 
ALT 
(per 10 U/L 
increase) 
28%*** 
(16 – 38) 
27%*** 
(30 – 50) 
29%*** 
(19 – 40) 
Model 1: No adjustment 
Model 2: adjustment for age and sex 
Model 3: adjustment for age, sex and body fat 
*** p < 0.001 
GGT: Gamma-Glutamyl Transferase, ALT: Alanine Aminotransferase 
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Table 3-13: Linear regression model showing the associations of circulating adiponectin vs. 
mir-221, mir-192, and mir-193b at baseline. Effect estimates are % effect on miRNA dCt 
values. 
miRNA Predictor 
Model 1 Model 2 Model 3 
B (95% CI) 
p-value 
B (95% CI) 
p-value 
B (95% CI) 
p-value 
mir-221 
Adiponectin 
(per 1µg/mL) 
 5 %* 
 (1 – 9) 
 5 %*  
(0.6 – 9) 
5 %* 
 (0.6 – 10) 
mir-192 
4 %*  
(0.4 – 8) 
3 % 
 (0.1 – 7) 
4 %  
(0.1 – 8) 
mir-193b 
4 %*  
(0.7 – 8) 
3 % 
 (0.3 – 7) 
3 %  
(0.3 – 7) 
Model 1: No adjustment 
Model 2: adjustment for age and sex 
Model 3: adjustment for age, sex and body fat 
* p < 0.05 
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3.6 DISCUSSION: 
The present study was conducted to investigate cross-sectional associations of the 
expression of targeted circulating miRNAs (mir-222, mir-221, mir-192, mir-193b, 
mir-144, and mir-155) with metabolic health markers, using a large cross-sectional 
design. It also presents a framework for quality control of circulating miRNA 
measurement in large scale studies. 
3.6.1 Analytical and pre-analytical Conditions for miRNAs 
expression 
Despite their promising potential use in clinical application, there are several 
problems that prevent the use of circulating miRNAs as diagnostic tools for now. 
One of the problems is the lack of a standardised protocol; each study used 
different samples, different collection methods, and different profiling 
methodologies. Additionally, there is no proper control to normalise the 
circulating miRNAs expression. Finally, most studies published have been carried 
out using small numbers of participants. These factors can contribute to the 
variation seen in results among different studies. Before beginning this study, a 
specific protocol was planned to standardise both preanalytical and analytical 
variables as much as possible to make sure that the results are reliable.  
For samples a decision was made to use samples from the CAMERA trial because it 
was a well-defined large sample of participants (154) who were subjected to a 
strict inclusion/exclusion criterion, and although the participants didn’t have 
diabetes, they were high risk participants (previous CHD and high WC) who will be 
good candidates for exploring the expression of circulating miRNAs. 
A hypothesis-driven approach was used to select the candidate circulating miRNAs 
to include in this study instead of exploratory approach because it is more focused, 
more efficient, require less time, and cheaper which makes it more suitable for 
large studies. This led to a decision to include six circulating miRNAs in this study 
based on previous exciting evidence that changing in weight, glycemia and 
inflammation affect their expression (mir-222, mir-221, mir-192, mir-193b, mir-
155, and mir-144.  
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For starting material, I decided to use EDTA plasma samples from the CAMERA trail 
were decided to be used and not whole blood because cellular fraction (white and 
red blood cells) can add and influence the total amount of circulating miRNAs. 
Moreover, haemolysed samples were excluded because haemolysis can alter 
plasma miRNA biomarker levels by up to 50-fold (Pritchard et al., 2012). 
Unnecessary freezing and thawing were avoided as much as possible despite the 
fact that circulating miRNAs are found to be stable in harsh conditions (Sohel, 
2016). For total RNA extraction, miRNeasy Mini kit from Qiagen was used as it 
produces the highest yield of total RNA compared to another kit (Sourvinou, 
Markou & Lianidou, 2013). Quantification reverse transcription polymerase chain 
reaction (qRT-PCR) was used for the measurement of miRNAs expression cause it 
is one of the well-established methods for the quantification of circulating miRNAs 
and considered as the golden standard method (Sohel, 2016). Beside unlike 
microarray, it is more suitable to use for our approach (hypothesis-driven). The 
final challenge was choosing an appropriate control to normalise the expression 
of circulating miRNAs. A trial run was conducted to test the two types of controls, 
endogenous (mir-520d-5p) and exogenous (cel-mir-39) using eight random 
samples. The endogenous control results showed low and inconsistent expression 
although it was reported to be an excellent housekeeping control candidate for 
measuring plasma miRNA due to its consistent results and a very narrow standard 
deviation (Rice et al., 2014). Alternatively, the exogenous (cel-miR-39) results, 
which is one of the widely accepted controls for circulating miRNA, showed 
generally acceptable variation between the triplicates (SD = 0.15, CV = 0.6%) and 
between the 8 samples (SD = 0.2, CV = 0.8%) (Table 3-2). These CVs should be 
interpreted as a guide due to the exponential nature of the Ct value. According 
to the results from conducting a trail, a decision was made to exclude mir-520d-
5p and use mir-cel-39 as a control. 
After that, the expression of mir-39 in the entire study samples (308 plasma 
samples) was measured (Table 3-3), and the results showed low variation between 
the duplicates (SD = 0.11%, CV = 0.45%) and more variation between the samples 
(SD = 0.88%, CV = 3.5%). Although the inter-assay CV between the samples is low 
(3.54%) and acceptable (< 15%), it still showed more variation between runs 
compared to intra-assay (SD > 0.25). One reason for this variation is batch effect, 
which represents a common source of variability (Marabita et al., 2016), especially 
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when dealing with a large number of samples (308 extractions). Another reason 
could be the effect of RNases. Despite the presence of RNase activity in plasma, 
endogenous circulating miRNAs exist in a form that is protected from its effect, 
suggesting that they are found in a protective form. Some studies showed that 
circulating miRNAs remain stable even after boiling, high or low pH, prolonged 
storage time and multiple freeze-thaw cycles (Gilad et al., 2008; Moldovan et al., 
2014; Shaffer, Schlumpberger & Lader, 2012). It is likely that separation of plasma 
from cells is the critical pre-analytical variable. By contrast, synthetic external 
miRNAs added directly to plasma were naked, sensitive, not stable, and can be 
degraded rapidly (Mitchell et al., 2008). To assure that the test run was valid, and 
results were reliable, a decision was made to include quality control (QC) samples 
in each run. The QC sample results were stable and reproducible in all the miRNAs 
measured (Table 3-4). 
3.6.2 The association between circulating miRNAs expression 
and markers of metabolic disturbance 
3.6.2.1 Circulating miRNAs Expression and Anthropometrics Variables   
In this study, none of the six selected circulating miRNAs were associated with 
anthropometric measurements (weight, BMI, waist, and body fat). It was expected 
to observe the association of circulating mir-222 and mir-221 with markers of 
adiposity since mir-222 has been reported to be highly expressed in obese patients 
while mir-221 was low (Ortega et al., 2013). Surprisingly, the observation of 
similar expression was not seen in this study. The reason for this could be because 
the finding of Ortega group was in morbid obesity (mean BMI ≥ 40) while our study 
population mean BMI was 30. 
3.6.2.2 Circulating miRNAs with markers of insulin sensitivity 
The key finding of the present study was that among the six circulating miRNAs 
included, the expression of mir-144 was the only circulating miRNA to display a 
positive association with HOMA-IR and insulin. Also, among the six selected 
circulating miRNAs, mir-144 showed the highest association with glucose 
concentration. All these associations remained significant even after adjusting for 
age, gender, and body fat.  
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The level of circulating mir-144 has been found to be increased in patients with 
T2DM. A meta-analysis of controlled profiling studies showed that the expression 
of 40 miRNAs were dysregulated in T2DM in several tissues (blood, liver, pancreas, 
muscle, adipose tissue, and glomeruli) (Zhu & Leung, 2015). One of these 40 
miRNAs were circulating mir-144, which was upregulated in human T2DM blood 
samples. Additionally, Yang et al. showed that the expressions of platelet and 
plasma mir-144 were altered in T2DM patients with (n = 56) or without (n = 58) 
ischemic stroke compared to healthy controls (n = 30) (Yang et al., 2015). 
Moreover, mir-144 appear to contribute to the regulation of insulin signalling. This 
was supported by the findings of Karolina et al., which showed that elevated 
circulating mir-144 correlate with the downregulation of insulin receptor substrate 
1 (IRS1) at both mRNA and protein levels. Although the participants in this study 
did not have diabetes, all of them were high-risk patients for developing T2DM, 
and most of them were IR thus highlighting the potential plasma mir-144 as a key 
player in insulin resistance which could develop to diabetes over time. This study 
provides additional evidence for the role of plasma mir-144 in the pathogenesis of 
T2DM and the possibility of using it as a diagnostic biomarker. 
Wang et al. reported a higher expression of circulating miR-144 seems to be 
ethnicity related; it was only associated with T2DM in native Sweden (Caucasian, 
n = 68) and not Iraqis patients (Arabs, n = 84) (Wang et al., 2014). In this study, 
ethnicity was not a factor since all participants were Caucasians.     
MiR-221 and miR-222 are two highly homologous miRNAs that have been studied 
extensively in human malignancies (Song et al., 2017). Few studies have 
associated the alteration in their expression with diabetes. Ortega et al. reported 
that circulating mir-222 was highly expressed in Caucasian male patients with 
T2DM (n = 48) compared to patients with normal glucose tolerance (n = 45) and 
were associated with fasting glucose and HbA1c (Ortega et al., 2014). Also, insulin 
administration rapidly altered the expression of circulating mir-222. Shi et al. also 
reported higher mir-222 expression in the omental adipose tissue of Chines women 
with gestational diabetes (n = 13) at the time of caesarean delivery compared with 
pregnant women with normal glucose tolerance (n = 13) (Shi et al., 2014). The 
authors further used 3T3-L1 adipocytes to demonstrate that stimulation with a 
relatively high concentration of oestrogen increased mir-222 expression and seems 
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to negatively regulate adipose insulin sensitivity via suppression of oestrogen 
receptor α (ER-α) protein and insulin-sensitive membrane transporter glucose 
transporter 4 (GLUT4) protein. In another study done by Coleman et al. showed 
that the levels of mir-221 and mir-222, measured in whole tissue homogenates of 
the internal mammary artery (IMAs) taken from 73 patients undergoing coronary 
artery bypass surgery, were higher in patients with diabetes compared to normal 
controls and it remained significantly associated even after adjustment for age, 
body mass index, and serum lipids (Coleman et al., 2013). Additionally, Meerson 
and colleagues reported a positive correlation between the expression of mir-221 
in subcutaneous adipose sample and BMI, glucose, and insulin in 29 Pima Indian 
participants without diabetes (Meerson et al., 2013). 
Similar association with both mir-222 and mir-221 and glucose, insulin, and HOMA-
IR were not observed in this study. Such disparity between the results could be 
explained by multiple reasons. Firstly, different population studied. The 
association found between mir-222 and mir-221 and markers of glycemia was in 
patients with diabetes, whereas the population in this study included patients 
without diabetes. Secondly, different ethnicity. For example, Meerson et al. study 
population were Pima Indian participants not suffering from diabetes, one of the 
highest prevalence of diabetes and obesity of any population in the world 
(Pearson, 2015), while the participants in this study were Caucasians. A previous 
study showed that racial/ethnic differences in circulating miRNAs expression 
between ethnic groups (Wang et al., 2014). Thirdly, different samples (tissue vs. 
plasma). It is still not known whether miRNAs extracted from cellular or 
extracellular sample should be utilized interchangeably, and it remains unknown 
if expression from these distinct sources is suitable. In a large human cohort (2,391 
participants) done by Shah et al. showed that whole blood and plasma miRNA 
expression is distinct and that miRNA expression from different human sources 
should not be used interchangeably as biomarkers of disease (Shah et al., 2016). 
For example, in Coleman et al. study, cellular miRNAs (IMAs tissues) were used to 
measure the expression of miRNAs, which probably demonstrate local intracellular 
function, while circulating miRNAs (plasma samples) were used in this study which 
may demonstrate systemic function. Finally, the different methodology used to 
process samples and measure the expression of miRNAs, which is considered the 
major factor for the inconsistency between studies. 
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Meanwhile, the association found in this study between both mir-222 and mir-221 
and HbA1c was similar to Ortega et al. findings (Ortega et al., 2014). Glycated 
haemoglobin (HbA1c) has been considered as a good indicator of overall glycaemic 
control in 2-3 months. Studies have shown the possibility of using it as a surrogate 
marker for insulin resistance (Borai et al., 2011; Saha & Schwarz, 2017) which can 
explain why there was an association between mir-222 and HbA1c and not glucose 
in the current study. 
Adiponectin is an insulin-sensitising and anti-inflammatory adipocytokine, which 
is considered as a potential mediator between obesity, insulin resistance, and 
diabetes (Lindberg et al., 2017; Weber et al., 2017). It has been shown that mir-
221 may regulate IR via effects on adiponectin receptor 1 (ADIPOR1). Meerson et 
al. displayed that mir-221 directly downregulates ADIPOR1 expression suggesting 
that it may be possible that obesity-associated upregulation of mir-221 can result 
in a decrease in ADIPOR1, which may, in turn, lead to the development of obesity-
related metabolic consequences such as insulin resistance or T2DM (Meerson et 
al., 2013). In another study done by  Hwang et al., showed that there was a 
negative correlation between mir-221 expression and ADIPOR1 (Adiponectin 
receptor 1) mRNA expression in breast tumours as well as in breast cancer cell 
lines (Hwang et al., 2013). In the present study, total plasma adiponectin was 
negatively associated with the expression of circulating mir-221. In multiple linear 
regression models adjusting for age, gender, and body fat didn’t change the 
association. The result demonstrates that the association between circulating 
adiponectin and the expression of circulating mir-221 is independent of obesity.  
Upregulation of the expression of circulating mir-192 and mir-193b in the pre-
diabetes state was previously reported by Párrizas et al. (Párrizas et al., 2015). 
Their study included 92 participants (29 healthy control, 22 pre-diabetes with 
impaired fasting glucose (IFG), 21 prediabetes with impaired glucose tolerance 
(IGT), and 20 newly diagnosed T2DM). Out of the 176 circulating miRNAs they 
tested (most frequently detected in human serum/plasma), circulating levels of 
three miRNAs (mir-150, mir-192, and mir-193b) achieved high levels in both the 
IFG and IGT groups but were not altered in patients with T2DM. Interestingly, they 
also found that mir-192 and mir-193b decrease to normal in insulin resistant 
humans after therapeutic lifestyle intervention consisting of a monitored exercise 
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program and diet recommendations. Also, Jaeger et al. did a longitudinal study 
where they assessed the association of four circulating miRNAs, including mir-192 
with incident T2DM (Jaeger et al., 2018). The study included 213 patients from 
the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) cohort 
who didn’t have T2DM at baseline and followed for six years. Patients who 
developed diabetes (n = 35) had higher levels of mir-192 compared to those who 
did not (n = 178). In agreement with previous findings, the results of this study 
showed that both mir-192 and mir-193b were positively correlated with glucose in 
patients without diabetes but high-risk, and most of them were IR.  In contrast to 
the findings of the present study, Ortega et al. reported decreased levels of mir-
192 in the serum of patients with T2DM (Ortega et al., 2014).  
Furthermore, the expression of mir-155 was positively associated with glucose, 
HbA1c. In a study done by Lin et al., showed that downregulation of mir-155 levels 
was found in serum from patients with T2DM (n = 30) compared to healthy controls 
and showed a negative correlation with HOMA-IR suggesting that mir-155 might be 
involved in glucose homeostasis and insulin action. (Lin et al., 2016). Moreover, 
mir-155 expression in PBMCs (peripheral blood mononuclear cells) from patients 
with T2DM (n = 20) was decreased compared to normal controls (n =20) (Corral-
Fernández et al., 2013). A possible reason for these variations could be the 
different population studied and different samples used. 
3.6.2.3 Circulating miRNAs and liver enzymes 
In this study, the expression of both mir-192 and mir-193b were associated with 
liver enzymes (ALT and GGT) independent of age, sex, and body fat. Párrizas et 
al. also reported a good correlation between mir-192, mir-193b and FLI (Fatty 
Liver Index, a mathematical index calculated from blood TAG, BMI, waist 
circumference, and hepatic enzyme GGT and has been used as a substitution for 
hepatic steatosis). Jaeger et al. reported a positive correlation between serum 
levels of mir-192 and AST, ALT, and GGT using baseline samples.  
3.6.2.4 Circulating miRNAs and inflammatory biomarkers 
Increased levels of mir-155 have been associated with various inflammatory 
diseases, including rheumatoid arthritis (RA) (Alivernini et al., 2018), and it is 
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considered as a potential regulator of inflammation. It plays a key role in the 
immune response, and studies have demonstrated its involvement in the 
development of atherosclerosis (Li et al., 2016; Faccini et al., 2017). C-reactive 
protein (CRP) is a sensitive, nonspecific marker for systemic inflammation and a 
powerful predictor for cardiovascular diseases (Koenig, 2013). A recent study 
included 132 patients who underwent coronary angiography to measure coronary 
flow, 66 patients with coronary slow flow and 66 patients with normal coronary 
flow showed that plasma mir-155 was positively correlated with CRP (Su, Yang & 
Li, 2018). In the present study, there was no association between mir-155 and 
both CRP and WBC although. A possible reason for these variations could be the 
different population studied and different samples used. 
3.6.3 Circulating miRNAs as novel minimally invasive biomarkers 
Data presented in this study showed significant associations between the selected 
circulating miRNAs and markers of metabolic health. These circulating miRNAs 
appears to be promising biomarkers for metabolic. Importantly, the miRNAs had 
specific associations with different metabolic biomarkers suggesting that they are 
not providing overlapping information. Particularly, mir-144 which showed a 
specific association with insulin and HOMA-IR. This is crucial information which 
should be incorporated into future study design. Further prospective evaluation 
of these circulating miRNAs, diabetes and other metabolic diseases is needed, to 
validate these findings and to further explore the exciting potential of circulating 
miRNAs to emerge as clinically useful novel biomarkers for metabolic diseases. 
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3.7 Conclusion 
This study offers one of the first sets of sizeable data using circulating miRNAs as 
reproducible biomarkers, with acceptable quality control, in stored plasma 
samples. This provides a platform for further work on the possibility of using them 
as biomarkers in future. 
The present study showed broadly expected cross-sectional associations of the six 
selected circulating miRNAs (mir-222, mir-221, mir-192, mir-193b, mir-144, and 
mir-155) with biomarkers of metabolic risk in a population with coronary heart 
disease but without diabetes. These data support the putative utilities of miRNAs 
as reproducible biomarkers; however, there is still a long way to go to prove their 
usefulness in clinical practice as diagnostic biomarkers. Inconsistency in results 
from different studies making it difficult to interpret and compare various 
investigations. Standardization of both preanalytical and analytical procedures 
must be implemented for the analysis of circulating miRNAs before their use as a 
diagnostic tool. Also, a large cohort of patients is needed in future studies. 
3.7.1 Strength and limitation 
One of the strong features of this study is the use of CAMERA trial samples. The 
CAMERA trail was a high-quality study with several strengths. Firstly, its design as 
a randomised placebo-controlled double-blind trial, which is considered as the 
‘gold standard’ in evidence-based medicine for evaluating the effects of an 
intervention. Secondly, a well-defined large sample of participants (154) who 
were subjected to a strict inclusion/exclusion criterion. Finally, the well 
standardized approach to sample collection (from a single local centre) and 
sample handling (quickly processed and stored in െͺͲԨሻ. Besides, using a robust 
planned method to measure the expression of circulating miRNAs. 
There were also limitations to our study. First, the lack of endogenous control to 
normalize miRNAs expression. As known, the optimal method for normalisation of 
gene expression is to use a constantly expressed housekeeping gene, because they 
represent endogenous controls that are affected by the same source of variability 
as the target gene. However, using this method on plasma/serum samples is 
challenging because very few studies are available and different studies reported 
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different miRNA reference genes (Moldovan et al., 2014; Shaffer, Schlumpberger 
& Lader, 2012). Alternatively, I used a spiked-in exogenous (cel-miR-39) control 
to normalize our results. Although it is one of the widely accepted controls for 
circulating miRNA, it does not correct for variation and quality of the sample 
(Schwarzenbach, Calin & Pantel, 2016).  Second, the study is a cross-sectional 
analysis, and this type of study does not suggest a cause and effect relation. To 
make the case for use of circulating miRNA as clinical biomarkers, prospective 
studies would be required to establish whether the dysregulation of the expression 
of the studied miRNAs are associated with incident type 2 diabetes.
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4 THE EFFECT OF METFORMIN ON THE 
EXPRESSION OF CIRCULATING MIRNAS: 
CAMERA TRIAL 
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4.1 Introduction 
Metformin (1,1-dimethylbiguanide), a first line oral glucose-lowering agent for 
patients with type 2 diabetes (T2DM), is derived from a natural product used in 
herbal medicine, biguanide derivate. It is considered as the drug of choice for the 
treatment of individuals with T2DM with BMI in the overweight and obese range in 
whom diet, and exercise treatments have failed. Both the American Diabetes 
Association (ADA) and the European Association for the Study of Diabetes (EASD) 
official guidelines have recommended metformin as first-line oral therapy (Yang 
et al., 2017). These recommendations were based on the results published by the 
UK Prospective Diabetes Study (UKPDS) (Turner, 1998). The study was initiated in 
1977 as a multi-centre randomised control trial including newly diagnosed T2DM. 
The objective of the study was to determine whether improved glucose control in 
individuals with T2DM will prevent the complications of diabetes and whether 
there are differences between conventional treatment (diet) and drug treatments 
with three different drugs (sulfonylurea, metformin, or insulin). The study 
concluded that glucose control with metformin appears to decrease diabetes-
related complications in patients who have a body mass index in the overweight 
range with less weight gain and hypoglycaemic attacks compared to the other two 
drugs. Specifically, the CAMERA trial reported no effect of metformin on cIMT, but 
it did induce a small weight loss of ~3kg (SD = 4·2) versus 0·0 kg (SD = 3·8) in the 
placebo group at 18 months. In addition, HbA1c, fasting insulin concentration, and 
HOMA- IR were reduced in the metformin group compared with placebo at 18 
months. 
Although It has been known that the antihyperglycemic effect of metformin is 
mainly due to decreases in hepatic glucose production, decreases in intestinal 
absorption of glucose, and improved insulin sensitivity by increasing peripheral 
glucose uptake and utilization, the molecular mechanisms of action remain 
unclear (Rena, Hardie & Pearson, 2017).  
Beyond its effect on lowering blood glucose, a growing body of evidence suggested 
that metformin appears to be a potential drug with multiple therapeutic effects. 
Recent studies demonstrated that metformin could exert protective effects in 
cardiovascular diseases, pancreatic β cell failure, cancer, and aging (Yang et al., 
2017). It has been used to treat other conditions where insulin resistance is 
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involved such as obesity (Seifarth, Schehler & Schneider, 2013), extreme insulin 
resistance with acanthosis nigricans (Akter et al., 2016), polycystic ovarian 
syndrome (Study et al., 2010). 
Metformin has been reported to modify the expression of several miRNAs. This 
relationship was first studied using cancer cells in culture and murine tumour 
xenografts where they found that metformin inhibits tumorigenesis by 
upregulating DICER1, which is a key enzyme in microRNAs (miRNAs) processing 
(Blandino et al., 2012).  
Recent evidence suggests that metformin treatment affects the miRNA profile in 
patients with T2DM (Coleman et al., 2013; Ortega et al., 2014). In a recent study 
published in 2018, the authors measured the expression of 86 circulating miRNAs 
in plasma of 47 patients with T2DM before and after three months of metformin 
treatment (Demirsoy et al., 2018). The patients received no diabetes treatment 
before the start of the study. The expression level of 13 circulating miRNAs (mir-
let- 7e-5p, let-7f-5p, mir-21-5p, mir-24-3p,mir-26b-5p, mir-126-5p, mir-129-5p, 
mir-130b-3p, mir-146a- 5p, mir-148a-3p, mir-152-3p, mir-194-5p, mir-99a- 5p) 
were found to be downregulated in patients with T2DM following metformin 
treatment. This information was not published at the time of study design.  
Having established the cross-sectional associations of the six selected circulating 
miRNAs with metabolic biomarkers, the next logical question was whether an 
intervention with metformin, which is widely acknowledged to improve metabolic 
health, would influence the expression of the six targeted circulating miRNAs. 
Beside, although metformin did not affect carotid intima-media thickness (CIMT) 
and other markers of cardiovascular diseases in the CAMERA study, there was a 
notable reduction in measurements of adiposity and glycaemia in metformin 
groups after 18 months, and from our previous analysis, the selected miRNAs 
showed variable associations with glycaemic markers but not adiposity markers.
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4.2 Hypothesis 
Randomisation to metformin will alter the expression of the selected circulating 
miRNAs (mir-221, mir-222, mir-192, mir-193b, mir-144, and mir-155). After the 
cross-sectional data I hypothesised specifically that mir-144 was the most likely 
candidate biomarker (associated with HOMA) to be influenced by metformin. 
4.3 Aim 
To explore the effect of randomisation to metformin on circulating miRNAs (mir-
222, mir-221, mir-192, mir-193b, mir-155, and mir-144) using samples from the 
CAMERA RCT. 
 
107 
 
4.4 Methods 
4.4.1 Samples 
Samples from the CAMERA trial were used to conduct this study. A total of 154 
participants without diabetes and have large waist and CHD, were included in this 
study. Participants were randomly assigned to metformin or placebo and followed 
for 18 months (metformin = 73, placebo = 81) (Figure 3-1). Two stored EDTA 
plasma samples were used for each participant; one sample was taken at baseline, 
and the other after 18 months of treatment. A total of 308 paired stored plasma 
samples were processed. Samples were thawed and immediately processed. The 
paired samples were processed simultaneously. 
4.4.2 Total RNA extraction and miRNA quantification 
Details on RNA extraction and miRNA quantification can be found in the general 
methods chapter. Samples from each participant (baseline and 18 months) were 
extracted within a single run to reduce the variability of measurements within 
individuals. 
4.4.3 Statistical Analysis 
The selected miRNAs (mir-221, mir-222, mir-144, mir-155, mir-192, and mir-193b) 
were normalized to cel-mir-39 and expressed as dCt. All continuous classical risk 
factor variables were tested for normality by visual inspection of their histograms 
and normal Q-Q plots. Descriptive statistics were expressed as mean ± SD for 
normally distributed variables, and median ± inter-quartile range for non-normally 
distributed variables. Non-parametric variables were normalised by log 
transformation to use parametric tests. Categorical variables were summarised as 
number (%). Comparison between mean values of continuous variables between 
two groups (placebo and metformin) were evaluated using Student’s two-tailed t-
test for continues variables and chi-square test for categorical parameters.  
The relative quantification method (RQ) was used to compare the effect of 
metformin on the expression of the selected six miRNAs. It allows the 
quantification of the change in the gene expression level of a target gene across 
two samples, in our case baseline and 18-month samples. The results were 
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expressed as fold change of expression level in samples at 18 months compared to 
the baseline sample. This is done by first, calculating the differences in Ct 
between the target miRNA with that of the spiked-in external control (mir-39) 
from the same sample delta Ct (∆Ct) or dCt. After that, the ∆Ct was then used to 
calculate the delta Ct (∆∆Ct) (∆Ct baseline - ∆Ct after 18 months). Finally, RQ was 
calculated using the formula (2-∆∆Ct). The RQ value was considered significant 
when there was a minimum of two-fold change. The RQ change between the two 
groups (placebo and metformin) were calculated for each miRNA and plotted using 
a line graph. To confirm and extend the results of the RQ analysis, a mixed design 
two-way repeated measures ANOVA analysis was done to determine the effect of 
time (baseline and 18 months) on the expression of the six targeted circulating 
miRNAs (the dependent variable) in the metformin group compared to the placebo 
group. The ∆Ct for each miRNA at each time point was entered into the model, 
and the values were approximately normally distributed. The p-value from the 
interaction between randomisation group and time was reported as evidence 
against the null hypothesis that randomisation group had no effect on the miRNA. 
A p-value of < 0.05 was considered statistically significant evidence against the 
null hypothesis. 
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4.5 Results 
4.5.1 Baseline characteristics 
A total of 154 participants were studied, 73 in the metformin group and 81 in the 
placebo group. Table 4-1 summarises the baseline (before intervention) 
demographics, anthropometric measurements, biochemical characteristics, and 
miRNA expression of the two randomised groups (placebo and metformin).  
As the table demonstrates, the average age of our study population was 63 years, 
with a mean BMI of 30 kg/m2. Although all participants had no diabetes (mean 
glucose = 5.3), most of them were insulin resistance (mean HOMA-IR = 2.7). Among 
the six circulating miRNAs selected, mir-221 and mir-222 showed the highest 
expression in plasma while mir-144 showed the lowest expression. 
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Table 4-1: Baseline characteristics of the study population 
 Placebo group 
(n = 81) 
Metformin group 
(n = 73) 
Demographic Characteristics   
Age (years) 64 (8) 63 (8) 
Gender 
Male 
Female 
 
61 (74%) 
20 (25%) 
 
58 (80%) 
15 (20%) 
Smoking history 
Current 
Former 
Never 
 
16 (20%) 
45 (55%) 
20 (25%) 
 
16 (22%) 
33 (45%) 
24 (33%) 
Blood pressure (mm Hg) 140 / 79 (20 / 11) 140 / 79 (18 / 11) 
Anthropometric Characteristics   
Body weight (kg) 87.5 (14.8) 87.3 (11.9) 
Body mass index (kg/m2) * 30.7 (27.1 - 33.1) 29.4 (27.5 - 32.3) 
Waist circumference (cm) 104 (10) 105 (9) 
Body fat (kg) * 29.4 (23.4 - 32.9) 27.0 (23.1 - 32.1) 
Biochemical Characteristics (Fasting)   
Glucose (mmol/L) 5.2 (0.5) 5.3 (0.3) 
Insulin (pmol/L) * 9.7 (7.5 - 14.4) 10.0 (7.2 - 13) 
HOMA-IR* 2.3 (1.6 - 3.4) 2.3 (1.6 - 3.1) 
HbA1c (mmol/mol) * 38.2 (36 - 40) 38.7 (37 - 41) 
Adiponectin (µg/mL) * 5.6 (4.1 – 7.3) 5.8 (4.0 - 9.1) 
Triglyceride (mmol/L) *  1.5 (1.1 - 1.9) 1.4 (1.1 - 2.0) 
Total Cholesterol (mmol/L) * 4.3 (3.6 - 4.7) 4.2 (3.6 - 4.7) 
HDL (mmol/L) * 1.1 (1.0 - 1.4) 1.1 (1.0 - 1.3) 
Alanine aminotransferase (U/L) * 26.0 (18.5 - 33.5) 23.0 (19.5 - 35) 
γ-glutamyl transferase (U/L) * 35.0 (21.5 - 54) 34.0 (22.5 - 64) 
Inflammatory markers (fasting)   
High sensitivity C-reactive protein (mg/L) * 1.6 (0.9 - 3.2) 1.8 (0.8 - 3.9) 
WBC (x109 /L) * 6.5 (5.7 - 8.0) 7.0 (5.9 - 7.5) 
miRNA Expression   
mir-222 (dCt) 3.9 (1.6) 4.0 (1.8) 
mir-221 (dCt) 1.7 (1.6) 1.8 (1.7) 
mir-144 (dCt) 10.1 (1.4) 10.2 (1.3) 
mir-155 (dCt) 8.1 (1.2) 7.9 (1.3) 
mir-192 (dCt) 8.9 (1.4) 8.9 (1.8) 
mir-193b (dCt) 9.3 (1.4) 9.2 (1.7) 
*: Variables are not normally distributed, median (inter-quartile range) were used. 
HOMA-IR: Homeostatic model assessment for insulin resistance, HDL: high density lipoprotein, CRP: 
high sensitivity C reactive protein, WBC: white blood cells, mir: micro RNA, dCt: delta cycle 
threshold. 
111 
 
4.5.2 The Effect of Randomisation to Metformin 
Table 4-2 shows the effect of metformin treatment over 18 months on 
anthropometric measurements, biochemical characteristics, inflammatory 
markers, and circulating miRNAs expression. Metformin led to a significant 
reduction in all anthropometric measurements (weight, BMI, WC, and body fat 
weight) in the available samples used in this study, consistent with previously 
reported data in the intention to treat analysis (Preiss et al., 2014).  
Mean weight loss after 18 months for the metformin group was 3.3 kg versus 0 kg 
in the placebo group (p < 0.0001). Also, metformin treatment improved 
measurements of insulin and insulin resistance (insulin and HOMA-IR). There were 
no differences in lipid measurements (TAG, TC, and HDL), circulating adiponectin, 
and liver enzymes (ALT and GGT) between the two groups after 18 months of 
metformin treatment. Likewise, metformin did not affect both inflammatory 
markers used in this study (CRP and WBC) (p > 0.05). Furthermore, the expression 
of the selected circulating miRNAs between the two groups (placebo and 
metformin) were compared. There was no difference between both groups after 
18 months (P > 0.05).  
Change in the expression of circulating miRNAs after 18 months between the two 
groups are represented as line graphs in Figure 4-1 for mir-221, Figure 4-2 for 
mir-222, Figure 4-3 for mir-192,  
Figure 4-4 for mir-193b,  
Figure 4-5 for mir-155, and Figure 4-6 for mir-144. For all the selected 
circulating miRNAs, there was an increase in their expression in time in both 
groups. Results showed no differences in the expression of circulating mir-221, 
mir-222, mir-192, and mir-193 between the placebo and metformin groups (P > 
0.05). Although the expression of mir-144 and mir-155 were slightly reduced in 
the metformin group (Figure 4-6 and  
Figure 4-5 respectively), the reduction was not significant (P > 0.05).  
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Table 4-2: Effect of randomisation to metformin treatment at 18 months on anthropometric 
and biochemical characteristics and circulating miRNAs expression. 
 Placebo group 
(n = 81) 
Metformin group 
(n = 73) 
P-Value 
 
Anthropometric Characteristics 
 
   
Body weight (kg) 87.5 (15.2) 84.0 (12.4) < 0.001 
Body mass index (kg/m2) * 30.7 (27.1 - 33.0) 28.7 (26.1 - 31.3) < 0.001 
Waist circumference (cm) 104.4 (11.4) 101.8 (8.9) < 0.001 
Body fat (kg) * 28.2 (23.2 - 33.5) 25.1 (20.9 - 31.0) 0.046 
 
Biochemical Characteristics 
(Fasting) 
 
   
Glucose (mmol/L) 5.4 (0.9) 5.2 (0.6) 0.062 
Insulin (pmol/L) * 10.8 (7.6 - 17.6) 8.2 (6.3 – 12.4)  0.031 
HOMA-IR* 2.6 (1.7 – 4.1) 1.9 (1.4 – 2.9)  0.024 
HbA1c (mmol/mol) * 38 (36 - 40) 37 (36 - 39) 0.20 
Adiponectin (µg/mL) * 4.8 (3.3 – 7.7) 6.1 (4.3 – 9.3)  0.201 
Triglyceride (mmol/L) *  1.4 (1.1 - 1.8) 1.4 (1.1 – 1.9) 0.353 
Total Cholesterol (mmol/L) * 4.3 (3.7 - 4.9) 4.1 (3.4 - 4.5) 0.430 
HDL (mmol/L) * 1.1 (1.0 - 1.5) 1.1 (1.0 - 1.4) 0.065 
Alanine aminotransferase (U/L) * 25.0 (19 - 34) 22 (17 - 30) 0.346 
γ-glutamyl transferase (U/L) * 33.0 (21 – 54.5) 31.0 (18.5 – 47.5) 0.408 
Inflammatory markers (fasting)    
High sensitivity C-reactive protein 
(mg/L) * 
1.5 (0.7 - 2.9) 1.7 (0.8 - 3.3) 0.311 
WBC (x109 /L) * 6.5 (5.5 - 8.0) 6.7 (5.8 - 8.3) 0.231 
 
miRNA Expression 
 
   
mir-222 (dCt) 3.4 (1.7) 3.6 (1.7) 0.907 
mir-221 (dCt) 1.4 (1.7) 1.4 (1.6) 0.507 
mir-144 (dCt) 9.7 (1.4) 10.0 (1.5) 0.251 
mir-155 (dCt) 7.4 (1.3) 7.4 (1.2) 0.972 
mir-192 (dCt) 8.6 (1.6) 8.6 (1.5) 0.892 
mir-193b (dCt) 9.1 (1.5) 9.0 (1.6) 0.694 
*: Variables are not normally distributed, median (inter-quartile range) were used. 
HOMA-IR: Homeostatic model assessment for insulin resistance, HDL: high density lipoprotein, CRP: high 
sensitivity C reactive protein, WBC: white blood cells, mir: micro RNA, dCt: delta cycle threshold. 
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Figure 4-1: Line graph illustrating the RQ method for change for mir-222 between placebo 
and metformin groups over the 18 months.
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Figure 4-2: Line graph illustrating the RQ method for change for mir-221 between placebo 
and metformin groups over the 18 months.
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Figure 4-3: Line graph illustrating the RQ method for change for mir-192 between placebo 
and metformin groups over the 18 months.
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Figure 4-4: Line graph illustrating the RQ method for change for mir-193b between placebo 
and metformin groups over the 18 months.
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Figure 4-5: Line graph illustrating the RQ method for change for mir-155 between placebo 
and metformin groups over the 18 months.
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Figure 4-6: : Line graph illustrating the RQ method for change for mir-144 between placebo 
and metformin groups over the 18 months. 
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4.5.3 The effect of time and randomisation on the expression of 
circulating miRNAs  
ANOVA analysis was also performed to determine the effect of time (baseline and 
18 months) on the targeted circulating miRNAs expression and is it different 
between treatment groups (placebo and metformin). The results are shown in 
Table 4-3 (for mir-221), Table 4-4 for mir-222, Table 4-5 for mir-192, Table 4-6 
for mir-193b, Table 4-8 for mir-155, and Table 4-7 for mir-144. 
For all the targeted circulating miRNAs except mir-193b, there was an increase in 
their expression (lower ∆Ct) over time. This increase was shown in both groups 
separately and combined (placebo and metformin). However, in line with the RQ 
plots there was no evidence that metformin randomisation had an effect different 
from placebo across time for any miRNA. 
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Table 4-3: mixed design two-way repeated measures ANOVA time by treatment analysis for 
mir-221.  
Time p-value indicates evidence against the null hypothesis that time (in both treatment groups 
combined) has no effect on miRNA expression. Interaction p-value indicates evidence against the 
null hypothesis that metformin the same effect as placebo across time.  
Randomised Treatment * Time  
Randomised 
Treatment 
Time Mean 
95% Confidence Interval 
Lower Bound Upper Bound 
Placebo 
1 1.74 1.38 2.09 
2 1.45 1.09 1.81 
Metformin 
1 1.78 1.41 2.16 
2 1.42 1.04 1.80 
Time 1 = baseline, 2 = 18 months 
 
Table 4-4: mixed design two-way repeated measures ANOVA time by treatment analysis for 
mir-222. 
Time p-value indicates evidence against the null hypothesis that time (in both treatment groups 
combined) has no effect on miRNA expression. Interaction p-value indicates evidence against the 
null hypothesis that metformin the same effect as placebo across time. 
Randomised Treatment * Time 
Randomised 
Treatment 
Time Mean 
95% Confidence Interval 
Lower Bound Upper Bound 
Placebo 
1 3.89 3.52 4.26 
2 3.37 2.99 3.75 
Metformin 
1 4.02 3.63 4.41 
2 3.55 3.15 3.95 
Time 1 = baseline, 2 = 18 months 
 
Table 4-5: mixed design two-way repeated measures ANOVA time by treatment analysis for 
mir-192. 
Time p-value indicates evidence against the null hypothesis that time (in both treatment groups 
combined) has no effect on miRNA expression. Interaction p-value indicates evidence against the 
null hypothesis that metformin the same effect as placebo across time. 
Randomised Treatment * Time 
Randomised 
Treatment 
Time Mean 
95% Confidence Interval 
Lower Bound Upper Bound 
Placebo 
1 8.94 8.59 9.29 
2 8.63 8.29 8.96 
Metformin 
1 8.93 8.56 9.30 
2 8.59 8.24 8.95 
Time 1 = baseline, 2 = 18 months 
 
 
Time P = 0.014 
Interaction P = 0.775 
Time P < 0.001 
Interaction P = 0.509 
Time P = 0.007 
Interaction P = 0.920 
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Table 4-6: mixed design two-way repeated measures ANOVA time by treatment analysis for 
mir-193b. 
Time p-value indicates evidence against the null hypothesis that time (in both treatment groups 
combined) has no effect on miRNA expression. Interaction p-value indicates evidence against the 
null hypothesis that metformin the same effect as placebo across time. 
Randomised Treatment * Time 
Randomised 
Treatment 
Time Mean 
95% Confidence Interval 
Lower Bound Upper Bound 
Placebo 
1 9.26 8.92 9.60 
2 9.08 8.75 9.42 
 Metformin 
1 9.16 8.80 9.52 
2 8.99 8.64 9.34 
Time 1 = baseline, 2 = 18 months 
 
Table 4-7: mixed design two-way repeated measures ANOVA time by treatment analysis for 
mir-155. 
Time p-value indicates evidence against the null hypothesis that time (in both treatment groups 
combined) has no effect on miRNA expression. Interaction p-value indicates evidence against the 
null hypothesis that metformin the same effect as placebo across time. 
Randomised Treatment * Time 
Randomised 
Treatment 
Time Mean 
95% Confidence Interval 
Lower Bound Upper Bound 
Placebo 
1 8.11 7.84 8.38 
2 7.45 7.16 7.73 
Metformin 
1 7.91 7.63 8.20 
2 7.44 7.14 7.74 
Time 1 = baseline, 2 = 18 months 
 
Table 4-8: mixed design two-way repeated measures ANOVA time by treatment analysis for 
mir-144. 
Time p-value indicates evidence against the null hypothesis that time (in both treatment groups 
combined) has no effect on miRNA expression. Interaction p-value indicates evidence against the 
null hypothesis that metformin the same effect as placebo across time. 
Randomised Treatment * Time 
Randomised 
Treatment 
Time Mean 
95% Confidence Interval 
Lower Bound Upper Bound 
Placebo 
1 10.10 9.80 10.40 
2 9.72 9.40 10.03 
Metformin 
1 10.20 9.89 10.52 
2 9.99 9.65 10.32 
Time 1 = baseline, 2 = 18 months 
 
 
Time P = 0.152 
Interaction P = 0.982 
Time P < 0.001 
Interaction P = 0.370 
Time P = 0.009 
Interaction P = 0.457 
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4.6 Discussion 
In the previous chapter, it was shown that circulating mir-144, mir-222, mir-221, 
mir-192, mir-193b, and mir-155 showed a broadly associations with markers of 
metabolic risk using baseline samples of the CAMERA trial. In this chapter, the aim 
was to explore the effect of metformin on the same circulating miRNAs using both 
the baseline samples and the 18-month plasma samples from the CAMERA trial. As 
far as I’m aware, this is the first large randomised study of circulating miRNAs 
ever conducted. 
4.6.1 The Effect of Randomisation to Metformin 
In this study, randomisation to metformin showed no effect on the expression of 
circulating mir-221, mir-222, mir-144, mir-155, mir-192, and mir-193b. This was 
true in analysis using both achieved ∆Ct levels and using the RQ method 
traditionally employed in miRNA studies.  
An effect of metformin on circulating mir-222, mir-221, and mir-192 expression 
has been reported in previous studies.  Ortega et al. investigate the expression of 
10 circulating miRNAs (including mir-222 and mir-192) in plasma of patients with 
T2DM before (baseline) and three months after treatment in a randomised, 
placebo-controlled which they previously showed their dysregulation in 93 
patients with T2DM (Ortega et al., 2014). The study consisted of 18 patients with 
T2DM in the placebo group and 17 patients with T2DM in the metformin group. 
The study reported that metformin lead to a marked decrease of circulating mir-
222 (െ47%, P = 0.03), and increased mir-192 (49.5%, P = 0.022) in the metformin 
group and not placebo group. They also showed improvements in insulin resistance 
measured by hyperinsulinemic-euglycemic clamp Plus Intralipid/Heparin Infusion 
(െ 28%, P = 0.02), fasting glucose and HbA1c (െ12.7%, െ9.5%, respectively P = 
0.0001) in the metformin group. These changes are consistent with metabolic 
improvement in UKPDS (Holman et al., 2008).  Although participants in this study 
showed similar improvement in insulin resistance and not in glycaemia (Glucose 
and HbA1c) in the metformin group compared to placebo, there was no change in 
the expression of circulating mir-222 and mir-192. The discrepancy in the result 
may be due to differences in study population. The population in Ortega et al. 
study included participants with diabetes (FBG = 12 ± 3.4 mmol/L), whereas 
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participants in this study had no diabetes (FBG = 5.3 ± 0.5 mmol/L). Thus, the 
relationship between metformin and the selected circulating miRNAs found can 
be explained by an indirect effect of metformin on improving glycemia rather than 
a direct effect of metformin on these circulating miRNAs.  
Furthermore, a cross-sectional study done by Coleman et al. included 37 
participants undergoing coronary artery bypass surgery reported that subjects 
with diabetes on metformin (DMMet+, n = 10) exhibit lower levels of both mir-221 
and mir-222 measured in whole tissue homogenates of the internal mammary 
arteries tissue (IMAs) compared to subjects with diabetes whose current 
medications do not include metformin (DMMet-, n = 9) and comparable to the 
subjects without diabetes (ND, n = 18) (Coleman et al., 2013). They also found 
that there was an inverse correlation between the dose of metformin and the level 
of mir-221 and mir-222 (R2 = 0.3577, p < 0.01; R2 = 0.245, p < 0.05, respectively). 
Similar results were not observed in this study. The disagreement in results can 
be due to differences in study population (with diabetes vs. without diabetes) as 
was explained above. Also, different samples and different methodology used to 
measure the expression of miRNAs, which is considered the major factor for the 
inconsistency between studies. 
4.6.2 The effect of time and randomisation on the expression of 
circulating miRNAs  
For all the selected circulating miRNAs, there was an increase in their expression 
in time in both groups (placebo and metformin) as shown in Table 4-3 for mir-221, 
Table 4-4 for mir-222, Table 4-5 for mir-192, Table 4-6 for mir-193b, Table 4-8 for 
mir-155, and Table 4-7 for mir-144.  
As previously discussed, circulating miRNAs are stable in plasma despite the 
presence of RNase (Glinge et al., 2017; Moldovan et al., 2014). Moreover, studies 
have shown that circulating miRNAs remain stable even after boiling, high or low 
pH, prolonged storage time and multiple freeze-thaw cycles (Gilad et al., 2008; 
Moldovan et al., 2014; Shaffer, Schlumpberger & Lader, 2012). The reason for the 
increase could be pre-analytical variation. Different sample processing that were 
used to obtain plasma may varied between the baseline samples and the 18-month 
samples which may influence the number of circulating miRNAs. It is more likely 
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that separation of plasma was the critical pre-analytical variable that causes this 
increase and since I used stored plasma samples, I don’t have data to demonstrate 
this. Although this was a single centre trial with local blood separation performed 
rapidly, future studies should more clearly study the effects of pre-analytical 
variation on miRNA levels in plasma.  
The results observed in CAMERA are therefore somewhat inconsistent with the 
published literature. Cross-sectional studies are prone to confounding by 
indication, and small RCTs are notoriously difficult to evaluate for quality 
indicators. This study substantially advances the evidence base because of its 
large size and more credible RCT design.  
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4.7 Conclusion 
To the best of my knowledge, this study is one of the first studies to investigate 
the effect of a randomised intervention on miRNA expression using a large sample 
size. Randomisation to metformin failed to show any effect on the expression of 
circulating mir-222, mir-221, mir-192, mir-193b, mir-144, and mir-155 in 
population with coronary heart disease, and large waist but without diabetes. 
Inconsistency in results from different investigations could possibly be due to 
different clinical features and ethnicity of participants and different 
inclusion/exclusion criteria in different trials, which can lead to difficult 
interpretation and comparison between various investigations. Furthermore, 
miRNAs expression from different sources of samples (cellular and extracellular) 
should not be compared to each other and cannot be used interchangeably as 
biomarkers of disease. Besides, metformin, although first line drug and widely 
used, it has a relatively moderate metabolic effect. There are other glucose-
lowering drugs which are proven to have better metabolic benefits such as GLP-1 
Agonists (Hinnen, 2017). It has been found that GLP1 agonists can modulate the 
expression of different microRNAs (Capuani et al., 2018). It might be useful, to 
explore the effect of GLP-1 Agonists on the expression of the selected circulating 
miRNAs in an RCT setting. 
4.7.1 Strength and Limitations 
The CAMERA trial was a high-quality study with several strengths. First, its design 
as a randomised placebo-controlled double-blind trial, which is considered as the 
‘gold standard’ in evidence-based medicine for evaluating the effects of an 
intervention. Second, a well-defined large sample of participants (154) which 
were subjected to a strict inclusion/exclusion criterion. Finally, the well-
standardised approach to sample collection (from a single local centre) and 
sample handling (quickly processed and stored in െ 80Ԩ). The major weakness in 
this study is data normalisation, which is a major challenge in data analysis 
because there is no universal/well-accepted control for normalisation of 
circulating miRNA data. Other potential weaknesses were mentioned in the trial 
itself. First, fewer participants than needed completed the trial (158 completed 
vs. 180 needed according to our sample size calculation) and extra four 
participants were excluded in this study because they did not have both samples 
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baseline and 18 months (Total participants included = 154). Second, several 
participants discontinued or reduced treatment. Participants were followed up for 
18 months rather than 24 months. The study drug had a very moderate effect on 
metabolic profile in the selected patients. All these factors might have reduced 
our ability to detect a meaningful effect. 
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5 THE ASSOCIATION OF BODY FAT 
DISTRIBUTION WITH INFLAMMATION AND 
T2DM IN THE UK BIOBANK STUDY   
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5.1 Introduction 
The fact that most individuals with T2DM have overweight or obesity highlights 
the strong association between excess body fat and the development of T2DM. 
Although there is convincing evidence that links the two together, the actual 
mechanism not fully understood because metabolic effects of obesity are not 
always proportional to the amount of total body fat mass.   
Obesity has been evaluated mainly based on BMI, but recently strong evidence 
showed that the distribution of body fat might be critical to the development of 
T2DM (Neeland et al., 2012; Wander et al., 2013; Verboven et al., 2018). For 
instance, substantial weight loss in patients with type 2 diabetes can lead to a 
recovery of glycemic control and is related to loss of ectopic fat in the liver and 
pancreas. The causal link between fat distribution and diabetes is not entirely 
clear but thought to be because of a combination of insulin resistance, systemic 
inflammation, and lipotoxicity, direct toxic effects from triglyceride accumulating 
ectopically within organs instead of subcutaneous adipose tissue (SAT).  
Visceral adipose tissue (VAT), as a marker of adipose tissue dysfunction, plays a 
great role in metabolic dysfunction. Previous studies have considered VAT 
accumulation as a strong risk factor for developing T2DM (Sattar & Gill, 2014; 
Nordström et al., 2016; Janochova, Haluzik & Buzga, 2019). Moreover, excess 
visceral fat contributes to the increases in systemic inflammation by secreting 
more pro-inflammatory molecules (Osborn & Olefsky, 2012).  
It is still an ongoing debate whether dysfunctional adipose tissue (AT) leading to 
ectopic fat accumulation, inflammation or interaction between both, is a cause 
or rather a consequence of insulin resistance (IR) in obesity leading to T2DM. 
Therefore, this study was designed to investigate the relationship between fat 
location and T2DM and to identify if inflammation plays a role in this relation using 
data from the UK Biobank study.  
5.1.1 UK Biobank 
UK Biobank is a large scale prospective epidemiological study established by 
the Welcome Trust, Medical Research Council, Department of Health, Scottish 
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Government, and the Northwest Regional Development Agency and it was 
supported by the National Health Service (NHS). Also, it received funding from 
the Welsh Government, British Heart Foundation, Cancer Research UK, 
and Diabetes UK. The aim of the study was to improve, prevent, diagnose, and 
treat a wide range of illnesses, including cancer, heart diseases, and diabetes. It 
was approved by the North West - Haydock Research Ethics Committee in the UK 
(REC reference: 11/ NW/03820). The National Health Service (NHS) records were 
used to identify people to participate in the study. The invitation letters were 
sent to people who were 40-69 years old and living nearby one of the 22 
assessment centres (Figure 5-1) covering a variety of different socioeconomic and 
ethnic groups from all around the UK. This ensured a reliable detection of the 
associations between exposure and health outcomes. All participants gave written 
informed consent before enrolment following the principles of the Declaration of 
Helsinki. The study was conducted in stages. It started with two pilot studies. 
Afterward, the main recruitment for baseline assessment began. Later, several 
further assessments have been carried out for more phenotyping assessments (for 
example, the imaging study). Finally, follow-up data on health outcomes are 
collected mainly through linkage with routinely available national health datasets. 
5.1.2 Baseline assessment 
Baseline assessment recruited more than 502,000 people between the years 2006 
and 2010. It was done using a touchscreen questionnaire, a verbal interview with a 
trained member of staff, a series of physical examination, and a consent to access 
participants medical records. Participants also provided biological samples (blood, 
urine, and saliva) for future analysis.  
5.1.2.1 Imaging study 
The imaging study began in May 2014 and aims to recall 100,000 participants for 
detailed imaging scans of vital organs (brain, heart, abdomen, bones, carotid 
artery, and body composition) as well as a repeat of the baseline measurements. 
The study included Cardiac MRI scan, Body MRI scan, Brain MRI scan, 12-lead 
Electrocardiogram (ECG), Carotid ultrasound, and DEXA scan of the whole body, 
bone, and joint. Invitation letters were sent to people who live within a reasonable 
traveling distance to one of the imaging assessments centres and not on any other 
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information that has already been collected about the participants. Participants 
were excluded from the study if they have any metal or electrical implant (e.g., 
pacemaker) in their body, or if they have had recent surgery (less than six weeks), 
or if they had any medical problem that makes it difficult to take the scans (e.g., 
severe hearing or breathing problems, or tremors). 
5.1.3 Measurement of inflammation 
Activation of the immune system and inflammation associated with obesity has 
been implicated in the pathogenesis of T2DM. This activation can be detected by 
an increase in several markers, including cytokines and WBC. Most previous 
epidemiological research has focused on the role of CRP in predicting risk of type 
2 diabetes (Wang et al., 2013). Unfortunately, CRP measurement was not 
available at the time of analysis, so a decision was made to use only WBCs count 
as a marker of inflammation. Besides, total and differential WBCs (neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils) are widely recognized as a 
non-specific marker for systematic inflammation (Dixon & Brien, 2006). They are 
an objective marker of acute infection, tissue damage, and other inflammatory 
conditions. Studies have shown that an increase in the WBC count is closely related 
with all-cause mortality (Sun et al., 2005; Willems et al., 2010; Wang et al., 2018). 
In addition, evidence from large epidemiological studies suggests an association 
between total and peripheral WBCs count and diabetes risk (Schmidt et al., 1999; 
Vozarova et al., 2002; Twig et al., 2013). Furthermore, Chen et al. showed that 
both CRP and WBC were elevated in obesity, and weight loss results in reductions 
of both CRP and WBC to similar extents (Chen et al., 2009). 
Unlike cytokines or even CRP, WBC is measured routinely and cheaply, which 
makes the biomarker interesting to study academically for potentially wider 
indications than infection. Therefore, study of WBC as a biomarker of metabolic 
disease is at the opposite end of the spectrum of pragmatism compared to our 
previous novel work on miRNA.  
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Figure 5-1: Locations of UK Biobank assessment centres throughout the UK 
Taken from: https://biobank.ctsu.ox.ac.uk/crystal/exinfo.cgi?src=UKB_centres_map 
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5.2 Hypothesis 
I hypothesised that: 
1. Fat accumulation and distribution and WBC count differ between 
participants with and without T2DM. 
2. Abdominal fat accumulation, particularly VAT, is independently 
associated with T2DM. 
3. WBC count is more associated with abdominal fat accumulation. 
4. WBC count is the link between the relationship of VAT accumulation and 
T2DM.  
5.3 Aims 
Using the UK Biobank cohort, I will investigate in a cross-sectional analysis: 
1. Different patterns of body fat distribution (anthropometrics measurements, 
bio-impedance measurements, DEXA measurements, and MRI 
measurements) in both sexes and their association with T2DM. 
2. The association between the body fat distribution measurements and WBC 
count. 
3. The association of WBC count with T2DM. 
4. Investigate whether WBC count is a link between adiposity and the 
development of T2DM.
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5.4 Methods 
5.4.1 Study population 
To conduct this cross-sectional study, I included all body fat measurements 
available in the UK Biobank cohort at the time of analysis (data download Sept 
2018). To do this, I used two datasets, the baseline assessment dataset, which 
includes the anthropometric measurements and the bio-impedance analysis 
variables, and the imaging study dataset, which included the DEXA and MRI body 
fat variables. The total number of participants included were ≈ 500,462 
participants from the baseline study and ≈ 5995 participants from the imaging 
study. Due to these cohorts being substantially different in size and having 
different baseline dates, I treated them as separate cohorts in analysis and used 
all available data for each model. 
The present study was superficially ethically approved by UK Biobank in July 2017: 
application ID 20152. 
https://www.ukbiobank.ac.uk/2017/07/ms-tahani-al-ramah-the-relationship-
between-adiposity-and-low-grade-inflammation-as-mediators-of-metabolic-
dysfunction/ 
5.4.2 Variables included 
This section provides brief information on the variables used to conduct the 
current study. More details are available at the UK Biobank website:  
http://www.ukbiobank.ac.uk/    
5.4.2.1 Demographic variables 
Age 
Age of attending assessment centre variable was used. It is a derived variable from 
date of birth and date of attending assessment centre. Age was recorded in years. 
More details are available at: 
https://biobank.ctsu.ox.ac.uk/showcase/field.cgi?id=21022 
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Ethnicity 
In this study, I used the ethnic background variable to categorise the ethnicity of 
the participants. This variable was created from the combination of consecutive 
branching questions asked during the baseline assessment using the touchscreen. 
In this variable, ethnicity was categorised into eight groups (white, black, Asian, 
mixed, Chinese, other ethnic groups, do not know, and prefer not to answer). I 
recorded the ethnicity group as white, south Asian, black, Chinese, and others. 
Participants with “Don’t know” and “Prefer not to answer” responses were 
excluded from our analysis (n = 1961). More details are available at: 
https://biobank.ctsu.ox.ac.uk/showcase/field.cgi?id=21000 
Townsend Deprivation index 
The Townsend deprivation index is a measure of material deprivation within a 
population that was first introduced by sociologist Peter Townsend in 1987. It is 
calculated by using four variables of the population of each area, and a score is 
given accordingly. These variables are unemployment, non-car ownership, non-
home ownership, and household overcrowding. The higher the Townsend index 
score, the greater the degree of deprivation in this area. Townsend deprivation 
index was measured for each participant joining UK Biobank, and I used continuous 
scores derived for and published by the study. The score was calculated using the 
preceding national census output areas and their postcode. More details are 
available at: 
https://biobank.ctsu.ox.ac.uk/showcase/field.cgi?id=189 
Smoking and Alcohol status 
These variables were taken during the initial assessment visit using the 
touchscreen. Both variables were categorised into never, former, current, or 
prefer not to answer. More details are available at: 
https://biobank.ctsu.ox.ac.uk/showcase/field.cgi?id=20116 
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5.4.2.2 Type 2 Diabetes (T2DM) variable 
I identified participant as having baseline T2DM if they reported yes in diabetes 
diagnosed by doctor variable, which was obtained by touchscreen input, or if they 
self-reported specific conditions related to diabetes during interview (specifically, 
diabetes associated neuropathy/ulcers, diabetes associated nephropathy, and 
diabetes associated eye disease). 
http://biobank.ctsu.ox.ac.uk/crystal/coding.cgi?id=6  
I excluded patients with type one diabetes (T1DM) if the patient reported starting 
insulin within the one-year diagnosis of diabetes. This means patients with T1DM 
are not in the comparator group.  
5.4.2.3 Anthropometric measurements 
Weight  
Weight was measured by a variety of means during the assessment. I used the field 
that merges all these values into a single item. Weight was recorded in Kg. More 
details are available at: 
https://biobank.ctsu.ox.ac.uk/showcase/field.cgi?id=21002 
Height measurement 
Standing height variable was used which was obtained using a Seca 240 cm height 
measure stand. Height was recorded in centimetres. More details are available at: 
https://biobank.ctsu.ox.ac.uk/showcase/field.cgi?id=12144 
Body Mass Index (BMI) 
BMI was calculated using weight in kilograms divided by the square of the height in 
metres (kg/m2). Height and weight used for the calculation were measured during 
the initial assessment centre visit. More details are available at:   
https://biobank.ctsu.ox.ac.uk/showcase/field.cgi?id=21001 
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Hip and waist circumference measurements 
Hip and waist circumference measurements were collected from participants 
using a Seca 200 cm tape measure. Waist circumference was measured at the level 
of the umbilicus. For hip circumference measurement, the tape was lowered to 
the broadest part of the hips. Readings were recorded in centimetres. More details 
are available at:  
https://biobank.ctsu.ox.ac.uk/showcase/field.cgi?id=48 and 49  
5.4.2.4 Bioimpedance measurement 
Whole-body bio-impedance data were measured using a Tanita BC418MA body 
composition analyser. Measurement was done by passing an extremely low 
alternating current via the trunk, legs, and arms. All the data captured by the 
Tanita analyser were transmitted directly into the assessment centre software. 
Data included are: Whole-body fat mass, right and left legs fat mass, right and 
left arms fat mass, and trunk fat mass. More details are available at: 
https://biobank.ctsu.ox.ac.uk/showcase/label.cgi?id=100009 
5.4.2.5 Dual-Energy X-Ray Absorptiometry (DEXA) 
Dual-energy X-ray absorptiometry (DEXA) measurements were taken using the GE-
Lunar iDXA machine. A radiographer analysed scans and all measurements, 
including bone mass and body composition, were directly transferred to the UK 
Biobank servers. DEXA variables included are android fat mass, gynoid fat mass, 
arms fat mass, legs fat mass, total fat mass, trunk fat mass, and VAT mass. More 
details are available at: 
https://biobank.ctsu.ox.ac.uk/showcase/label.cgi?id=124 
5.4.2.6 MRI 
All measurements were performed using a Siemens Aera 1.5 T scanner (Syngo MR 
D13) (Siemens, Erlangen, Germany) with the dual-echo Dixon Vibe protocol, 
covering neck to knees. All fat measurements were measured in Volume (ml). 
Visceral adipose tissue (VAT) was defined as the fat within the abdominal cavity 
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between the top of the femoral head and the top of the thoracic vertebrae T9, 
excluding fat outside the abdominal skeletal muscles and fat and lipids within and 
posterior of the spine and posterior of the back muscles. Abdominal subcutaneous 
adipose tissue (ASAT) was defined as subcutaneous fat in the abdomen from the 
top of the femoral head to the top of the thoracic vertebrae T9. Total trunk fat 
was a derived variable calculated as a sum of VAT and ASAT volumes. More details 
are available at: 
https://biobank.ctsu.ox.ac.uk/showcase/refer.cgi?id=163332 
5.4.2.7 White Blood Cells (WBCs) Analysis 
The Complete Blood Count (CBC) was measured on fresh samples collected in a 4 
ml EDTA during baseline recruitments. Samples were analysed within 24 hours of 
blood draw at the UK Biobank central laboratory using Beckman Coulter LH750 
instruments. Total and differential WBCs (lymphocytes, monocytes, neutrophils, 
eosinophils, and basophils) results were measured as an absolute number per unit 
volume and proportions of the overall WBCs. Instrument quality control and 
calibration were performed according to the manufacturer’s recommendations. 
More details are available at: 
https://biobank.ctsu.ox.ac.uk/showcase/label.cgi?id=100002 
5.4.3 Statistical Analysis 
All analyses were pre-specified with an analysis plan, and a specific application to 
UK biobank to undertake this work. All body fat measurements were treated as 
continuous variables. Variables were tested for normality by visual inspection of 
their histograms and normal Q-Q plots. Descriptive statistics were expressed as 
mean ± SD. Comparison between mean values of a continuous variable in the two 
groups, no baseline diabetes (ND) and type 2 diabetes (T2DM) were evaluated 
using Student’s two-tailed t-test. Separate tables were done for each 
measurement method (anthropometric, bio-impedance, DEXA, and MRI).  
Pearson correlation (r) was used to investigate the association of WBC count with 
body fat measurements. Separate tables were done for each measurement method 
(anthropometric, bio-impedance, DEXA, and MRI). Additionally, a simple linear 
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regression analysis was performed to determine whether WBC count is an 
independent predictor for the presence of T2DM. Multiple linear regression 
analysis was also performed to adjust for potential confounders: age, ethnic 
background, smoking status, and socioeconomic status, as they are proven to be 
associated with both body fat and inflammation. I included BMI in the adjustment 
models although it is not a confounder for body fat, as I wanted to test if the 
associations of a specific body fat measurements with T2DM remained significant 
even after correcting for body mass using BMI. Standardised beta coefficient (SBC) 
was used to compare the effect each fat measurement has on WBC count. Specific 
assumptions of linearity were checked for linear regression models, constant 
variance, the linear association, and normality of residuals. Both sexes were 
analysed separately, regardless of evidence for interaction as a pre-specified. 
The association between body fat measurements and T2DM risk was determined 
by calculating the odds ratio (OR) and 95% confidence interval (CI) using binary 
logistic regression analysis, assumption for logistic regression analysis was checked 
(dependent variable were binary, little or no multicollinearity among the 
independent variables, linearity of independent variables and log odds, and large 
sample size). Similarly, different models were run to adjust for potential 
confounders, the same confounders as for linear regression. Both genders were 
analysed separately as pre-specified. 
All the statistical tests were performed using IBM SPSS (Statistical Package for 
Social Sciences) windows version 24 (SPSS Inc. Chicago, USA) and Microsoft Excel 
2016. The criterions for statistical significance was p < 0.05. As this is a hypothesis-
generating exploratory study, I did not employ any formal correction for multiple 
comparisons.  However, this should be borne in mind when interpreting p-values 
from comparisons.
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5.5 Results 
5.5.1 Description of adiposity in the UK Biobank Cohort grouped 
by sex and diabetes 
The baseline assessment data were used for both anthropometric and bio-
impedance analysis (N ≈ 500,462 participants). The imaging study data were used 
for DEXA and MRI (N ≈ 5,170 and 5,995 participants, respectively). Both data set 
were classified according to sex and the presence or absence of baseline Type 2 
diabetes (T2DM). Each group was analysed separately. Results were summarized 
in Table 5-1 for anthropometric characteristics, Table 5-2 for bio-impedance 
measurements, Table 5-3 for DEXA measurements, and Table 5-4 for MRI 
measurements.  
Overall, data from this study confirmed well-documented differences in body fat 
composition and distribution between males and females. Males were 14.3 kg 
heavier than females. Meanwhile, females had higher total body fat measured by 
both bio-impedance (4.8 kg higher) and DEXA (1.9 kg higher). Regarding fat 
location, females accumulate more fat in the peripheral area, which was 
demonstrated mainly by DEXA measurements (Table 5-3). Females had more fat 
in the gynoid area (1.1 kg), legs (2.2 kg) and arms (0.5 kg). In contrast, men 
accumulate more fat in the central area shown by the waist (12.1 cm), trunk fat 
(1.9 kg), android fat (0.5 kg), and VAT (1.1 kg).   
Table 5-4 shows the details of the truncal fat measured by MRI. Both sexes had 
almost similar truncal fat in both groups ND and T2DM. After separating each 
compartment of the truncal region into ASAT and VAT, men had more VAT fat (ND 
= 4.9 ± 2.3 and T2DM = 6.9 ± 2.9) while women had more ASAT fat (ND = 8.0 ± 3.4, 
T2DM = 11.2 ± 4.4). 
The prevalence of diabetes in this study population was higher in males (6%) 
compared to females (3%). All body fat measurements were higher in patients with 
T2DM compared to patients without diabetes (ND) in both sexes (p < 0.001). In 
comparison with males, the mean difference between the ND and T2DM groups for 
most body fat measurements were higher in females compared to males except 
for VAT (measured by both DEXA and MRI), which was higher in males. In fact, VAT 
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measurements in females with diabetes (1.7 ± 0.9 for DEXA and 4.7 ± 2.0 for MRI) 
was similar to VAT measurements in males without diabetes (1.7 ± 0.9 for DEXA 
and 4.9 ± 2.3 for MRI). The mean amounts of visceral fat were 1.7 kg for DEXA and 
4.7L for MRI in females with diabetes and 2.4 kg for DEXA and 6.9L for MRI in males 
with diabetes. 
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5.5.2 The association between adiposity and type 2 diabetes  
Binary logistic regression models were used to examine which body fat 
measurements were associated with diabetes.  First, I used univariate binary 
logistic regression to examine the crude association between each adiposity 
measurement and T2DM. After that, all the models were re-run adjusting for age, 
BMI, ethnic background, smoking status, and socioeconomic status. The binary 
logistic results were summarised in Table 5-5 for anthropometric characteristics, 
Table 5-6 for bio-impedance measurements, Table 5-7 for DEXA measurements, 
and Table 5-8 for MRI measurements. 
The univariate logistic regression analyses showed a significant association 
between all adiposity measurements and T2DM in both sexes (p < 0.001). 
Specifically, VAT measured by both DEXA and MRI showed the strongest association 
with T2DM and was greater in females compared to males;  in females OR (95% CI) 
= 4.90 (3.34 - 7.07) for DEXA and 1.858 (1.61 – 1.94) for MRI and in males OR (95% 
CI) = 1.94 (1.60 - 2.35) for DEXA and 1.39 (1.28 – 1.50) for MRI.  Android fat was 
also strongly associated with diabetes. 
After adjusting, the direction of the effect of some of the body fat measurements 
on T2DM changed from positive to inverse, making it appear as if this body fat 
measurement protects against T2DM. For example, for hip circumference the 
crude effect was, OR (95% CI) = 1.06 (1.06 - 1.06) in females and 1.062 (1.06 - 
1.06) in males p < 0.001. After adjustment including BMI, the direction of the 
effect changed to 0.95 (0.95 – 0.96) in females and 0.97 (0.96 – 0.97). This pattern 
was also true for arms fat, legs fat, and gynoid fat. Moreover, all the bio-
impedance body fat measurements (total body fat, trunk fat, arms fat, and legs 
fat) change the direction of the association with diabetes from positive to negative 
(p < 0.001) after adjustment (Table 5-6). This includes truncal fat, which was 
positively associated with type 2 diabetes using both DEXA and MRI measurement. 
In females, after adjusting for age, BMI, ethnic background, smoking status, and 
socioeconomic status, the relationship between diabetes and most measurements 
of adiposity disappeared except for waist, trunk fat measured by both DEXA and 
MRI, android fat, and VAT measured by both DEXA and MRI. The highest association 
was with VAT measured by DEXA, OR (95% CI) = 3.97 (2.32 - 6.79), android fat, OR 
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(95% CI) = 1.63 (1.14 – 2.23),  VAT measured by MRI, OR (95% CI) = 1.58 (1.29 – 
1.94), and trunk fat measured by MRI, OR (95% CI) = 1.11 (1.02 – 1.22). In males, 
after adjusting for age, BMI, ethnic background, smoking status, and 
socioeconomic status the association disappeared between adiposity and diabetes 
except for waist, OR (95% CI) = 1.04 (1.04 – 1.04), VAT measured by DEXA, OR (95% 
CI) = 1.59 (1.20 – 2.12), and VAT measured by MRI, OR (95% CI) = 1.27 (1.14 – 1.41). 
All the associations continued to be higher in females. 
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5.5.3 The association between adiposity and WBCs 
Person correlation analysis was used to examine the relationship between total 
WBC and differential WBC (neutrophils, lymphocytes, and monocytes) with 
adiposity measurements. Results are shown in Table 5-9 for anthropometric 
characteristics, Table 5-10 for bio-impedance measurements, Table 5-11 for DEXA 
measurements, and Table 5-12 for MRI measurements.  
All the adiposity measurements were positively correlated with total and 
differential WBC (p < 0.01). Total WBC showed positive correlation with android 
fat (r = 0.203) and trunk fat (r = 0.202 for DEXA and r = 0.182 for MRI). Monocytes 
showed the strongest correlation with VAT (r = 0.187 for DEXA and 0.183 for MRI) 
compared to the other WBCs. 
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To measure the association of each measurement of adiposity with total WBC 
count, I performed simple linear regression analysis. Multiple linear regression 
analysis was also performed to adjust for: age, BMI, ethnic background, smoking 
status, and socioeconomic status. Each sex was analysed separately, Table 5-13 
for females and Table 5-14 for males. In females, WC, android fat, and VAT (both 
DEXA and MRI) showed the strongest effect on WBC count (SBC = 0.189, 0.232, 
0.258, and 0.190 respectively). These results were modestly attenuated after the 
adjustment. In males, the same fat measurements had a similar but slightly lesser 
effect on WBC count with the addition of trunk fat measured by both DEXA and 
MRI (SBC = 0.185 and 0.198 respectively).  
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Table 5-13: Linear regression analysis of the association of WBC count with adiposity (females) from UK biobank 
 
Exposure N 
Model R 
square 
Beta coefficient (per 1 unit 
increase in exposure) 
(95% CI) 
Standardized 
beta 
coefficient  
(per 1 SD) 
P-value 
Anthropometric measurements 
Weight^ (kg) 258135 0.018 0.020 (0.019 - 0.020) 0.134 < 0.001 
Weight# 257826 0.061 0.021 (0.020 - 0.021) 0.141 < 0.001 
WC^ (cm) 258390 0.035 0.031 (0.03 - 0.031) 0.186 < 0.001 
WC* 257677 0.077 0.020 (0.018 - 0.021) 0.119 < 0.001 
HC^ (cm) 258374 0.017 0.026 (0.025 - 0.026) 0.129 < 0.001 
HC* 257682 0.077 - 0.023 [- 0.025 – (- 0.021)] - 0.115 < 0.001 
Bio-impedance measurements 
Total body fat^ (kg) 254562 0.024 0.032 (0.031 - 0.033) 0.155 < 0.001 
Total body fat* 254194 0.075 - 0.013 [- 0.016 - (- 0.011)] - 0.065 < 0.001 
Trunk fat^ (kg) 254471 0.020 0.055 (0.054 - 0.057) 0.141 < 0.001 
Trunk fat * 254105 0.054 - 0.011 [- 0.014 - (- 0.008)] - 0.027 < 0.001 
Arms fat^ (kg) 254555 0.027 0.471 (0.460 - 0.482) 0.165 < 0.001 
Arms fat* 254188 0.075 - 0.276 [- 0.321 - (- 0.231)] - 0.097 < 0.001 
Legs fat^ (kg) 254614 0.026 0.187 (0.182 - 0.191) 0.160 < 0.001 
Legs fat* 254247 0.076 - 0.177 [- 0.195 - (- 0.159) - 0.152 < 0.001 
DEXA measurements 
Total body fat^ (kg) 2619 0.038 0.033 (0.027 - 0.039) 0.196 < 0.001 
Total body fat* 2612 0.094 - 0.002 (- 0.013 - 0.01) - 0.011 0.750 
Trunk fat^ (kg) 2619 0.052 0.061 (0.051 - 0.071) 0.227 < 0.001 
Trunk fat* 2612 0.097 0.025 (0.007 - 0.042) 0.092 0.006 
Arms fat^ (kg) 2619 0.033 0.283 (0.225 - 0.341) 0.183 < 0.001 
Arms fat* 2612 0.094 - 0.001 (- 0.092 - 0.093) 0.00 0.988 
Legs fat^ (kg) 2619 0.010 0.052 (0.032 - 0.071) 0.099 < 0.001 
Legs fat* 2612 0.103 - 0.073 [ - 0.101 - (- 0.046)] - 0.142 < 0.001 
Android fat^ (kg) 2619 0.054 0.326 (0.274 - 0.378) 0.232 < 0.001 
Android fat* 2612 0.098 0.147 (0.059 - 0.235) 0.105 0.001 
Gynoid fat^ (kg) 2619 0.02 0.150 (0.110 - 0.190) 0.142 < 0.001 
Gynoid fat* 2612 0.097 - 0.092 [- 0.152 - (- 0.032)] - 0.088 0.003 
VAT^ (kg) 2586 0.066 0.713 (0.609 - 0.816) 0.258 < 0.001 
VAT* 2579 0.109 0.510 (0.366 - 0.654) 0.184 < 0.001 
MRI measurements 
Trunk fat^ (L) 3018 0.030 0.072 (0.057 - 0.087) 0.172 < 0.001 
Trunk fat* 3012 0.054 0.026 (0.000 - 0.051) 0.061 0.051 
ASAT^ (L) 3018 0.023 0.089 (0.066 - 0.106) 0.151 < 0.001 
ASAT* 3012 0.053 - 0.002 (- 0.038 - 0.033) - 0.004 0.899 
VAT^ (L) 3018 0.036 0.247 (0.201 - 0.292) 0.190 < 0.001 
VAT* 3012 0.061 0.161 (0.098 - 0.224) 0.124 < 0.001 
^: unadjusted, #: adjusted for age, ethnicity, and deprivation, *: adjusted for age, BMI, ethnicity, and 
deprivation. 
IDV: independent variable, USBC: unstandardized beta coefficient, SBC: standardised beta coefficient, 
CI: confident interval, WC: waist circumference, HC: hip circumference, ASAT: abdominal adipose 
tissue, VAT: visceral adipose tissue. 
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Table 5-14: Linear regression analysis of the association of WBC count with adiposity 
(Males) from the UK Biobank 
Exposure N 
Model R 
square 
Beta coefficient (per 1 unit 
increase in exposure) 
(95% CI) 
Standardize
d beta 
coefficient  
(per 1 SD) 
P-value 
Anthropometric measurements 
Weight^ (kg) 218539 0.006 0.011 (0.011 - 0.012) 0.074 < 0.001 
Weight# 218256 0.067 0.014 (0.013 - 0.014) 0.090 < 0.001 
WC^ (cm) 218847 0.023 0.029 (0.028 - 0.030) 0.151 < 0.001 
WC* 217999 0.079 0.020 (0.018 - 0.021) 0.102 < 0.001 
HC^ (cm) 218813 0.005 0.02 (0.019 - 0.021) 0.069 < 0.001 
HC* 218001 0.079 - 0.024 [- 0.026 – (- 0.021)] - 0.084 < 0.001 
Bio-impedance measurements 
Total body fat^ (kg) 214403 0.018 0.036 (0.035 - 0.037) 0.135 < 0.001 
Total body fat* 213949 0.078  0.018 (0.015 - 0.021)  0.068 < 0.001 
Trunk fat^ (kg) 214971 0.018 0.058 (0.056 - 0.060) 0.133 < 0.001 
Trunk fat* 214512 0.078  0.024 (0.020 - 0.028)  0.056 < 0.001 
Arms fat^ (kg) 215065 0.014 0.553 (0.534 - 0.573) 0.119 < 0.001 
Arms fat* 214606 0.077 0.065 (0.051 - 0.106)  0.013  0.009 
Legs fat^ (kg) 215102 0.018 0.224 (0.217 - 0.231) 0.133 < 0.001 
Legs fat* 214643 0.078 0.094 (0.079 - 0.108)  0.056 < 0.001 
DEXA measurements 
Total body fat^ (kg) 2388 0.028 0.030 (0.028 - 0.038) 0.168 < 0.001 
Total body fat* 2385 0.065  0.017 (0.005 - 0.029)  0.095 0.006 
Trunk fat^ (kg) 2388 0.032 0.047 (0.037 - 0.058) 0.180 < 0.001 
Trunk fat* 2385 0.067 0.033 (0.015 - 0.050) 0.123 < 0.001 
Arms fat^ (kg) 2388 0.023 0.307 (0.226 - 0.387) 0.151 < 0.001 
Arms fat* 2385 0.063  0.108 (- 0.013 - 0.228) 0.053 0.079 
Legs fat^ (kg) 2388 0.014 0.084 (0.056 - 0.112) 0.120 < 0.001 
Legs fat* 2385 0.062 0.010 (- 0.029 - 0.049)  0.014 0.631 
Android fat^ (kg) 2388 0.034 0.243 (0.191 - 0.295) 0.185 < 0.001 
Android fat* 2385 0.068 0.173 (0.088 - 0.258) 0.131 < 0.001 
Gynoid fat^ (kg) 2388 0.020 0.173 (0.124 - 0.222) 0.140 < 0.001 
Gynoid fat* 2385 0.062 0.044 (- 0.031 - 0.119) 0.035 0.253 
VAT^ (kg) 2363 0.034 0.319 (0.250 - 0.387) 0.185 < 0.001 
VAT* 2360 0.066 0.188 (0.090 - 0.287) 0.109 < 0.001 
MRI measurements 
Trunk fat^ (L) 2761 0.039 0.074 (0.061 - 0.088) 0.198 < 0.001 
Trunk fat* 2757 0.075 0.050 (0.028 - 0.072) 0.133 < 0.001 
ASAT^ (L) 2761 0.030 0.114 (0.09 - 0.139) 0.173 < 0.001 
ASAT* 2757 0.072 0.059 (0.021 - 0.097) 0.090 0.009 
VAT^ (L) 2761 0.036 0.137 (0.111 - 0.163) 0.191 < 0.001 
VAT* 3012 0.075 0.074 (0.039 - 0.110) 0.104 < 0.001 
^: unadjusted, #: adjusted for age, ethnicity, and deprivation, *: adjusted for age, BMI, ethnicity, and 
deprivation. 
IDV: independent variable, USBC: unstandardised beta coefficient, SBC: standardised beta coefficient, CI: 
confident interval, WC: waist circumference, HC: hip circumference, ASAT: abdominal adipose tissue, VAT: 
visceral adipose tissue. 
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5.5.4 The association of WBC count with type 2 diabetes by sex 
Binary logistic regression analysis was used to investigate the association between 
WBC count and diabetes. Results are shown in Table 5-15. Total WBC count was 
associated with diabetes in both sexes, OR = 1.21 (1.20 - 1.23), p > 0.001 for 
females and 1.12 (1.12 - 1.13), p < 0.001 for males. After controlling for BMI, age, 
smoking, and deprivation, the association remained strong in females while it 
deteriorated in males but remained significant. Furthermore, when analysing each 
type of WBC separately, they were associated with diabetes, but these 
associations change after adjusting. Out of the three types of WBC types, 
monocytes showed the strongest relationship with diabetes in males, OR (95% CI) 
= 1.73 (1.63 - 1.83) which decreased after adjustment for age, BMI, smoking status 
and deprivation, OR (95% CI) = 1.20 (1,12-1.28). In females, monocytes were highly 
associated with diabetes, OR (95% CI) = 1.43 (1.32 - 1.54) but adjustment led to a 
massive reduction in the association, OR = 1.10 (1.01 - 1.19). Moreover, 
neutrophils showed association with diabetes, OR (95% CI) = 1.31 (1.29 - 1.33) for 
females and 1.21 (1.20 - 1.23) for males, which didn’t change much after adjusting 
for age, BMI, smoking status and deprivation. The association between T2DM and 
neutrophils were considerably higher in females compared to males.  
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Next, I repeated Table 5-5, Table 5-6, Table 5-7, and Table 5-8 (Binary logistic 
regression analysis of the association between adiposity and diabetes) showing 
only central adiposity measurements since they are more associated with T2DM. I 
adjusted for age, BMI, smoking status, and deprivation and adjusted for the total 
WBC count. The reason for adjusting for total WBC count was to investigate 
whether the relationship between adiposity and diabetes was mediated by WBC 
count. Results are demonstrated in Table 5-16. In females, the association 
between diabetes and WC, trunk fat, android fat, and VAT remained significant 
even after the adjustment for age, BMI, smoking status and deprivation and total 
WBC count.  
The strongest association with T2DM was by VAT measured by DEXA, OR (95% CI) 
= 3.67 (2.10 – 6.43), android fat measured by DEXA, OR (95% CI) = 1.67 (1.15 – 
2.42), and VAT measured by MRI, OR (95% CI) = 1.64 (1.33 – 2.02). In males, the 
association between diabetes and both WC and VAT remained significant after the 
adjustment for age, BMI, smoking status and deprivation and total WBC count with 
VAT showing the strongest association, OR (95% CI) = 1.53 (1.14 – 2.05) measured 
by DEXA and OR (95% CI) = 1.27 (1.14 – 1.42) measured by MRI. 
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Table 5-16: Binary logistic regression analysis of the association between central adiposity 
and T2DM from the UK Biobank by sex 
Variable 
Females Males 
N 
OR  
(95% CI) 
P-Value N 
OR  
(95% CI) 
P-Value 
Anthropometric measurements 
Waist^ (cm) 272372 
1.08  
(1.08 - 1.08) 
< 0.001 228090 
1.07 
 (1.064 - 1.067) 
< 0.001 
Waist* 270531 
1.08  
(1.08 - 1.09) 
< 0.001 225912 
1.04  
(1.04 - 1.04) 
< 0.001 
Waist
♦
 256686 
1.08  
(1.08 - 1.09) 
< 0.001 216806 
1.04  
(1.03 - 1.04) 
< 0.001 
Bio-impedance measurements 
Trunk fat^ (kg) 268163 
1.14 
 (1.13 - 1.14) 
< 0.001 224000 
1.14  
(1.14 - 1.14) 
< 0.001 
Trunk fat* 266727 
0.97  
(0.97 - 0.98) 
< 0.001 222280 
1.01  
(1.00 - 1.02) 
0.006 
Trunk fat
♦
 253139 
0.98  
(0.98 - 0.99) 
< 0.001 213346 
1.01  
(1.00 - 1.02) 
0.004 
DEXA measurements 
Trunk fat^ (kg) 2713 
1.14  
(1.10 - 1.19) 
< 0.001 2457 
1.09  
(1.06 - 1.12) 
< 0.001 
Trunk fat* 2700 
1.09  
(1.01 - 1.17) 
0.029 2447 
1.05  
(0.99 - 1.10) 
0.107 
Trunk fat
♦
 2607 
1.09  
(1.01 - 1.17) 
0.025 2378 
1.04  
(0.98 - 1.10) 
0.172 
Android fat^ (kg) 2713 
2.03  
(1.69 - 2.45) 
< 0.001 2457 
1.54  
(1.34 - 1.77) 
< 0.001 
Android fat* 2700 
1.63  
(1.14 - 2.23) 
0 .008 2447 
1.23  
(0.95 - 1.59) 
0.110 
Android fat
♦
 2607 
1.67  
(1.15 - 2.42) 
0.007 2378 
1.20  
(0.93 - 1.56) 
0.169 
VAT^ (kg) 2678 
4.90  
(3.34 - 7.07) 
< 0.001 2457 
1.94  
(1.59 - 2.35) 
< 0.001 
VAT* 2607 
3.97  
(2.32 - 6.79) 
< 0.001 2421 
1.59 
 (1.20 - 2.12) 
0.001 
VAT
♦
  2575 
3.67  
(2.10 - 6.43) 
< 0.001 2353 
1.53  
(1.14 - 2.05) 
0.004 
MRI measurements 
Trunk fat^ (L) 3145 
1.20  
(1.15 - 1.26) 
< 0.001 2850 
1.15  
(1.10 – 1.19) 
< 0.001 
Trunk fat*  3131 
1.11  
(1.02 – 1.22) 
0.023 2837 
1.08 
 (1.00 – 1.15) 
0.045 
Trunk fat
♦
  3005 
1.13  
(1.03 - 1.24) 
0.014 2748 
1.07  
(1.0 - 1.15) 
0.066 
ASAT^ (L) 3145 
1.23  
(1.153 - 1.311) 
< 0.001 2850 
1.16 
 (1.09 – 1.23) 
< 0.001 
ASAT* 3131 
1.02  
(0.90 - 1.61) 
0.713 2837 
0.92 
 (0.82 – 1.04) 
0.167 
ASAT
♦
   3005 
1.00 
(0.91 - 1.18) 
0.626 2748 
0.91 
(0.81 - 1.03) 
0.133 
VAT^ (L) 3145 
1.86  
(1.61 - 2.14) 
< 0.001 2850 
1.38  
(1.28 – 1.5) 
< 0.001 
VAT* 3131 
1.58  
(1.29 – 1.94) 
< 0.001 2837 
1.27  
(1.14 – 1.41) 
< 0.001 
VAT
♦
   3005 
1.64  
(1.33 - 2.02) 
< 0.001 2131 
1.27 
 (1.14 - 1.42) 
< 0.001 
^: unadjusted, *: adjusted for age, BMI, ethnicity, and deprivation, ♦:  adjusted for age, BMI, ethnicity, 
deprivation, and WBC  
T2DM: type two diabetes mellitus, OR: odds ratio, CI: confident interval, ASAT: abdominal adipose tissue, 
VAT: visceral adipose tissue. 
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Finally, I repeated Table 5-15, but this time, I investigated whether the 
association of WBC with diabetes was mediated by body fat distribution. Here, I 
wanted to test whether the association between diabetes and WBCs was linked to 
these specific adiposity measurements (Table 5-17, for total WBC count), (Table 
5-18, for Lymphocytes count), (Table 5-19, for monocytes count), and (Table 5-20, 
for neutrophil count). 
In females, the association between T2DM and WBC count remained significant 
even after adjusting for the different body fat measurements. Out of the three 
sub-types of WBC count, neutrophils showed the strongest association with T2DM 
after adjusting for all the chosen body fat measurements (Table 5-20). The 
strongest association between T2DM and neutrophils was shown after the 
adjustment of trunk fat and android fat measured by DEXA, OR (95% CI) = 1.48 
(1.22 – 1.81), and 1.46 (1.19 – 1.78) respectively.  
In males, the adjustment of BMI and WC didn’t change the association between 
T2DM and WBC count. The strongest associations were with monocytes, OR (95% 
CI) = 1.20 (1.12 – 1.28), and 1.18 (1.11 – 1.26) respectively. Adjusting for the other 
body fat measurements (android fat, trunk fat, and VAT) remove the association 
between WBC count and T2DM. 
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5.6 Discussion 
The present study was conducted to explore the links between body fat 
distribution, WBC count, and T2DM using the UK Biobank cohort. To accomplish 
that, all the adiposity measurements available in the UK Biobank study were used: 
anthropometric measurements, bio-impedance measurements, DEXA scans, and 
MRI scans to conduct this study. Each of these methods employs different ways to 
measure body fat, either direct or indirect measurement. 
5.6.1 Adiposity and T2DM 
In the current study, the prevalence of diabetes was higher in males (6%) 
compared to females (3%). This was similar to previous studies done in several 
large cohort studies (Yang, Dou & Song, 2010; Anjana et al., 2011; Logue et al., 
2011; Soriguer et al., 2012).  
This study showed that central obesity was independently associated with T2DM 
in both sexes and was a strong predictor for the development of T2DM than total 
body fat. Out of all the central obesity measurements used in this study, VAT was 
a strong predictor for T2DM. The association of central adiposity with diabetes is 
well established. Several longitudinal studies have confirmed that visceral fat is 
more strongly associated with T2DM than total body fat (Neeland et al., 2012; 
Wander et al., 2013; Nordström et al., 2016). Moreover, the association between 
VAT and T2DM in this study was stronger in females compared to males, although 
females with T2DM had less VAT than males with T2DM. In general, sex plays an 
important role in fat distribution. Adult females have more subcutaneous fat and 
can accommodate excess energy better than males by expanding the SAT. 
Therefore, females must put on more weight to reach the point where SAT become 
dysfunctional, leading to ectopic fat accumulation. Meanwhile, males ability to 
store excess fat in SAT is low leading to more ectopic fat accumulation with weight 
gain (Sattar, 2013). Also, studies have shown that differences in body fat 
distribution between males and females tend to diminish after menopausal age. 
Female body fat distribution after the menopause shows an increase of abdominal 
fat shifting to android or visceral adiposity, leading to a similar risk for diabetes 
to males. This provides an explanation of why men develop diabetes at a lower 
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BMI leading to a higher prevalence of diabetes among men. In general, younger 
females need to gain more weight than males to reach a threshold of ectopic fat 
accumulation that leads to insulin resistance and dysglycaemia. 
5.6.2 Total and peripheral WBC count 
Total and peripheral WBC count has been suggested to be associated with diabetes 
risk (Vozarova et al., 2002; Veronelli et al., 2004; Twig et al., 2013; Vatcheva et 
al., 2015). A recent meta-analysis of 20 studies including ;90,000 participants 
demonstrated a positive correlation between increased WBC level and diabetes 
risk (Gkrania-Klotsas et al., 2010). The aim of this study was to assess whether 
WBC count is associated with both body fat distribution and T2DM and can be a 
link between the two. 
5.6.2.1 Adiposity and WBC count 
In the current study, the association of adiposity with WBC count was investigated. 
All adiposity measurements were positively correlated with total and differential 
WBCs with VAT showing the strongest correlation with monocyte concentration. 
Generally, in this study VAT showed the strongest association with WBC count in 
both sexes. These findings were in agreement with previous studies showing that 
obesity, and more particularly central obesity, are associated with elevated 
peripheral and total WBC count (Panagiotakos et al. 2005; Dixon & Brien 2006; 
Farhangi et al. 2013), but extend these by comparing a range of different 
measurements in far larger samples size. All previous reports used anthropometric 
measurements or bioimpedance to measure body fat, which does not adequately 
represent the distribution and the actual amount of body fat, and they are less 
useful as an independent marker for metabolic risk. 
Borga et al. have examined different modes of adiposity measurement in UK Bio 
bank, using data from 4753 subjects (Borga et al., 2018). They report that whole-
body measurements of adipose tissue (AT) by DEXA and quantitative MRIs show 
excellent agreement with linear correlation of 0.99, and coefficient of variation 
(CV) of 4.5% for fat (computed from AT), but the agreement was found 
significantly lower for visceral adipose tissue, with a CV of >20%. Our study adds 
to this information by relating adiposity measurements to real clinical outcomes. 
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In UK Biobank, our use of DEXA, and MRI scans which are proven to be a more 
reliable and precise for body fat measurements. A recent study by Sung et al. 
using a non-contrast computed tomography (CT) to measure visceral fat showed 
that visceral adiposity was associated with higher circulating WBC count (Sung et 
al., 2018). The study included 3291 Taiwanese with a mean age of 49.8 ± 9.8 years. 
Together with MRI scans, CT is considered the gold standard for analysing body fat 
composition and distribution (Borga et al., 2018). Therefore, by including MRI for 
body fat measurements, the results of this study add robust evidence on the 
relationship between VAT and WBCs. In line with chapter 1, there are clear 
biological mechanisms to suggest why VAT is particularly proinflammatory (Figure 
1-7). The evolutionary reasons that VAT may be proinflammatory are still being 
debated (West-Eberhard, 2019). 
5.6.2.2 WBC count and T2DM 
A growing body of evidence suggests that inflammation can activate various signal 
transduction cascades, including many of the pathways that are associated with 
insulin action and pancreatic β-cell function which leads to insulin resistance and 
T2DM (Prattichizzo et al., 2018). In the current study, this possibility was 
investigated using total and differential WBC count. The results showed that 
elevated total and differential WBC count were risk factors for developing T2DM 
in both sexes, although this appears to be mediated by visceral fat deposits. 
Previous prospective studies have investigated the association between WBC count 
and T2DM; a recent prospective study was done by Gu et al. examined the 
relationship between the incidence of diabetes and WBC count in 47,678 Chinese 
participants without diabetes (Gu et al., 2018). In a period of 9 years, 1463 
participants developed diabetes. They found that participants with elevated WBC 
count were at higher risk of developing T2DM in both groups’ participants with 
obesity and participants without obesity compared with participants with low WBC 
count. In addition, a prospective cohort study by Volzorova et al. on Pima Indians 
with baseline normal glucose tolerance found that total WBC counts to be an 
independent risk factor for the development of T2DM, after controlling for age, 
gender and percent of body fat (Vozarova et al., 2002). All these studies showed 
that the relationship between T2DM and WBC was independent of body weight. 
However, this study has specific strengths beyond existing relevant literature by 
using a large sample size (> 400,000 participants).  
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In contrast, other studies showed that the relation between WBC and T2DM was 
found only in patients with obesity. A cohort study was done by Twig et al. to 
examine if WBC count was independently associated with T2DM among 24,897 
young Israeli men (Twig et al., 2013). Participants were periodically screened for 
diabetes during a mean follow-up of 7.5 years. They found that high WBC count 
was associated with an increased risk of diabetes in men with overweight or 
obesity and not normal-weight men (BMI ≤ 25). Furthermore, a second cohort 
study was done on 3000 Mexican American adults with obesity and followed them 
for ten years (Vatcheva et al., 2015). They showed that WBC count was related to 
the risk of T2DM. The relationship they found was only seen in participants with 
obesity, and not in overweight or normal-weight participants. Age and ethnicity 
can partially explain the cause for conflicting results as these studies included 
participants of varying age and ethnicity, which are independent risk factors for 
T2DM. Besides, these studies use BMI to try to link the association between T2DM 
and WBC count which cannot distinguish between lean and fat mass and provides 
no indication of body fat distribution which may be a key for the association with 
WBCs and not total obesity per se.  
5.6.3 WBC count a putative link between obesity and T2DM 
Further examination of the association between body fat distribution, WBC count, 
and T2DM was done. In the previous sections, it was shown that VAT was an 
independent risk factor for developing diabetes in both sexes and VAT was 
associated with an increase in total and differential WBC concentration. Also, 
T2DM was associated with a high WBC count. Thus, the possibility that WBCs could 
be the link between VAT and T2DM was examined since it has been shown that 
VAT is an independent risk factor for T2DM (Frikke-Schmidt et al., 2016; 
Janochova, Haluzik & Buzga, 2019). In the current study, WBC count was 
associated with VAT but was not linked to T2DM. This was observed by the higher 
odds ratio in participants with T2DM that remained significant even after adjusting 
for WBC count (Table 5-16). The results of this study was in agreement with other 
study that showed that inflammation agreed with a recent far smaller study done 
by Rakotoraivelo et al. were they compare the expression of several pro- and anti-
inflammatory cytokines in serum, SAT, and VAT from 89 obese patients undergoing 
bariatric surgery to 13 control patients (Rakotoarivelo et al., 2018). They showed 
that in obese patients, the expression of cytokines is higher in VAT compared to 
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SAT and is independent of their diabetes status. Moreover, a study was done using 
the randomised double-blind CANTOS trial to test the effects of canakinumab (IL-
1b inhibitor) on reduces incident diabetes (Everett et al., 2018). The authors 
randomised 10,061 patients with prior myocardial infarction and C-reactive 
protein (CRP) ≥ 2 mg/l to placebo or canakinumab. Despite significant reductions 
in CRP and IL-6, IL-1β inhibition with canakinumab over five years did not reduce 
the risk of new-onset diabetes. There was only temporary improvement of HbA1c, 
nor did it have long-lasting effects on glycemia among those with diabetes.  
The findings of the current study were consistent with the hypothesis that ectopic 
fat accumulation as a marker for subcutaneous adipose tissue dysfunction is the 
link between obesity and T2DM (Sattar & Gill, 2014) and that inflammation 
associated with T2DM could simply be a bystander related ectopic fat 
accumulation. That does not mean that inflammation derived from adipose tissue 
is necessarily unimportant to other chronic conditions such as CVD (West-
Eberhard, 2019).  
Another major finding of this study was gender differences in the immune response 
in T2DM. In this study, it was shown that central obesity was responsible for the 
association between WBCs and T2DM in males. While in females, the association 
between WBCs, particularly neutrophils, and T2DM is not entirely explained by 
central adiposity. This was evident by the remainder of the association even after 
adjusting for central adiposity measurements. The reason for this is not clear but 
may be due to differences in their responses to inflammatory stimuli. Gender 
differences in immune responses have been documented (Bhatia, Sekhon & Kaur, 
2014). Females have better immune capabilities with higher immunoglobulin 
levels and stronger immune and inflammatory responses than males. This is 
evident in their lower incidence of infections but increased susceptibility to 
autoimmune diseases (Zandman-Goddard et al., 2013). Nevertheless, this 
difference diminishes after menopause, which may indicate that it is most 
probably due to the effect of sex hormones (Yang et al., 2016). 
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5.7 Summary 
5.7.1 What was already known? 
· Excess VAT is associated with insulin resistance (IR) and type 2 diabetes 
(T2DM). 
· VAT and central fat mass generally are associated with inflammation 
measured by cytokines 
· Inflammation may play a role in the development of T2DM. 
5.7.2 What does this study add? 
· VAT is an independent risk factor for developing T2DM: after adjustment 
each kg increase in VAT measured by DEXA was associated with 4-fold 
higher odds of T2DM in females and 1.5-fold in males. 
· WBCs count was associated with VAT. 
· The association between WBCs and T2DM is probably mainly explained by 
fat deposits in the visceral region, although the converse is not true. 
5.7.3 What are the implications and future research needs? 
· For metabolic risk assessment, body fat distribution measurements 
provide supporting information to crude total body fat. 
· Understanding the role of body fat distribution in the pathogenesis of 
T2DM is important for the development of therapeutic strategies to treat 
the disease. 
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5.8 Conclusion 
Assessing body fat distribution is likely to be more important to clinical metabolic 
risk than total body fat. Visceral fat despots measured by DEXA or MRI are best, 
but if not pragmatic, waist circumference may be acceptable. Bio-impedance is 
not a useful substitute for measuring regional fat deposits.  
5.8.1 Strength and limitation 
One of the major advantages of using UK Biobank to conduct our study, besides 
its large sample size, is that all the measurements have been performed in a 
unified and standardized way on all participants. Although the UK biobank cohort 
is not representative of the general population, its well-design, comprehensive 
phenotyping, and large size sample make it a reliable source to measure 
associations and risk factors between baseline characteristics and disease 
outcomes. There are potential limitations of this study. Lack of laboratory data to 
accurately diagnose T2DM. First, the cross-sectional approach used does not 
provide strong evidence in cause-effect relationships. Therefore, causality cannot 
be inferred from this work. Second, although I adjusted for many variables to 
minimize the potential for confounding, I cannot rule out the role of unmeasured 
confounders. Third, participants in the UK Biobank cohort are relatively healthy 
and may not be fully representative of the U.K. population (Manolio et al., 2012). 
The work requires external validation and will have greater power as greater 
numbers of participants undergo MRI. 
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6 REDUCTION OF ADIPOSE LEVELS OF 
INFLAMMATION WHEN TREATING OBESITY: 
FEASIBILITY STUDY  
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6.1 Introduction 
Given the fact that obesity is one of the strongest risk factors for developing T2DM 
(De Ferranti & Mozaffarian, 2008; Malnick, 2006; Bray, 2004), strong evidence 
suggests that tackling obesity early before the development of β-cell dysfunction, 
or even after diagnosis, can improve or even reverse T2DM (American Diabetes 
Association, 2018). Obesity is a complex problem with no single solution to apply 
to everyone. Several strategies for weight loss have been introduced; among these 
methods, bariatric surgeries were considered the most effective treatment in 
obtaining substantial and durable weight loss in severe obesity. 
Bariatric surgery (BS) can be defined as a surgical intervention that leads to large 
scale weight loss in obese patients. Since its development in the early 1950s, a lot 
of modification and improvements have been done to the original procedure 
(Nguyen & Varela, 2016). The development of new techniques led to the following 
two types of bariatric surgeries: 1. Gastric restriction procedures that decrease 
food intake and promote a feeling of satiety after meals, 2. Gastric restriction 
procedures with malabsorption that reduce the absorption of calories, proteins, 
and other nutrients. Recently, all procedures are done laparoscopically and 
include four types which are: laparoscopic adjustable gastric banding (LAGB), 
sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and biliopancreatic 
diversion with or without duodenal switch (BPD+DS), Figure 6-1 (Pareek et al., 
2018). The efficacy of bariatric surgery for sustained weight loss over time is well 
established. In a meta-analysis including 136 studies, 5 of them were randomised, 
with a total of 22,094 patients undergoing metabolic surgery showed a mean 
weight loss of 40 kg (Buchwald et al., 2004). In another meta-analysis done by 
Gloy et al. including 11 randomised control trials with 796 obese patients (Gloy et 
al., 2013b), bariatric surgery resulted in a 26 kg greater weight loss than 
nonsurgical treatment (95% confidence interval 21-26kg).  
Recent evidence has shown that bariatric surgery is not just better for losing 
weight but is also superior in improving the metabolic dysfunction associated with 
obesity, particularly diabetes. The glycaemic improvement was thought to be only 
related to caloric restriction and malabsorption, but more recent studies have 
demonstrated that alterations of the gastrointestinal tract associated with 
bariatric surgery change the secretion of gut hormones and neurotransmitters 
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Figure 6-1: Types of bariatric surgeries. 
LAGB: Laparoscopic adjustable gastric banding, SG: sleeve gastrectomy, RYGB: Roux-en-Y gastric 
bypass, BPD/DS: biliopancreatic diversion with or without duodenal switch. Reproduced from 
(Schauer et al., 2016) with permission. 
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affecting appetite, satiety, energy expenditure, and glucose metabolism (Le Roux 
et al., 2006; Miras & le Roux, 2013). Evidence continues to accumulate, showing 
that bariatric surgery is superior in achieving glycaemic control than conventional 
medical therapy. Recently, 11 randomised controlled clinical trials Table 6-1 were 
published comparing bariatric surgery with medical intervention in 794 obese 
patients with T2DM (Schauer et al., 2016). The surgical procedures evaluated were 
RYGB (7 studies), LAGB (4 studies), BPD (1 study), and SG (1 study). The number 
of patients in each study ranged from 38 for the smallest study and 150 patients 
for the most extensive study. Postoperative follow up in each study ranged from 
6 months to 5 years. Despite the variability in the 11 RCTs in both design and 
patients’ characteristics, they were all, except one study (Ding et al., 2015), 
supportive of the superiority of bariatric surgery compared to non-surgical 
treatments for glycaemic control. The study that didn’t agree (Ding et al., 2015) 
showed that LAGB and intensive medical diabetes and weight management 
program have similar 1-year benefits on diabetes control (remission for LAGB and 
medical treatment was 33% and 23%, respectively, P = 0.46). The reason for this 
result could be because the BS used was LAGB, which is less effective than the 
other BS (Himpens, 2008). Also, the studied population included patients with 
advanced T2DM (HbA1c 8.2% ± 1.2%, 40% on insulin) who might have less response 
to intervention.  
The most apparent effect of BS is loss of up to half of total adipose tissue mass 
within the first year after surgery along with improvements in metabolic function 
(Galanakis et al., 2015). The improvement in metabolic health observed after BS 
could be related to the restore function of SAT and most importantly the change 
in adipocyte size since the size of adipocytes dramatically influence the body 
metabolic function. Several studies investigating adipocyte size after BS found 
that adipocytes become smaller reaching diameters similar to lean controls 
(Cancello et al., 2013; Aghamohammadzadeh et al., 2013). In line with these 
observations, Anderson et al. reported that improvements in whole body insulin 
sensitivity 2 years after RYGB correlated strongly with a larger reduction in 
adipocyte size (Andersson et al., 2014).  
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Also, it is worth considering the impact of bariatric surgery on the function of 
adipose tissue as an immunological organ capable of modulating not only immune 
populations in other tissues but also metabolic outcomes. 
To advance our understanding of metabolic disturbance associated with obesity 
and why bariatric surgery is superior to other treatment options the REduction of 
Adipose Levels of Inflammation when Treating obesitY (REALITY) study was 
proposed. In this study BS will be used as a model of metabolic change (before 
and after weight loss) to study inflammatory markers, hormonal changes, 
adipocyte size, and miRNA expression. Conducting such a study is not easy, and 
Glasgow has specific practical challenges. Firstly, getting patients to participate 
in such studies and donating tissue samples is challenging. Secondly: there is low 
number of bariatric surgeries performed per year (~ 45) carried out at only two 
hospitals: Queen Elizabeth hospital or Glasgow Royal Infirmary, which means small 
sample number, and it is vital to be available for opportunities to enrol. Thirdly is 
the location of hospitals in Glasgow. Tissue sample collected must remain viable 
to be used for further analysis. The hospitals are located far away (~3.1 miles) 
from the university lab, so transportation of the samples must be organised. 
Finally, there is no standard published method for sample collection, handling, 
and processing, and analysing, to use directly therefore, the assessment of the 
reproducibility of the methods that will be used must be done before 
implementing them in a large-scale study. So, before starting this study, I will do 
a feasibility study to test the ability to overcome these challenges. 
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6.2 Aims 
Before starting the REALITY (Reduction of adipose levels of inflammation when 
treating obesity) study, a pilot study was done to assess the feasibility of 
conducting such a study in Glasgow. The aim of the study was to: 
1. Assess patient willingness to participate and to give adipose tissue 
samples at the time of surgery. 
2. Determine the optimal collection, handling, and storage of blood and 
adipose samples for studying adipocyte morphology and miRNA 
expression. 
3. Test the reproducibility of the chosen methods that will be used later in 
the large-scale study. 
Research Questions: 
Can I recruit patients to the study? 
Can I transport samples to the University within a sufficient time window? 
How best to transport samples to the university? 
Do I have the resources and equipment needed to conduct the study? 
Am I able to extract enough (> 100 ng) total RNA? 
What is the best way to normalise miRNA expression in both adipose tissue and 
plasma samples? 
Am I able to measure the expression of selected miRNAs in both plasma and 
adipose tissue? 
Am I able to get good quality Haematoxylin and Eosin (H&E) slides to measure 
adipocyte diameter? 
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6.3 Methods 
6.3.1 Generation of protocol  
In order to determine the optimal collection, handling, and storage of blood and 
adipose tissue samples, I need first to decide what type of analytical methods I 
am going to use in our study. This was done by first, going through the literature 
to look for methods and protocols for studying adipocyte morphology and miRNA 
expression. Second, discuss the methods with other groups in the building who are 
expert in this field (Dr. Ian Salt) to make sure that I can conduct these protocols 
in our lab and to receive the proper training on these protocols under their 
supervision, and our own Standard Operating Procedure developed.  
6.3.1.1 MiRNA expression 
RNA is highly sensitive to degradation, and although this may not be as much of 
an issue for mature miRNA the issue requires study. Collection and handling 
samples can significantly affect the amount and quality of RNA extracted from 
samples. For circulating miRNAs, I decided to use the same protocol I standardised 
in the previous studies (Chapter 2.2). For adipose tissue, I will compare two 
methods for tissue preservation: 1. Snap freezing, on dry ice, is the most common 
method used for stabilising tissue samples intended for RNA analysis. 2. 
Submerging the tissue in RNALater, which is a stabilising reagent that helps to 
stabilise the RNA and prevent degradation.  
6.3.1.2 Adipocyte diameter 
Two methods are commonly used for measuring adipocyte diameter: Collagenase 
digestion and histological analysis. The histological method is the commonly used 
method when the main aim is adipose tissue morphology. The disadvantages of 
this method are, it is more time consuming, require well-trained personnel, and 
the mean fat cell size is lower compared with collagenase digestion (Laforest et 
al., 2017). In the collagenase digestion, adipose tissue is digested with collagenase 
to separate mature adipocytes from the stroma-vascular fraction by floatation. 
This method can be performed using basic laboratory equipment and is less time 
consuming. The main limitation of this method is it must be determined 
immediately after isolation, if the cell suspension is stored it causes changed in 
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the cell morphology such as distortion in larger isolated adipocytes (Gamage, 
Yashodara & Senanayake, 2018). Therefore, I decided to use the histological 
method because immediate analysis cannot be done in our arrangement. Besides, 
histological slide can be stored and used to assess adipocyte cell size in a 
retrospective manner. 
6.3.2 Analytical plan 
The next step was to organise with hospital staff involved in specimen collection 
to explain the study and what is exactly needed from them. I first met with the 
surgeon involved, Mr. Simon Gibson, and the Anaesthetist to develop a system that 
worked with the normal flow of their operating theatre. After that, instructions 
on how to collect and preserve the sample were explained to the surgeon and all 
the medical staff involved in the process of sample collection.  
Finally, a Letter of access to conduct research through NHS Greater Glasgow and 
Clyde was approved (Appendix 4) and GCP (Good clinical practice) license was 
granted (Appendix 5) to start our study.  
6.3.3 Patient Recruitment 
This study was conducted in accordance with the protocol approved by the 
Research Ethics Committee based on the ethical standards in the Helsinki 
declaration (Appendix 6). 
Invitation letters (Appendix 7) and information leaflet explaining the scientific 
background of the study were sent by post to 5 patients who were: participating 
in the SCOTS Study (Logue et al., 2015), were due to have bariatric surgery in 
Greater Glasgow and Clyde and have consented to be contacted for future 
research studies. During their pre-operative clinic appointment, the researcher 
explained the study further and answered the patient’s questions. Patients who 
agreed to participate signed informed consent (Appendix 8). Details demographic, 
anthropometric, and biochemical characteristics were taken from the 
preoperative assessment, around two weeks prior to the operation. Bariatric 
procedures were performed laparoscopically by a single surgeon. 
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6.3.4 Sample Collection and Processing 
All surgeries were performed by Mr. Simon Gibson at the Queen Elizabeth 
University Hospital (QEUH). All preparations such as tubes, fixatives, equipment, 
labelling were done early in the morning at the day of the surgery in the University 
Lab then taken to QEUH by taxi before the surgery started. Upon arrival at the 
surgical theatre, tubes were hand into the surgical staff for samples collection.  
For blood samples, they were taken by the Consultant anaesthetist before general 
anaesthesia was induced. All patients were fasting before the surgery.  Samples 
were kept on ice until processed. After approximately 2 hours, at the end of the 
surgery, 2cm3 of subcutaneous adipose tissue was taken by the surgeon from the 
laparoscopic port site. The AT sample was divided by the surgeon in the operation 
theatre into three small pieces and placed in the labelled sterile tube. After that, 
non-sterile theatre staff delivered the sample outside the theatre.  Immediately, 
one sample was snap frozen on dry ice, and the other two were fixed, one in 
RNALater, and the other one in Zinc Formalin. The sample was then transferred 
by the researcher using a taxi back to the university lab. Upon arrival at the 
University Laboratory (approximately within 1 hour of the collection), samples 
were immediately processed and stored at െ 80 Ԩ for subsequent analysis (Figure 
6-2). 
6.3.4.1 Blood 
Fasting blood samples were taken by the Consultant Anaesthetist from the patient 
having their bariatric surgery, having fasted for at least 12 hours and before 
general anaesthesia was induced (3 ൈ 9 ml EDTA tube and 1 ൈ 4 ml plain). Samples 
were kept on ice until processed within 4 hours of collection. Upon their arrival to 
University Laboratory, one plain tube and one EDTA tube were immediately 
centrifuged at 3000 rpm for 15 min. The harvested serum and plasma were stored 
frozen at െͺͲԨ for subsequent analysis in 300 µl labelled aliquots to avoid 
frequent freezing and thawing. The second EDTA tube was used for measuring 
glycated haemoglobin (HbA1C). The last EDTA blood tube was aliquoted and stored 
at െͺͲԨ  as whole blood for total RNA extraction (which was carried out within 
one month of blood collection) and subsequent measuring miRNA expression. 
Serum samples were used for measuring glucose, insulin, and high sensitivity C 
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reactive protein (CRP). The plasma sample was used for measuring total 
adiponectin. 
6.3.4.2 Adipose Tissue 
Two cm3 of subcutaneous adipose tissue was removed by the surgeon via the port 
site of the laparoscopic equipment at the end of the bariatric surgery procedure. 
Freshly excised adipose tissue was immediately dissected into three small pieces 
and kept in the sterile labelled tubes handed in before the surgery. Two of the 
three pieces were used for RNA extraction and miRNA quantification and 
expression. The first piece was fixed in RNALater (Thermo Fisher Scientific, 
Loughborough, Cat: AM7020), which is an aqueous solution that rapidly penetrates 
fresh tissues to stabilize and protect RNA and eliminates the need to process or 
freeze samples immediately. The second piece was immediately snap frozen on 
dry ice. The last piece was fixed in zinc formalin for morphological studies. All 
samples were kept on ice until they were transported to the university lab (~ 1 
hour). 
6.3.5 Biochemical Analysis 
Fasting blood Glucose (FBG), high sensitivity CRP, HbA1C, and insulin were 
analysed in the clinical biochemistry laboratory at the University of Glasgow.  FBG, 
CRP, and HbA1C were analysed using an automated clinical analyser Cobas C311 
(Roche Diagnostics; Burgess Hill, UK). Insulin was measured by a commercial ELISA 
(Mercodia, Uppsala, Sweden). The intra-assay coefficient of variation was 5·5%, 
and the inter-assay coefficient of variation was 9·7% for insulin. Insulin sensitivity 
was calculated using the HOMA-IR formula (Chapter Error! Reference source not 
found.). Plasma adiponectin was measured with ELISA Kit (Quantikine Human 
Adiponectin/Acrp30 Immunoassay, Cat. No. SRP300). Intra- and Inter- coefficient 
of variation is 4.1% and 4% respectively at adiponectin concentration = 7 μg/ml. 
Details on methods used are found in the general methods (Chapter 2.4.1). 
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6.3.6 miRNA Extraction and Expression 
Total RNA was extracted from plasma and adipose tissue samples (RNALater and 
snap frozen). The expressions of mir-221, mir-222, mir-144, mir-155, mir-192 and 
mir-193b (targeted based on previous literature, chapter 3.1.2) were measured 
using real-time quantitative polymerase chain reaction (RT-qPCR). Samples from 
each patient were run simultaneously. Details on the methodology are found in 
the general methods of chapter 2.2.  
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Figure 6-2: Sample processing in the Feasibility study
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6.3.6.1 Normalisation and quality control for qRT-PCR results 
Normalisation of qRT-PCR results in reference (housekeeping) gene was done for 
both samples plasma and adipose tissues. 
Plasma 
Mir-16 was tested as an endogenous control for plasma in this study in addition 
to using mir-39 as an exogenous control. Details are found in chapter 2.3.1. 
Adipose Tissue 
Three endogenous controls miRNAs were tested (mir-103, mir-331, and RNU44) 
using both snap frozen adipose tissue and RNAlater fixed adipose tissue. 
6.3.7 Measuring Adipocyte Diameter 
Adipose tissue fixed in 10% zinc formalin was used for adipose tissue morphological 
analyse.  
6.3.7.1 Slide Preparation 
Adipose tissue ̱Ͷ݉݃pieces taken were fixed in 10 % Zinc Formalin Fixative 
(ZFF) over 24 hours at room temperature. After that, tissue was switch to 70% 
alcohol and kept at 4Ԩ until processing. 
6.3.7.2 Processing and Embedding 
Fixed tissues were placed into embedding cassettes in a tissue processor (Shandon 
Excelsior, Thermo Scientific), and dehydrated through a serial alcohol gradient 
and xylene before placing in paraffin wax ready for sectioning. Conditions for 
embedding were as follows: 
1. 70 % alcohol 2 hours  
2. 80 % alcohol 3 hours  
3. 95 % alcohol 4 hours  
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4. 100 % alcohol (1) 4 hours  
5. 100 % alcohol (2) 5 hours  
6. 100 % alcohol (3) 5 hours 
7. 100 % alcohol (4) 6 hours  
8. 50 % alcohol / 50 % Xylene 4 hours  
9. Xylene (1) 5 hours 
10. Xylene (2) 5 hours  
11. Wax (1) 5 hours 
12. Wax (2) 5 hours  
13. Wax (3) 6 hours 
6.3.7.3 Sectioning of Tissue Block 
Adipose tissue blocks were trimmed on a manual rotary microtome (RM2235, 
Leica) to a five μm thick ribbons. Paraffin ribbons were placed in a water bath at 
40Ԩ after they were collected onto silane treated slides (Clarity Microscope 
Slides). Eight slides were obtained from each sample with 3 - 4 sections on each 
slide. Sections were baked on to slides at 60Ԩ for 4 hours followed by 40Ԩ 
overnight. Once slides were prepared, they were stored at room temperature until 
staining. 
6.3.7.4 Haematoxylin & Eosin staining  
Paraffin-embedded adipose tissue sections were rehydrated by moving down an 
alcohol gradient. Paraffin was removed from sections by two consecutive washes 
in Histoclear for 7 minutes. This was followed by washing in 100% ethanol for 7 
minutes, 95% ethanol for 7 minutes, and finally, 70% ethanol for 7 minutes. 
Sections were rehydrated by keeping them in water for 7 minutes. After that, 
sections were stained in Haematoxylin for 2 minutes, followed by 5 minutes wash 
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under running tap water. Slides were dipped into 70% ethanol for 30 seconds then 
stained with Eosin for 2 minutes. Sections were dehydrated again by running them 
up a concentration gradient of ethanol: Two 30 seconds washes of 95% ethanol, 
followed by two washes in 100% alcohol (one for 1 minute and the second for 7 
minutes). Finally, slides underwent two washes in Histoclear for 5 minutes before 
being mounted using DPX. Slides were left overnight to dry.  
6.3.7.5 Images 
Slides were first viewed using a light microscope (Olympus BX41) on an X 10 
objective lens. Images from each section were taken with a QImaging Go-3 camera 
attached to the microscope. Generated images were then opened using QCapture 
Pro 6.0 software. Serial static digital images were captured and stored in separate 
folders corresponding to specimen number. The total number of images per 
sample were 12. All images were stored in uncompressed 24-bit color TIFF format. 
6.3.7.6 Image Analysis (Semiautomated method)  
All images generated were analysed using Adiposoft, an open-source ImageJ 
plugin software for the analysis of adipose tissue cellularity in histological sections 
which was developed in MATLAB (MathWorks, Natick, MA). The software can be 
downloaded from: 
http://imagej.net/Adiposoft#Installation 
The software was validated and considered to be a fast and accurate quantitative 
analysis for adipocytes measurements (Galarraga et al., 2012). Calibration of the 
software was carried out before image analysis. This was achieved by using a 
Micrometre Glass Slide, also known as a Stage Graticule Slide, for Microscope 
Calibration 1mm Horizontal Scale 100 divisions -10 µm intervals (Olympus, Tokyo) 
(Figure 6-3). The calibration was done using the same microscope and 
magnification lens (X 10 magnification). The minimum threshold for adipocyte 
diameter was set to 25 µm (Galarraga et al., 2012). Adipocyte number, area, and 
diameter data were generated by the program after scanning 12 images for each 
patient. The histological images were also manually analysed and edited. Cells 
touching the screen edge, overlapping with adjacent cells or distorted by tissue 
cutting were excluded from the analysis. The final image represented whole 
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undistorted adipocytes of variable dimensions and shape (Figure 6-4). Data were 
saved as spreadsheet files for further statistical analysis. 
6.3.8 Statistical Analysis 
The selected miRNAs were normalized to cel-mir-39 and expressed as Ct. Variables 
were tested for normality by visual inspection of their histograms and normal Q-Q 
plots. Non-parametric variables were normalized by log transformation to use 
parametric tests. Descriptive statistics were expressed as mean ± SD for normally 
distributed variables, and median ± inter-quartile range for non-normally 
distributed variables. Comparison between mean values of the two methods of 
adipose tissue fixation, RNALater (RL), and snap freezing on dry ice (SF) was 
evaluated using Student’s two-tailed t-test. Adipocyte size was grouped according 
to diameter into four groups small < 50 µm, medium 50 – 69 µm, large 70 – 89 µm, 
and very large > 90 µm (Verboven et al., 2018). Bar chart graphics were used to 
describe adipocyte diameter distribution 
All the statistical tests were performed using IBM SPSS (Statistical Package for 
Social Sciences) windows version 22 (SPSS Inc. Chicago, USA) and Microsoft Excel 
2016. The criterions for statistical significance was p < 0.05. 
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Figure 6-3: Micrometre glass slide used to calibrate adipocyte images 
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Figure 6-4: Adipose tissue image from a study patient, analysed by Adiposoft program 
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6.4 Results 
6.4.1 General characteristics of patients included in the study 
Table 6-2 summarises the general characteristics of the study population. A total 
of 5 patients undergoing bariatric surgery (4 Females and 1 Male) were included 
with a mean age of 37.4 ± 11.1 years. All patients were apparently healthy, with 
two patients showing slightly elevated blood pressure. Four patients were non-
smokers, and one patient quit smoking prior to surgery. Mean BMI was 45 ± 3.7 
kg/m2, which is categorised as class III obesity according to WHO guidelines. 
Patients were normoglycemic, glucose = 5.3 ± 0.4 mmol/L and HbA1C = 38.6 (36-
41) mmol/mol. In addition, patients were insulin sensitive, mean HOMA-IR = 1.1 
and adiponectin = 3.2 µg/ml. High sensitive CRP was slightly elevated mean CRP 
= 5.3 mg/L.  
6.4.2 Adipose tissue samples 
I compared the two methods, snap freezing, on dry ice (SF) and submerging the 
tissue in RNALater (RL), in terms of total RNA extracted, expression of 
housekeeping genes, and the expression of the six miRNA I am interested in. 
6.4.2.1 Total RNA Extracted 
The total RNA concentration was isolated from both snap frozen and RNALater 
adipose tissue samples from all five patients (Table 6-3). The mean concentration 
of total RNA extracted was 36.4 ng/µl from snap frozen adipose tissue samples 
and 40.4 ng/µl from RNALater adipose tissue sample. There was no difference in 
RNA concentration between the RNALater adipose tissue samples and the snap 
frozen adipose tissue samples (p > 0.05) in terms of the amount of total RNA 
extracted. 
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Table 6-2: Patients Characteristics 
Demographic Characteristics Mean (SD) 
Age (years) 37.4 (11.1) 
Blood pressure (mm Hg) 119/81 (16/9) 
Anthropometric Characteristics  
Body weight (kg) 127.6 (7.1) 
Body mass index (kg/m2) * 45 (3.7) 
Biochemical Characteristics (Fasting)  
Plasma Glucose (mmol/L) 5.3 (0.4) 
Insulin (pmol/L) *  5.2 (2.1-9.3) 
HOMA-IR* 1.1 (0.25-2.3) 
HbA1C (mmol/mol) 38.6 (36-41) 
Adiponectin (µg/mL) *  3.2 (1.1-9.9) 
High sensitivity C-reactive protein (mg/L) * 5.3 (2.6-21.2) 
*: Variables w not normally distributed were summarized as median (inter-quartile range).  
HOMA-IR: Homeostatic model assessment for insulin resistance, HbA1c: Haemoglobin 
A1c, SD: standard deviation. 
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Table 6-3: Total RNA concentration from five patients using two preservative methods (snap 
frozen and RNALater). 
Patient RNALater Conc. (ng/µL) Snap Frozen Conc. (ng/µL) 
1 20.8 39.5 
2 23.6 29.9 
3 40.4 36.4 
4 44.5 27.9 
5 42.3 41.6 
Median (IQR) 
40.4 
(22.2 – 43.4) 
36.4 
(28.9 – 40.3) 
Conc : concentration, IQR : inter quarter range 
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6.4.2.2 Normalisation of miRNA expression 
Housekeeping genes or control genes were used to normalise the expression of 
genes between different samples. However, the expression level of these 
housekeeping genes may vary among tissues. In this study, I tested three 
housekeeping genes (mir-103, mir-331, and RNU44) which have been used for 
normalizing miRNA expression adipose tissue. Table 6-4 show the comparison 
between the expression of these housekeeping genes of the two adipose tissue 
samples (snap frozen vs. RNALater). There is no difference in the expression of 
these selected housekeeping genes between the two adipose tissue samples (p > 
0.05, for all three). When comparing the expression of the three housekeeping 
genes in adipose tissue RNU44 was highly expressed (Ct = 24) and more stable 
between samples (SD > 0.25) than the other two housekeeping genes (mir-103 and 
mir-331). 
6.4.2.3 Expression of targeted miRNAs 
Table 6-5 shows the expression of six miRNA in both adipose tissue samples. These 
miRNAs were chosen to be included in our study based on our previous literature 
search (Chapter 3.1.2), which showed evidence that their expression change by 
the influence of BMI and glycaemic control. There was no difference in their 
expression between the two adipose tissue methods (RNALater and snap frozen). 
In general, mir-193b was highly expressed in adipose tissue compared to the other 
miRNAs. 
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Table 6-4: Comparing the expression of housekeeping genes between adipose tissue 
samples collected using RNALater or snap frozen. 
miRNA 
AT (RL) 
Ct Mean (SD) 
AT (SF) 
Ct Mean (SD) 
P-Value 
Mir-103 31.9 (1) 31.9 (0.7) 0.972 
Mir-331 31.0 (1.5) 31.5 (1.7) 0.627 
RNU44 24.0 (0.2) 24.0 (0.1) 0.803 
miRNA: micro RNA, Ct: cycle threshold, AT: Adipose tissue, SF: snap frozen, RL: RNALater, SD: standard 
deviation 
 
 
Table 6-5: Comparing the expression of the selected six miRNAs in both snap frozen and 
RNALater adipose tissue samples. 
miRNA 
AT (RL) 
Ct Mean (SD) 
AT (SF) 
Ct Mean (SD) 
P-Value 
Mir-222 30.5 (1.6) 31.0 (1.4) 0.590 
Mir-221 31.4 (0.9) 32.3 (1.2) 0.232 
Mir-192 34.7 (0.7) 35.1 (0.4) 0.073 
Mir-193b 26.6 (1.5) 27.2 (1.3) 0.971 
Mir-144 34.0 (0.9) 35.0 (0.6) 0.422 
Mir-155 34.1 (1.1) 34.1 (1.1) 0.501 
miRNA: micro RNA, Ct: cycle threshold, AT: Adipose tissue, SF: snap frozen, RL: RNALater, 
SD: standard deviation 
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6.4.3 Adipocyte Diameter 
Adipocyte size was categorised into four groups small < 50 µm, medium 50 – 69 
µm, large 70 – 89 µm, and very large > 90 µm. A bar chart was constructed showing 
the adipocyte size distribution for each participant as shown in section b of 
figuresFigure 6-5, Figure 6-6, Figure 6-7, Figure 6-8, and  
Figure 6-9 while section a demonstrate one H&E section from each patient SAT 
sample. Table 6-6 describes the adipocytes measurements in SAT samples taken 
from all five patients. The mean adipocyte diameter was 58.2 ± 26 µm. In this 
study, participants had higher proportions of small adipocytes. 
Table 6-6: SAT adipocyte measurement analysis in all five patients 
Patients 
Total 
Adipocytes 
counted 
Adipocyte 
Diameter (µm) 
Mean (SD) 
Small 
< 50 
(%) 
Medium 
50 – 69 
(%) 
Large 
70 – 89 
(%) 
V. Large 
> 90 
(%) 
1 634 59.8 (29) 47.3 18.6 15.0 19.1 
2 839 58.2 (26) 46.8 21.8 16.4 14.9 
3 927 59.4 (23) 40.3 28.2 21.3 10.2 
4 721 57.7 (25) 46.6 23.9 16.8 12.8 
5 752 56.1 (27) 52.4 20.7 12.5 14.4 
SD: standard deviation     
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Figure 6-5: Patient 1 SAT 
a) H&E slide showing adipocytes. b) bar chart represents adipocyte size distribution categorised 
into small < 50 µm, medium 50 – 69 µm, large 70 – 89 µm, and very large > 90 µm. The mean 
adipocyte diameter = 59.8 ± 29µm. 
 
a 
b 
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Figure 6-6: Patient 2 SAT 
a) H&E slide showing adipocytes. b) bar chart represents adipocyte size distribution categorised 
into small < 50 µm, medium 50 – 69 µm, large 70 – 89 µm, and very large > 90 µm. The mean 
adipocyte diameter = 58.2 ± 26 µm. 
 
 
 
a 
b 
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Figure 6-7: Patient 3 SAT 
a) H&E slide showing adipocytes. b) bar chart represents adipocyte size distribution categorised 
into small < 50 µm, medium 50 – 69 µm, large 70 – 89 µm, and very large > 90 µm. The mean 
adipocyte diameter = 59.4 ± 23 µm. 
a 
b 
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Figure 6-8: Patient 4 SAT 
a) H&E slide showing adipocytes. b) bar chart represents adipocyte size distribution categorised 
into small < 50 µm, medium 50 – 69 µm, large 70 – 89 µm, and very large > 90 µm. The mean 
adipocyte diameter = 57.7 ± 25 µm. 
 
 
 
a 
b
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Figure 6-9: Patient 5 SAT 
a) H&E slide showing adipocytes. b) bar chart represents adipocyte size distribution categorised 
into small < 50 µm, medium 50 – 69 µm, large 70 – 89 µm, and very large > 90 µm. The mean 
adipocyte diameter = 56.1 ± 27 µm. 
a 
b 
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6.4.4 Plasma samples 
6.4.4.1 Normalisation of miRNA Expression 
Two types of controls to normalise the expression of circulating miRNAs were 
tested in our study, endogenous control (mir-16) and exogenous control (mir-39) 
(Table 6-7). The endogenous control, mir-16, was highly expressed in our samples 
(Ct = 21.2) but showed more variation between the samples (SD > 0.25). 
Alternatively, the exogenous control (cel-miR-39) results, which is one of the 
widely accepted controls for circulating miRNA, was highly expressed in our 
samples and showed less variation between the samples (SD < 0.25).  
6.4.4.2 Expression of targeted miRNAs 
All six-circulating miRNA was detected in the plasma of our patients. Circulating 
mir-221 and mir-222 were highly expressed in patient’s plasma samples (mean Ct 
= 24.3 and 25.1 respectively). Among the six circulating miRNAs, mir-193b showed 
the least expression in patient’s samples (Ct = 33.8) (Table 6-8). 
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Table 6-7: Normalising expression for circulating miRNAs  
Mir-16 
Mean (SD) 
Mir-39 
Mean (SD) 
21.2 (0.9) 23.6 (0.24) 
SD: standard deviation 
 
Table 6-8: The mean expression of circulating miRNAs in plasma samples 
miRNA 
Ct 
Mean (SD) 
Mir-222 25.1 (2.0) 
Mir-221 24.3 (1.8) 
Mir-192 29.0 (1.2) 
Mir-193b 33.8 (1.3) 
Mir-144 30.1 (1.0) 
Mir-155 29.8 (2.2) 
AT: Adipose tissue, Ct: cycle threshold, SD: standard deviation 
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6.5 Discussion 
The primary outcome of this study was to evaluate the feasibility of the proposed 
study, REduction of Adipose Levels of Inflammation when treating obesiTY 
(REALITY) study.   
6.5.1 Patient recruitment 
Patients recruitment is an essential part of any clinical study. Insufficient 
recruitment results in failure of the study leading to a waste of time, funds, and 
other resources. To establish recruitment potential using this study design, 
invitation letters were sent to five patients who were already in the SCOTS study. 
Bariatric dieticians offered to give information sheets and letter to patients who 
agreed to participate in a future study. All five patients approached agreed to 
participate and signed a consent form. Since none of the five patients refused, 
this reassured me that the study was acceptable to patients, and recruiting enough 
patients in the main study would be possible.  
6.5.2 Sample collection and processing 
Since the timing of sample collection and sample processing is a critical factor 
affecting the quality of results, effort was made to made sure that samples arrive 
at the lab as quickly as possible. In this study, transportation of viable samples to 
the lab was quick (~ 1 hour) although the hospital was ~ 3.1 miles distant. 
6.5.3 Adipose tissue samples 
6.5.3.1 Total RNA Extracted 
Isolating good quality RNA from adipose tissue was challenging due to its high 
content of triglyceride. Partially degraded or poor yield RNA can cause misleading 
results, and it is a big concern, especially when working with a limited amount of 
tissue from human biopsies. A variety of factors during sample collection, 
processing, and storage can negatively impact results and were considered in the 
current study.  
To avoid RNA degradation, endogenous RNases must be inactivated immediately 
after adipose tissue harvesting. Two methods for adipose tissue preservation were 
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tested: snap-freezing AT samples on dry ice and placing AT samples in RNALater 
solution (an aqueous, nontoxic collection solution that stabilizes and protects 
cellular RNA in freshly harvested tissue and cell samples). To decide which method 
was better for adipose tissue collection, comparison between the two methods 
was made in terms of total RNA yield. The total RNA concentration was isolated 
from both snap frozen and RNALater adipose tissue samples. There was no 
difference between the total RNA extracted from both samples (p > 0.05), but The 
RNALater method had a trend towards a slightly higher concentration of total RNA 
than snap-frozen method (mean of 40.4 ng/µl and 36.4 ng/µl, respectively). A 
disadvantage of the snap-frozen method was that samples must be preserved 
frozen until assay. Even brief thawing can result in RNA degradation and loss. 
During tissue processing (homogenization) samples will be at risk of thawing. 
Therefore, using RNALater to preserve adipose tissue was easier for transportation 
and handling of adipose tissue samples.  
6.5.3.2 Normalisation of miRNA expression 
Normalisation of gene expression with a reference gene (housekeeping gene) is a 
significant step in gene quantification and analysis. An ideal housekeeping gene 
should show minimal variation in expression between samples and under the 
experimental conditions used and be adequately expressed in the tissue of 
interest. In the current study, three housekeeping genes (mir-103, mir-331, and 
RNU44) were tested in adipose tissue which have been used as an endogenous 
control in previous studies (Chapter 2.3.2). There was no difference in the 
expression of these selected housekeeping genes between the two adipose tissue 
samples (p > 0.05, for all three housekeeping genes). When comparing the 
expression of the three housekeeping genes (Table 6-4), RNU44 was found to be 
highly expressed (mean Ct = 24) and more stable between samples (SD < 0.25) 
than mir-103 and 331 (SD > 0.25). RNU44 was found to be the most suitable 
housekeeping gene in this study samples while the others will be avoided in our 
future study.  
6.5.3.3 Expression of targeted miRNAs 
In the present study, the ability of measuring the expression of miRNAs in adipose 
samples were tested using the same targeted six miRNAs used in chapter 3 (mir-
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222, mir-221, mir-192, mir-193b, mir-155, and mir-144). The expression of these 
miRNAs was detected in SAT samples. After that, a comparison was made for the 
expression of the selected six miRNA between the two adipose tissue samples 
(RNALater and snap frozen). There was no difference in their expression between 
the two methods (p > 0.05).  
6.5.3.4 Adipocyte diameter 
Large adipocyte size is associated with many of the adverse effects observed in 
metabolic diseases. Several methods have been described for measuring adipocyte 
size, but not all these methods are suitable for large-scale studies. Furthermore, 
some of these methods utilize equipment that is not available to all laboratories. 
Manual techniques are considered the most accurate way, but these are laborious 
and not suitable for large scale studies. More recently, a semi-automated protocol 
for quantitatively analysing size and number of adipocytes within adipose tissue 
which reduce, but do not eliminate human interaction. In the present study, a 
semi-automated method was tested using Adiposoft software, which is open-
source software that provides fast and accurate quantitative measurements of 
adipose tissue cellularity in histological sections. The use of this technique to 
measure adipose tissue cellularity was feasible and can be easily implemented in 
a large-scale study. Total adipocytes were counted, and adipocyte diameter and 
percent were measured (Table 6-6). In this study, participants had higher 
proportions of small adipocytes than previously reported. In addition, the average 
SAT adipocyte diameter was 58.2 ± 26µm which is considered low compared to 
SAT adipocyte diameter in  a study was done by (Verboven et al., 2018). In their 
study, the average SAT adipocyte diameter for 17 men with obesity and without 
diabetes was 75.6 µm. There are several reasons for this difference. First, the 
average age for participants in this study were 37.4 ± 11 while in Verboven et al. 
was 48 (45-54) and age is an important factor that might affect adipocyte 
diameter. Secondly, participants in this study were insulin sensitive (HOMA-IR = 
1.1) while in the other study, participants were insulin resistant (HOMA-IR = 4.7). 
Although the participants in this study were obese, they seem to maintain a 
normal metabolic function, metabolically healthy obesity (MHO) (Bell, Kivimaki & 
Hamer, 2014; Hinnouho et al., 2015; Smith et al., 2019). It is also possible that 
different tissue fixation techniques have some impact on adipocyte diameter. 
Finally, it is also possible that there are differences in the absolute calibration 
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between the digital photography and image analysis software used. One way to 
resolve the issue of calibration would be for me to repeat the study using the same 
equipment and SOP as Verboven et al. Any differences in size would then be 
attribuatble to incorrect calibration rather than systematic differences in 
technique and pre-anaytical variables. However, although absolute calibration 
may not be in agreement between studies, it is highly likely that the associations 
and internal correlations remain valid; methods with different calibrations tend 
to maintain good correlations. 
6.5.4 Plasma samples 
6.5.4.1 Normalisation of miRNA expression 
For plasma samples, normalisation of the expression of the targeted six circulating 
miRNAs is a necessary step. Finding a suitable control gene to normalize the 
expression of the circulating miRNAs was challenging. For control genes, two types 
of controls were tested, mir-16, an endogenous control and cel-miR-39, an 
exogenous control (Table 6-7). The endogenous control (mir-16), was highly 
expressed in plasma samples (Ct = 21.2) but showed more variation between the 
samples (SD > 0.25). Alternatively, the exogenous control (cel-miR-39) results 
were highly expressed in the current samples and showed less variation (SD < 
0.25). According to these results, a decision was made to use cel-miR-39 to 
normalize the expression of circulating miRNAs in the present study.  
6.5.4.2 Expression of targeted miRNAs 
The expression of the targeted six miRNAs were tested. All the six-circulating 
miRNA were detected in the plasma of the present study (Table 6-8). 
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6.6 Conclusion 
In summary, the feasibility of the Reality study was tested and concluded that the 
protocol designed used was accomplishable and ready to be tested in a full-scale 
study. Overall, the validation of sample collection, processing, and the methods 
selected was done and were ready to apply. Most importantly, the study was 
acceptable to patients, and this will probably lead to satisfactory recruitment 
number for the main study. One of the significant strengths of this study was the 
establishment of teamwork among the bariatric surgery department in the QEUH 
and clinical research team at the University of Glasgow. The alliance created by 
this collaboration demonstrates the feasibility of conducting a future large-scale 
study.  
6.6.1 Study strengths and limitations 
This is the first study to test feasibility I was aware of using a formal protocol for 
adipose tissue and blood samples collection, handling, and transporting. A robust 
standard operating procedure for blood and adipose tissue was established for 
miRNAs extraction and expression as well as measuring adipocyte diameter that 
can be implemented in a large-scale study. Moreover, such study helped in dealing 
with critical issues raised and the appropriate respond to it. Although a feasibility 
study is a useful tool for large studies design, it has its limitations. First, there is 
no fixed pattern telling which components to include in the study and how-to 
assess and evaluate the outcomes; due to low power, it mostly relies on subjective 
judgment. Second, the costs of reliable and detailed analysis are high however, 
this was justified by the higher cost in case the large-scale study failure. Finally, 
the small sample size; but this is a facet of the pilot design. The study is sufficient 
to demonstrate more quantitively meaningful research is feasible. 
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7 General Discussion
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7.1  Summary 
The work presented in this thesis was intended to explore the connection between 
obesity and T2DM. As well as to assess the possibility of using circulating miRNA 
as potential biomarkers for both conditions. One of the advantages of the work in 
this thesis is use of multiple studies with different designs, size, and population 
phenotypes. This thesis included a small size feasibility study (5 participants from 
SCOT study) to, a medium cross-sectional and RCT study (154 participants from 
CAMERA trial), and finally, a very large-scale cross-sectional study (> 500,000 
participants). 
7.2 Major Findings 
7.2.1 Suitability of the miRNA methodology for a large-scale 
analysis in a laboratory 
This thesis presents some of the first large-scale epidemiological data 
investigating circulating miRNA biomarkers, and their associations with risk 
factors. In the initial stages of development of the thesis considerable laboratory 
time was spent developing a moderately high-throughput practical method to 
achieve this.  
Circulating miRNAs exhibited promising potential to serve as effective non-
invasive diagnostic biomarkers. To allow clinical use, larger scale studies are 
required to further test their sensitivity, specificity, and applicability as 
diagnostic biomarkers for clinical application and to reduce or prevent false 
positive or negative results. Unfortunately, all the methods currently utilised for 
the identification of miRNAs (such as PCR and microarrays) are expensive, time 
consuming, and require expertise which are not easy to apply in a large study. The 
development of a robust simple to use and sensitive methods for circulating 
miRNAs is a necessity before utilising them as diagnostic biomarkers. 
In the last few years, progress has been made in the development of novel assay 
methodologies for the detection of circulating miRNA. One of these new methods 
is the use of aptamers, which are single stranded oligonucleotides that have high 
affinity and specificity in identifying target molecules. Ding et al. develop highly 
sensitive new method that uses aptamers that could identify and capture the 
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miRNAs in plasma and then analyse them on a full-featured micro-well detector. 
This method enables direct analysis of miRNAs in plasma without the need of 
miRNA extraction, reverse transcription, amplification, and normalisation (Ding et 
al., 2019). This technology will make detection of circulating miRNAs in a large-
scale study easy such as Generation Scotland cohort: 19,500 blood samples (Smith 
et al., 2013) possible. 
7.2.2 Circulating miRNAs as biomarkers 
The emergence of circulating miRNAs as novel minimally invasive biomarkers is 
relatively new promising area of research. In addition to their exceptional 
stability, circulating miRNAs hold other unique characteristics including their ease 
of detection, detectability even in a small sample amount, and their association 
with established clinicopathological parameters. All these features make 
circulating miRNAs promising biomarker candidate for future clinical applications. 
Recently, accumulating body of evidence has been introduced to support 
circulating miRNAs as non-invasive diagnostic and prognostic biomarkers in a wide 
variety of diseases such as cancers (Sueta et al., 2017; Al-qatati et al., 2017), 
diabetes (Zhu & Leung, 2015; Sebastiani et al., 2017), autoimmunity (Heegaard et 
al., 2015) and cardiovascular diseases (Sayed et al., 2015). However, most of the 
studies have been limited by small numbers and inconsistencies in results. So far 
and due to these issues, none of the suggested circulating miRNAs, including those 
in this thesis, succeeded as a biomarker. This is because it is not possible to 
compare results from studies that uses different samples, methods, and controls 
for normalisation. 
In the first study (chapter 3), the selected circulating miRNAs (mir-221, mir-222, 
mir-192, mir-193b, mir-155, and mir-144) showed significant associations with 
markers of metabolic risk in a population without diabetes and with large waist 
and coronary heart disease. The associations were supported by an expanding 
literature showing their potential biological role for the biomarker shown in 
section3.6.2).  
Among the six targeted circulating miRNAs, mir-144 displayed a specific 
association with insulin, HOMA-IR thus highlighting the potential role of mir-144 
as a key player in insulin resistance, not mediated by body weight. This miRNA 
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appears to contribute to the regulation of insulin signalling which was supported 
by the findings of Karolina et al. were they showed that elevated circulating mir-
144 correlate with the downregulation of insulin receptor substrate 1 (IRS1) at 
both mRNA and protein levels (Karolina et al., 2011).  
The results of this thesis suggest that the selected circulating miRNAs are possible 
and reproducible biomarkers for the following reasons. First, the use of large 
samples to investigate circulating miRNA which most of the studies lack. Second, 
in the initial stages a considerable laboratory time was spent developing a 
moderately high-throughput practical method to standardise the analytical part. 
Third, the associations with metabolic risk factors were specific and not providing 
overlapping information particularly for mir-144 which was specific with insulin 
and HOMA-IR. Finally, the associations with metabolic health markers were 
underpinned by an expanding literature around a potential biological role for the 
biomarker. 
The present study supports the putative utilities of circulating miRNAs as 
reproducible biomarkers however, further standardisation of both preanalytical 
and analytical procedures, as well as automated solutions, are required before 
large scale epidemiological investigation and their use as a clinical tool can be 
considered.  
7.2.3 Body fat distribution 
It is well established that obesity is associated with increased risk for developing 
T2DM. People with obesity have a seven times greater risk of T2DM than people 
with normal weight (Abdullah et al., 2010). Nevertheless, the relation between 
these two conditions is complicated and is not explained by total fat alone. A 
number of factors have been suggested as possible links between the two 
conditions. One connection suggested was body fat distribution. Previous studies 
have shown that body fat location particularly in the central area is more 
associated with T2DM then total body fat (Sattar and Gill, 2014; Nordström et al., 
2016; Janochova, Haluzik and Buzga, 2019). Therefore, the third study (chapter 
5) was designed to look at the association between body fat distribution and T2DM. 
Here, the differences in body fat measurements between participants with and 
without T2DM in both genders using the UK biobank cohort was explored. In this 
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study, the hypothesis that fat mass and distribution vary by sex was conformed, a 
fact that has been previously well documented (Davis et al., 2013; Chang, 
Varghese & Singer, 2018). A striking data demonstrating how different fat depots 
were associated with T2DM were presented. Specifically, visceral fat was an 
independent risk factor for T2DM. The results of this study corroborated with 
findings by several longitudinal studies which confirmed that visceral fat is more 
strongly associated with T2DM than total body fat (Neeland et al., 2012; Wander 
et al., 2013; Nordström et al., 2016). If these associations were causal, it suggests 
interventions to mitigate visceral fat accumulation are most likely to be clinically 
beneficial in terms of reducing T2DM risk.  
7.2.4 WBC count  
Low-grade inflammation is a common phenomenon observed in both obesity and 
T2DM. Because of that, it has been speculated that inflammation plays a major 
role in the pathogeneses of T2DM. This was supported by several epidemiological 
studies demonstrating that markers of inflammation were correlated with or 
predicted incidents of T2DM (Duncan and Schmidt, 2006; Herder, Carstensen and 
Ouwens, 2013). In addition, a growing body of evidence suggested that 
inflammation can alter several pathways that are associated with insulin action 
and pancreatic β-cell function leading to insulin resistance and T2DM (Prattichizzo 
et al., 2018). Nonetheless, interventions with anti- inflammatory compounds have 
yielded limited or no benefit (Everett et al., 2018). For those reasons, this study 
sought to investigate the use of WBC count as a marker for this low-grade 
inflammation is the link between adiposity and T2DM. This was supported by large 
epidemiological studies showing an association between total and peripheral WBCs 
count and diabetes risk (Schmidt et al., 1999; Vozarova et al., 2002; Twig et al., 
2013).  
In this study it was shown that WBC count cannot be considered the sole or primary 
connection of T2DM rather than an important mechanism that is linked to the 
primary cause, VAT deposition. Our findings further added to the indecisive 
evidence surrounding the role of WBC count plays in T2DM. 
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7.2.5 Feasibility Study 
To move the work forward it is important to plan for the next steps. To further 
explore and expand the association found in the previous studies in adipose tissue, 
since adipose tissue expandability and inflammation appears to be the drive of 
the metabolic dysfunction. To understand the role of SAT adipocyte in metabolic 
homeostasis, the REALITY study was considered where bariatric surgeries are going 
to be used to compare, adipocyte size, inflammation, and miRNA expression 
before and after weight loss. In the fourth study (chapter 6), a pilot study was 
conducted to assess the feasibility of the REALITY study and to work out all the 
logistics and requirements before conducting a large-scale study. The final 
conclusion of this pilot study was that the REALITY study can be implemented to 
success as it was carefully planned.  
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7.3 Future Perspectives 
From the work I presented in this thesis I am planning to expand my analysis to 
further confirm my findings. This will be accomplished by: 
1. Continue with the UK Biobank study but with further development of the 
ideas. The UK Biobank imaging study is still accruing participants, and more 
data are released every 6 - 12 months. The imaging study will continue until 
it reaches 100,000 participants which is predicted to be in 2022. This will 
allow us to include more participants in our study. Recently, further data 
become available from a range of biochemical assays of baseline samples 
from all participants. I will use HbA1c to categorise our study population to 
three different groups (Normal: ≤ 42 mmol/mol, Pre-diabetes:  42 - 47 
mmol/mol, and Diabetes: ≥ 48 mmol/mol). This will allow us to monitor 
body fat distribution through the course of the disease, from pre to post 
disease establishment. Moreover, I will include CRP as an inflammatory 
biomarker. CRP is more widely used in epidemiological studies as a 
measurement of inflammation than WBC, and this will allow us to compare 
our findings with these studies.  Finally, forthcoming availability of primary 
care data will allow us to investigate prospective links with incident type 2 
diabetes, a stronger study design than cross-sectional data. 
2.  I will proceed with the full REALITY study with the implementation of the 
protocol I designed. The primary hypothesis to test is that subcutaneous 
adipocyte diameter is reduced after significant weight loss leading to 
metabolic improvement. The study will use bariatric surgery as a model of 
metabolic change by comparing before and after weight loss (after 1 year). 
I will measure SAT adipocyte size, inflammatory markers, hormonal 
changes, and miRNA expression. The first samples (baseline samples) of 
both blood and SAT samples will be collected during bariatric surgery. The 
other samples will be collected from the same patients after one year of 
surgery.   To accomplish that I will be using a novel biopsy method that 
allows sampling from deep SAT compartment by a percutaneous bedside 
approach (Alderete et al., 2015). The primary outcome will be reduction in 
SAT adipocyte diameter and its effect on inflammation and miRNA 
expression. For the sample size three scenarios were proposed: 
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a. To detect a clinically significant difference in one weight loss group 
of adipocyte size 63 µm and 76 µm with SD 21 µm at alpha = 0.05 
and 80% power, assuming a correlation of r = 0.8 at the two 
timepoints, 11 participants will be needed. 
b. To detect a clinically significant difference in one weight loss group 
of adipocyte size 63 µm and 70 µm with SD 21 µm at alpha = 0.05 
and 80% power, assuming a correlation of r = 0.8 at the two 
timepoints, 31 participants will be needed. 
c. To detect a clinically significant difference in one weight loss group 
of adipocyte size 63 µm and 68 µm with SD 21 µm at alpha = 0.05 
and 80% power, assuming a correlation of r = 0.8 at the two 
timepoints, 58 participants will be needed. 
Out of the three power calculations number c make more sense and will be use 
in future study.
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7.4 Concluding remarks 
This work has demonstrated the potential utility of circulating miRNA as 
biomarkers of metabolic disease, that also deserve further consideration as 
potential causal mediators. It also showed that ectopic fat deposition in the 
visceral area plays an important role in the development of metabolic diseases. 
Deeper understanding of how body fat distribution is regulated may lead to novel 
therapeutic treatments of metabolic complications associated with obesity.
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Appendix 1: Reverse Transcription 
miRNA Dilution for RT 
RNA must be diluted to 2 ng / µL. For each miRNA, a total of 9 ng of RNA is needed. 
Therefore, 9 ng x 8 miRNA=72. I rounded this up to 80 ng to account for potential 
loss of material while pipetting. To calculate volume of RNA needed, I used the 
following formula:  
଼଴்௢௧௔௟஼௢௡௖Ǥ௢௙ோே஺ ൌ  µl (amount of RNA) 
For each miRNA, a total volume of 5 µL of RNA is needed. Thus, for 8 miRNAs 40 
µL in total was needed. 40 µL Ȃ X ൌ amount of RNAse free water to make up the 
40 µL. 
Master Mix Preparation 
One master mix for each miRNA was prepared according to the following: 
 For 1 sample 
For 8 ̱ 10 
Samples 
dNTP (100 mM) 0.075 µL 0.75 µL 
Multiscribe 0.5 µL 5 µL 
10X RT Buffer 0.75 µL 7.5 µL 
RNase Inhibitor 0.095 µL 0.95 µL 
RNAse free water 0.08 µL 0.8 µL 
Primer (5X; RT) 1.5 µL 15 µL 
223 
 
Appendix 2: Quantitative Real-Time Polymerase 
Chain Reaction (qRT-PCR) 
Master Mix Preparation 
Number to prepare depends on number of samples + 1 negative in triplicate. 
e.g. for 8 samples: 
8 + 1 = 9 ൈ 3 = 27 ̱ 30 
 
 n = 1 n = 30 
2X TaqMan 
mastermix 
5 µL 150 µL 
Primers (20X) 0.5 µL 15 µL 
RNase free water µL  93 µL 
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Appendix 3: External Spike-in control (cel-miR-39) 
preparation 
Stock Solution 
Was prepared by adding 300 µL nuclease free water vortexed, spun. The final 
concentration was 2 x 1010 copies/µL stock. The stock control was aliquoted 
into 30 µL /tube and stored at െͺͲԨ.  
Working Control 
4 µL of the stock control solution was mixed with 16 µL nuclease free water to 
produce the First Step Solution (4 x 109 copies/µL). First Step Solution (2 µL) was 
further diluted with nuclease free water (48 µL) to produce a 1.6 x 108 copies/µL.
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Appendix 4: Letter of access for research 
 
01 June 2016 
Tahani ALRamah  
BHF Cardiovascular Research Centre  
University of Glasgow  
126 University Place  
Glasgow G12 8TA 
Dear Ms T ALRamah, 
 
Letter of Access for Research  
 
This letter confirms your right of access to conduct research through NHS Greater Glasgow and 
Clyde for the purpose and on the terms and conditions set out below. This right of access 
commences on 01/06/16 and ends on 31/06/17 unless terminated earlier in accordance with the 
clauses below. 
  
You have a right of access to conduct such research as confirmed in writing in the letter of permission 
for research from this NHS organisation. Please note that you cannot start the research until the 
Principal Investigator for the research project has received a letter from us giving permission to 
conduct the project.  
 
The information supplied about your role in research at NHS Greater Glasgow and Clyde has been 
reviewed and you do not require an honorary research contract with this NHS organisation. We are 
satisfied that such pre-engagement checks as we consider necessary have been carried out.  
 
You are considered to be a legal visitor to NHS Greater Glasgow and Clyde premises. You are not 
entitled to any form of payment or access to other benefits provided by this NHS organisation to 
employees and this letter does not give rise to any other relationship between you and this NHS 
organisation, in particular that of an employee. 
  
While undertaking research through NHS Greater Glasgow and Clyde, you will remain accountable 
to your employer the University of Glasgow but you are required to follow the reasonable 
instructions of Lorna Forde in this NHS organisation or those given on her/his behalf in relation to 
the terms of this right of access.  
 
Where any third party claim is made, whether or not legal proceedings are issued, arising out of or 
in connection with your right of access, you are required to co-operate fully with any investigation by 
this NHS organisation in connection with any such claim and to give all such assistance as may 
reasonably be required regarding the conduct of any legal proceedings.  
 
 
Coordinator/Administrator: Ms Joanne McGarry/Mrs Elaine O’Neill 
Telephone Number:0141 232 1815  
E-Mail: elaine.o’neill2@ggc.scot.nhs.uk Website: 
www.nhsggc.org.uk/r&d 
Research & Development  
West Glasgow ACH  
Dalnair Street  
Glasgow G3 8SW 
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You must act in accordance with NHS Greater Glasgow and Clyde policies and procedures, which 
are available to you upon request, and the Research Governance Framework.  
 
You are required to co-operate with NHS Greater Glasgow and Clyde in discharging its duties under 
the Health and Safety at Work etc Act 1974 and other health and safety legislation and to take 
reasonable care for the health and safety of yourself and others while on NHS Greater Glasgow 
and Clyde premises. You must observe the same standards of care and propriety in dealing with 
patients, staff, visitors, equipment and premises as is expected of any other contract holder and you 
must act appropriately, responsibly and professionally at all times.  
 
If you have a physical or mental health condition or disability which may affect your research role 
and which might require special adjustments to your role, if you have not already done so, you must 
notify your employer and the health board’s HR department prior to commencing your research role 
at the Health board.  
 
You are required to ensure that all information regarding patients or staff remains secure and strictly 
confidential at all times. You must ensure that you understand and comply with the requirements of 
the NHS Confidentiality Code of Practice 
(http://www.dh.gov.uk/assetRoot/04/06/92/54/04069254.pdf) and the Data Protection Act 1998. 
Furthermore, you should be aware that under the Act, unauthorised disclosure of information is an 
offence and such disclosures may lead to prosecution.  
 
You should ensure that, where you are issued with an identity or security card, a bleep number, email 
or library account, keys or protective clothing, these are returned upon termination of this 
arrangement. Please also ensure that while on the premises you wear your ID badge at all times or 
are able to prove your identity if challenged. Please note that this NHS organisation accepts no 
responsibility for damage to or loss of personal property.  
 
We may terminate your right to attend at any time either by giving seven days’ written notice to you 
or immediately without any notice if you are in breach of any of the terms or conditions described in 
this letter or if you commit any act that we reasonably consider to amount to serious misconduct or 
to be disruptive and/or prejudicial to the interests and/or business of this NHS organisation or if you 
are convicted of any criminal offence. You must not undertake regulated activity if you are barred 
from such work. If you are barred from working with adults or children, this letter of access is 
immediately terminated. Your employer will immediately withdraw you from undertaking this or any 
other regulated activity and you MUST stop undertaking any regulated activity immediately. 
  
Your substantive employer is responsible for your conduct during this research project and may in 
the circumstances described above instigate disciplinary action against you. 
  
NHS Greater Glasgow and Clyde will not indemnify you against any liability incurred as a result of 
any breach of confidentiality or breach of the Data Protection Act 1998. Any breach of the Data 
Protection Act 1998 may result in legal action against you and/or your substantive employer.  
 
If your current role or involvement in research changes, or any of the information provided in your 
Research Passport changes, you must inform your employer through their normal procedures. You 
must also inform your nominated manager in this NHS organisation. 
 
Yours sincerely, 
 
Ms Joanne McGarry  
Research Co-ordinator
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Appendix 5: Good clinical practice certificate  
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Appendix 6: R&D Management Approval 
GN15MD002 
 
 
  
Administrator: Lorn Mackenzie R&D  
Telephone Number: 0141 211 1743  
E-Mail: Lorn.Mackenzie@ggc.scot.nhs.uk  
Website: www.nhsggc.org.uk/r&d  
Management Office 
Western Infirmary 
Tennent Institute 
1st Floor 38 Church 
Street 
Glasgow, G11 6NT, 
       
  
20/01/2015  
 
Dr Jennifer Logue  
BHF Cardiovascular Research Centre  
126 University Place  
Glasgow, G12 8TA  
 
NHS GG&C Board Approval 
Dear Dr Logue, 
 
Study Title:  REALITY REduction of Adipose Levels of Inflammation when 
Treating obesitY -Feasibility Study  
Principal Investigator:  Dr Jennifer Logue  
GG&C HB site  GG&C Weight Management Service, Mansion house Unit  
Sponsor  NHS GG&C  
R&D reference:  GN15MD002  
REC reference:  15/EM/0018  
Protocol no:  
(including version and date)  
V1.0; 10.12.14  
 
 
I am pleased to confirm that Greater Glasgow & Clyde Health Board is now able to 
grant Approval for the above study.  
 
Conditions of Approval 
  
1. For Clinical Trials as defined by the Medicines for Human Use Clinical Trial 
Regulations, 2004  
a. During the life span of the study GGHB requires the following information 
relating to this site  
i. Notification of any potential serious breaches.  
ii. Notification of any regulatory inspections.  
 
It is your responsibility to ensure that all staff involved in the study at this site have the 
appropriate GCP training according to the GGHB GCP policy 
(www.nhsggc.org.uk/content/default.asp?page=s1411), evidence of such training to 
be filed in the site file.  
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2. For all studies the following information is required during their lifespan.  
a. Recruitment Numbers on a quarterly basis  
b. Any change of staff named on the original SSI form  
 
c. Any amendments – Substantial or Non-Substantial  
d. Notification of Trial/study end including final recruitment figures  
e. Final Report & Copies of Publications/Abstracts 
  
Please add this approval to your study file as this letter may be subject to audit 
and monitoring.  
Your personal information will be held on a secure national web-based NHS database.  
I wish you every success with this research study 
 
Yours sincerely, 
 
Lorn Mackenzie  
Senior Research Administrator 
 
230 
 
Appendix 7: Patient invitation Letter 
 
                             
 
 
 
 
 
 
 
 
 
Dear [Insert name] 
Thank you for already agreeing to take part in the Surgical Obesity Treatment 
Study (SCOTS) based at the University of Glasgow.  You previously gave us 
permission to contact you to let you know about any other studies that we are 
doing. We are doing a further small study and we are inviting participants who are 
due to have their surgery in Glasgow to take part in it.  
The extra study would involve donating a blood sample and a small piece of fat 
tissue which would be removed during your surgery.  I am writing to invite you to 
consider participating in this extra study.  
The study is funded by the NHS Greater Glasgow and Clyde Research Endowments 
and aims to recruit 5 people in the first instance. The study is supported by your 
bariatric surgery team in Glasgow. 
Please take some time to read the enclosed patient information sheet and 
consider if you would like to take part in our study. The research team will be 
available at one of your appointments prior to your surgery so you can ask any 
questions and let us know if you would like to take part. 
Institute of Cardiovascular & Medical 
Sciences 
BHF Glasgow Cardiovascular 
Research Centre 
University Of Glasgow 
126 University Place 
Glasgow  
G12 8TA 
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Yours sincerely 
 
Dr Jennifer Logue 
CSO Clinician Scientist  
Senior Clinical Lecturer and Honorary Consultant in Metabolic Medicine 
University of Glasgow 
 
BHF Glasgow Cardiovascular Research Centre      
Tel:  +44(0)141 330 2569 
Fax:  + 44(0)141 330 6955 
Email:  jennifer.logue@glasgow.ac.uk 
Website: scotsurgerystudy.org.uk 
The University of Glasgow, Charity number SC004401 
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Appendix 8: Consent Form for The Reality Study 
                                                
 
 SCOTS Participant Identification Number: 
 
CONSENT FORM 
 
Title of Project: REALITY - REduction of Adipose Levels of Inflammation 
when Treating obesitY - Feasibility Study 
 
 
Name of Researcher: Dr Jennifer Logue       
 
1. I confirm I have read and understand the information sheet dated 10/12/2014 (Version 
2.0) for the above study. I have had the opportunity to consider the information, ask 
questions, and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes may be looked at by individuals 
from regulatory authorities or the NHS board, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records. 
 
4. I agree to my blood and fat (adipose tissue) samples being stored for use in future studies 
 
 
5.   I agree to take part in the above study. 
 
 
__________________           ______________         ________________________ 
Name of Patient                     Date                              Signature  
 
 
 
__________________           ______________         ________________________ 
Name of Person                      Date                              Signature  
taking consent 
   
 
When completed 1 for patient, 1 for researcher site file, 1 for upload to electronic case notes 
2014_12_10 REALITY consent form v1. 
 
Please 
initial box 
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